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 General introduction
Chapter 1Insulin sensitivity of hepatic glucose and lipid metabolism in animal models of hepatic steatosis 
Hepatic steatosis: definitions, stages, prevalence and association with insulin resistance 
 
Hepatic steatosis refers to the, nowadays common, condition of ectopic accumulation of 
triglycerides (TG) in parenchymal cells (hepatocytes) of the liver. This condition is therefore 
also termed “fatty liver”. Several forms of hepatic steatosis are generally distinguished, 
depending on underlying cause of the condition and the progression of the disease. Excessive 
and chronic alcohol consumption has been known for decades to be associated with alcoholic 
fatty liver, a condition that is beyond the scope of this thesis. Interested readers are therefore 
referred to recently published, excellent reviews on this topic (1-4). 
In 1980, Ludwig et al. (5) were the first to describe the appearance of hepatic steatosis 
without excessive alcohol usage, a condition they termed nonalcoholic steatohepatitis 
(NASH). Nowadays, non-alcoholic fatty liver (NAFL) is considered the precursor of NASH 
and both conditions are non-alcoholic fatty liver diseases (NAFLDs) (6). Table 1.1 shows the 
major causes of NAFLD, as recently published by Adams et al. (7). Especially the   
association of hepatic steatosis with features of the metabolic syndrome is of interest for this 
thesis and will be discussed in more detail later in this introduction.  
Studies suggest that circa 20% of NASH will finally result in cirrhosis (8). A recent 
editorial in Gastroenterology (9), however, summarized  that ‘simple steatosis’ itself might be 
relatively benign: over a 15-20 years period, only 1-2% of the patients with this condition 
actually developed cirrhosis. In patients with fibrosis and NASH, this percentage might be up 
to 12% in 8 years. The largest natural history study performed so far in patients with NAFLD 
(10) showed that mortality in these patients is higher than in patients without NAFLD and 
associated not only with cirrhosis, but also with age and impaired fasting glucose. When 
cirrhotic patients were excluded, the overall mortality was not increased. Thus, these human 
data stress the importance of staging the hepatic steatosis found. 
In NAFLD, the liver contains more than normal amounts of TG, the most energy-
dense molecules in mammalian physiology. TG molecules consist of three fatty acids 
esterified to a glycerol backbone (figure 1.1). The fatty acids can either be saturated, 
monounsaturated, or polyunsaturated, reflecting the amount of double bonds. In NASH, the 
increased TG content is accompanied by hepatocellular ballooning and lobular inflammation 
(11). NASH can by graded and staged depending on which hepatocytes are inflamed, i.e., 
perivenously or periportally located hepatocytes, and whether ballooning of cells is minimal, 
present or marked (12). The progression of simple hepatic steatosis (NAFL) towards NASH 
and finally cirrhosis, is thought to involve two “hits”, a model first proposed by Day and 
James in 1998 (13). In this model, the first “hit” is the development of the hepatic steatosis: 
accumulation of TG in hepatocytes. The second “hit” induces the transition of NAFL to 
NASH and is the result of the actions of inflammatory molecules, i.e., reactive oxygen species 
(ROS). The second “hit” might be the result of the increased liver TG levels itself because 
fatty acids are cytotoxic: fatty acid oxidation in mitochondria and peroxisomes might generate 
ROS (14). However, one must keep in mind that inflammation itself is the major factor in the 
transition of NAFL to NASH (15). 
It is alarming that the prevalence of NAFLD in the adult population in Western 
societies is estimated at about 20% (11) and it is therefore suggested that 9.1 million 
individuals in the United States have NAFLD (16). The risk of NAFLD is almost 5-fold 
higher in persons with body mass index (BMI) ≥ 30 kg/m
2 (17). BMI is considered a good 
index for obesity, but waist-to-hip circumference ratio (WHR) is probably a better marker for 
fat distribution (18). The World Health Organisation (WHO) defines overweight as BMI ≥ 25 
kg/m
2, individuals with BMI ≥ 30 kg/m
2 are obese (19). In fact, NAFLD is associated with 
the metabolic syndrome, obesity and diabetes (20). These conditions all share insulin 
resistance as a diagnostic criterion. Insulin resistance is defined as a decreased biological 
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response to normal concentrations of circulating insulin. The role of insulin and the 
consequences of insulin resistance for (hepatic) metabolism will be discussed later. 
According to diagnostic criteria for the metabolic syndrome defined by the National 
Cholesterol Education Program (NCEP) panel (21), a person suffers from the metabolic 
syndrome when he/she shows at least three of the criteria listed in table 1.2. The WHO 
stresses even more the importance of insulin resistance in the diagnosis of the metabolic 
syndrome (22), as mentioned in table 1.3.  
Numerous clinical studies have shown that insulin resistance is a predisposing factor 
for NASH (20,23-27). The question that is still unanswered is whether hepatic steatosis is 
caused by insulin resistance, as suggested in the “two hit” hypothesis (13), or that hepatic 
steatosis predisposes to insulin resistance. Another possibility is that a common factor, such 
as the adipocyte-derived hormones leptin and adiponectin, contributes to development of both 
hepatic steatosis and insulin resistance. In the remaining part of this introduction, attention 
will be focussed on the first two possibilities. Considering the third possibility, recent studies 
show that people with low plasma leptin concentrations, e.g. subjects with congenital 
lipodystrophy, develop both NASH and insulin resistance (28). Leptin replacement therapies 
in lipodystrophic patients reverses their NASH (29). Leptin-deficient ob/ob mice develop 
hepatic steatosis, but not NASH, in combination with insulin resistance, hyperglycemia and 
hypertriglyceridemia (30). Low plasma adiponectin levels are associated with the 
development of insulin resistance (31) and administration of adiponectin to mice with 
alcohol-induced hepatic steatosis resulted in decreased liver TG concentrations (32). In ob/ob 
mice, adiponectin administration increased insulin sensitivity and reduced hepatic TG levels 
(32). 
 
Table 1.1. Major causes or associations of nonalcoholic fatty livers (7). 
 
Cause   Association 
Primary   Features  of  the metabolic syndrome 
Secondary  Nutritional  Total parental nutrition 
   Rapid  Weight  loss 
   Startvation 
   Intestinal  bypass  surgery 
 Drugs  Glucocorticoids 
   Estrogens 
   Tamoxifen 
   Amiodaron 
   Methotrexate 
   Aminosalicylate 
 Toxins   
 Metabolic  Lipodystrophy 
   Dysbetalipoproteinemia 
    Acute fatty liver of pregnancy 
   Reye’s  syndrome 
 Other  Inflammatory  bowel  disease 
   HIV  infection 
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Figure 1.1. Structure of A, triglyceride (tripalmitic acid); B, saturated fatty acid (palmitic acid, C16:0); C, 
monounsaturated fatty acid (palmitoleic acid, C16:1w7); D, polyunsaturated fatty acid (α-linoleic acid, 
C18:3w3). 
 
 
Table 1.2. NCEP diagnosis criteria for the metabolic syndrome (21). 
 
Risk factor  Abnormal level 
Waist circumference  > 102 cm (men) or > 88 cm (women) 
Fasting blood glucose  ≥ 6.1 mM 
Serum triglycerides  ≥ 1.7 mM 
Serum HDL cholesterol  < 1.0 mM (men) or < 1.3 mM (women) 
Arterial blood pressure  ≥ 130/85 mm Hg 
 
 
Table 1.3 WHO diagnosis criteria for the metabolic syndrome (22). 
 
Insulin   in top 25% 
Fasting blood glucose   ≥ 6.1 mM  Required 
2-hour glucose  ≥ 7.8 mM 
And ≥ 2 of:  Waist-to-hip circumference ratio  > 0.9 (men) or >0.85 (women) 
  Body mass index  ≥ 30 mg/kg
2
 Serum  triglycerides  ≥ 1.7 mM 
  Serum HDL cholesterol  < 0.9 mM (men) or < 1.0 mM (women) 
  Arterial blood pressure  ≥ 140/90 mm Hg 
12 General introduction 
 
Insulin: discovery, diabetes and intracellular actions 
 
The hormone insulin was discovered by Best and Banting in 1921 (33) when they investigated 
the role of the pancreas in diabetes mellitus. Because the first known feature of this disease 
was the high urinary glucose concentration, it was named diabetes mellitus. “Diabetes” is 
derived from the Greek word for “pipe-line” to stress the fact that nutrients begin to pass 
through the system rather than being utilised. “Mellitus” is Latin for “honey” to stress the 
sweet taste of the urine produced in this condition. Later on, it was discovered that diabetic 
patients also have increased blood glucose levels. 
Insulin is secreted by the B-cells located in the islets of Langerhans of the pancreas 
when blood glucose levels increase, for instance after a meal. Insulin has energy-saving 
properties: it enhances storage of glucose in the liver, inhibits hepatic glucose production 
(HGP) and stimulates uptake of glucose by the peripheral tissues, i.e., muscle and adipose 
tissue. Insulin also influences whole-body lipid metabolism by inducing hepatic fatty acid and 
TG synthesis (de novo lipogenesis) and inhibiting peripheral breakdown of TG into fatty acids 
(lipolysis). 
Two types of diabetes mellitus are generally distinguished. In diabetes mellitus type 1, 
high blood glucose levels are the result of the failure of the pancreas to produce sufficient 
amounts of insulin. Various auto-immune factors have been implicated herein (34) and 
genetic predisposition is thought to play a major role. Diabetes mellitus type 1 is usually 
diagnosed in childhood whereas diabetes mellitus type 2 has been associated with elderly but 
its prevalence in young people and even children is rapidly increasing. Diabetes mellitus type 
2 is preceded by insulin resistance. As a result of insulin resistance, the pancreas starts to 
produce more insulin, a process that in the end will exhaust the B-cells and result in an 
inability of these cells to produce sufficient insulin. As a result, plain diabetes will develop 
over time. 
Insulin actions are carried out via binding of the hormone to its receptor (a member of 
the tyrosine kinase receptor family) (figure 1.2). Upon binding, the receptor 
autophosphorylates and activates two distinct down-stream signaling pathways: the 
phosphatidylinositol-3-kinase (PI3K) pathway and the MAP kinase/ERK kinase (MEK) 
pathway. Protein tyrosine phosphatase 1B (PTP-1B) is an enzyme that dephosphorylates the 
insulin receptor and acts to terminate the signal. In mice, increased levels and activity of PTP-
1B result in insulin resistance (35,36). Insulin-mediated effects on glucose and lipid 
metabolism, most relevant for the work described in this thesis, are thought to be 
predominantly carried out via the PI3K-pathway but the MEK pathway will also be discussed 
briefly. 
Down-stream insulin receptor substrates (IRSs) are phosphorylated upon 
autophosphorylation of the insulin receptor. IRS1 and IRS2 are the two isoforms 
predominantly found in the liver. Recent studies with IRS1- and IRS2-specific knockout mice 
have shown that they control distinct metabolic pathways (37): IRS1 mainly controls the 
effects on glucose metabolism whereas IRS2 predominantly mediates the effects on lipid 
metabolism. In the MEK pathway, IRS phosphorylation results in phosphorylation of the SH2 
domain-containing adaptor protein Grb2. As a result, this protein dimerizes with the guanine 
exchange factor “son-of-sevenless” (SOS) and the subsequent exchange of GTP for GDP 
activates Ras. Next, GTP-bound Ras binds Raf, the first kinase in the Raf-MAPK route, that 
will subsequently activate MEK. MEK activates the extracellular signal-related kinase (ERK) 
1 and ERK2 that can activate various downstream targets involved in, for instance, gene 
expression and kinase activity (38). 
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Figure 1.2. Schematic representation of the intracellular insulin signaling cascade. IRS, insulin receptor 
substrate; ERK, extracellular signal-related kinase; FoxO1, forkhead box “Other”-1; GSK3β, glycogen synthase 
kinase-3β; MEK, MAP kinase/ERK kinase; PI3K, phosphatidylinositol-4-kinase; PIP2, phosphatidylinositol-4,5-
bisphosphate; PIP3, phosphatidylinositol-2,4,5-trisphosphate; PKB, protein kinase B; SOS, son-of-sevenless. 
 
 
The PI3K pathway also starts after IRS phosphorylation. Phosphorylated IRS has an increased 
affinity for the p85 subunit of PI3K. Activated PI3K will start the production of the second 
messenger phosphatidylinositol 2,4,5-trisphosphate (PIP3) from the phospholipid PI4,5P2 
(PIP2). This second messenger activates, amongst others, protein kinase B (PKB) via 
phosphorylation at two sites (Thr308 and Ser473). PKB is a key regulatory protein involved 
in many steps of insulin-mediated actions on hepatic glucose and lipid metabolism, as will be 
discussed in more detail in other paragraphs.  
Although this topic will not further be discussed in detail, insulin also stimulates 
peripheral glucose uptake via PKB-mediated translocation of vesicles containing the glucose 
transporter-4 (GLUT4) to the membrane (39,40). Exactly how PKB influences this 
translocation is currently not known. 
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The increasing world-wide prevalence of diabetes mellitus type 2 
 
As mentioned, insulin resistance will normally result in diabetes mellitus type 2, a disease 
mainly found in adults in their forties or fifties until recently. Nowadays, its prevalence is 
steeply rising and the condition is increasingly present also in children and adolescents 
(41,42). In Japanese children, diabetes mellitus type 2 already accounts for 80% of childhood 
diabetes (43). Not only is childhood prevalence for diabetes mellitus type 2 increasing 
rapidly, the total number of people world-wide with this condition is thought to rise from 189 
million (2003 situation) to 221 million in 2010 and to more than 300 million in 2025 (44-46). 
Remarkably, the 1995 to 2025 increase in diabetes is estimated to be stronger in developing 
countries than in developed countries (46). In developing countries, the increase will be 
170%, from 84 to 228 million; in developed countries, this increase will be 42%, from 51 to 
72 million. This marked difference can, in part, be explained by the “thrifty genotype 
hypothesis” (47). In ancient times, people in areas prone to famine, e.g., the developing 
countries, developed a biological mechanism to store more fat to survive prolonged periods of 
food deprivation. Nowadays, these people, especially in countries like India and China, have 
more easy access to food and as a result, they accumulate excess fat more easily. When this is 
also accompanied by a reduction in physical activity (i.e, a sedentary lifestyle), these factors 
result in obesity, attraction of the metabolic syndrome and diabetes mellitus type 2 (47). The 
data from Ogden et al. (48) show that, in the US, the incidence of obesity is markedly 
increasing in children. In 1999-2000, the prevalence of overweight (defined as at or above the 
95th percentile of the sex-specific BMI) was 15.5 % in 12- through 19-year-olds, 15.3% in the 
6- through 11-year-olds, and 10.4% in the 2- through 5-year-olds. In 1988-1994, these 
percentages were 10.5%, 11.3%, and 7.2%, respectively.  
 
 
Hepatic glucose metabolism and the actions of insulin 
 
In fed conditions, glucose from the intestine is transported via blood and taken up by tissues 
by a process regulated, in part, by insulin. Liver and muscle tissue can store excess glucose as 
glycogen, a highly branched, efficient storage form of glucose (49). The direct pathway from 
glucose to glycogen consists of two distinct steps (see figure 1.3 for an overview of the 
intrahepatic glucose fluxes). The first step involves conversion of glucose into glucose-6-
phosphate (G6P), a process mediated by hexokinase. The liver-type hexokinase is called 
glucokinase (GK). The second step involves production of glycogen via uridine diphosphate 
(UDP)-glucose. Glycogen synthase (GS) is thought to be rate-controlling in the latter process. 
Although production of glycogen is an efficient way for the liver to store glucose, the 
glycogen storage capacity is limited. A certain amount of glucose is therefore also broken 
down in the glycolytic pathway into carbon-3 compounds, i.e., pyruvate and lactate. This 
process is mediated by enzymes such as phosphofructo-1-kinase and pyruvate kinase (PK). 
As will be discussed later, the carbon-3 compounds can be the source of acetyl-CoA, that can 
be used for production of fatty acids (and subsequently TGs) in a process called de novo 
lipogenesis. 
In fasted conditions, in contrast, the body largely depends on the glucose produced by 
the liver. The liver and, to a minor extent, the kidney are the sole organs capable of glucose 
production and secretion (50). First, the glycogen stores are used to yield glucose, a process 
that can be considered as a three-step process. The first step is the cleaving of a single 
glucose-1-phosphate from glycogen, a process controlled by glycogen phospatase (GP). The 
second step involves the action of a debranching enzyme that converts glucose-1-phosphate to 
G6P. The final step is the dephosphorylation of G6P to glucose, mediated by glucose-6-
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phosphatase (G6Pase), an enzyme-complex only found in the liver (and kidneys), the reason 
why only the liver (and the kidney)  can produce glucose. Apart from breakdown of glycogen, 
the liver can produce glucose from other substrates, such as the carbon-3 compounds, in a 
process called gluconeogenesis (GNG). When fasting exceeds 8 hours in humans, GNG 
progressively replaces breakdown of glycogen to preserve complete breakdown of this 
storage form of glucose (51). This gluconeogenic process is controlled by 
phosphoenolpyruvate carboxykinase (PEPCK) that catalyses conversion of pyruvate to 
oxaloacetate to phosphoenolpyruvate, by fructose-1,6-bisphosphatase (F1,6BP) that catalyses 
conversion of fructose-1,6,-bisphosphate to fructose-6-phosphate, and by a number of other 
enzymes. The final step in GNG is the conversion of G6P to glucose by G6Pase. 
As mentioned, insulin lowers blood glucose via stimulation of glucose uptake by 
muscle and adipose tissue as well as by inhibition of HGP. In addition, insulin stimulates 
conversion of glucose into glycogen and into carbon-3 compounds that are subsequently 
converted acetyl-CoA, fatty acids, and TG. Studies demonstrate that, in humans, half maximal 
suppression of HGP occurs at insulin levels of 25 mU/ml, whereas half maximal stimulation 
of peripheral glucose uptake occurs at 50 mU/ml (52). Thus, HGP is more insulin sensitive 
than peripheral glucose clearance. Of particular interest are the studies with stable isotope 
techniques showing that, under basal conditions, HGP in type 2 diabetic individuals was 
unchanged or only modestly elevated (53-55). Under hyperinsulinemic or hyperglycemic 
conditions, however, insulin failed to suppress HGP, suggesting abnormal regulation of HGP 
in diabetes mellitus type 2 (56).  
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Figure 1.3. Schematic representation of the intrahepatic glucose fluxes and the regulation of these fluxes by 
insulin. F1,6BP, fructose-1,-bisphosphotase; FoxO1, forkhead box “Other”-1; G1P, glucose-1-phosphate; G6P, 
glucose-6-phosphate; G6Pase, glucose-6-phosphatase; GK, glucokinase; GLUT2, glucose transporter-2; GP, 
glycogen phosphorylase; GS, glycogen synthase; GSK3β, glycogen synthase kinase-3β; PEP, 
phosphoenolpyruvate; PEPCK, phosphoenolpyruvate carboxykinase; PFK, phosphofructo-1-kinase; PK, 
pyruvate kinase; SREBP-1c, sterol-regulatory element-binding protein-1c. 
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Via PI3K-induced PKB phosphorylation, insulin enhances phosphorylation of GS kinase-3β 
(GSK3β) (38), a protein whose activity is inhibited by phosphorylation. As a result, GS 
phosphorylation will be reduced and this enzyme will thus be more active. The final result is 
an increased storage of glucose in the form of glycogen. GK is also critically involved in 
insulin-mediated hepatic glucose metabolism. In insulin receptor-deficient mice, 
overexpression of GK improved glucose tolerance, emphasizing the importance of GK 
activity (57). Moreover, transcription of the GK gene is regulated by sterol-regulatory 
element-binding protein-1c (SREBP-1c) (58,59), a key transcription factor in the control of 
hepatic lipid metabolism (60) whose transcription and activation are regulated by insulin (61). 
SREBP-1c stimulates transcription of almost all genes involved in fatty acid and TG synthesis 
(60).  
For long time, it was known that insulin suppresses GNG. Recently, the forkhead box 
“Other”-1 (FoxO1) has been identified as a transcription factor with an important role in 
mediating the effects of insulin on GNG (62). FoxO1 appears to be a negative modulator of 
insulin action, as it binds to insulin response sequences found in promotor regions of genes 
encoding G6Pase (63,64) and PEPCK (65). The actions of FoxO1 on gene transcription are 
mediated by PKB. PKB can phosphorylate FoxO1 at three sites (Thr24, Ser256, and Ser319 
in human FoxO1), resulting in activation and nuclear exclusion of FoxO1 (66-72). Moreover, 
phosphorylation and cytoplasmic localization of FoxO1 promotes its degradation (73). In vivo 
evidence for the role of FoxO1 comes from the heterozygous FoxO1 knockout mouse (74,75) 
that showed reduced G6Pase gene expression and lower plasma insulin levels. Moreover, 
these heterozygous mice are, on a insulin receptor-knockout background, less insulin resistant 
than control mice. 
In conclusion, via its effects on GS (via GSK3β), on GK (via SREBP-1c), and on 
GNG (via FoxO1), insulin stimulates hepatic glucose utilisation and inhibits HGP. 
 
 
Triglyceride-rich lipoproteins and free fatty acids 
 
Chapter 8 of this thesis discusses hepatic lipid metabolism, very low density lipoprotein 
(VLDL) assembly and secretion, and the roles of the lipogenic transcription factors SREBP-
1c, liver X receptor (LXR) and carbohydrate responsive element binding protein (ChREBP) 
herein. This introduction will therefore only briefly discuss these issues. 
A surplus of (dietary) energy is incorporated into TG and stored in adipose tissue. In 
fasted conditions, the adipose TG store is used to deliver energy in the form of free fatty acids 
(FFA) and glycerol to liver and muscle to maintain whole-body energy homeostasis. To 
maintain this homeostasis, transport of lipids between various tissues (intestine, liver, adipose 
tissue) plays a crucial role. TGs are very hydrophobic and therefore need to be transported in 
association with lipoproteins together with cholesterol, phospholipids and proteins. The core 
of a lipoprotein contains TG and esterified cholesterol while the surface consists of 
phospholipids and free cholesterol. Embedded in the lipoprotein surface are apolipoproteins. 
These proteins are needed for stabilisation of the particle and solubility of the core lipids (76) 
Moreover, apolipoproteins act as ligands for specific receptors and are needed for the actions 
of enzymes (76).  
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Figure 1.4. Schematic representation of lipoprotein and fatty acid fluxes. FFA, free fatty acid; HDL, high density 
lipoprotein; IDL, intermediate density lipoprotein; LDL, low density lipoprotein; LPL, lipoprotein lipase; VLDL, 
very low density lipoprotein. 
 
Table 1.4. Characteristics of lipoproteins 
 
Lipoprotein Density  Diameter  Apolipoproteins  Percentage  lipids 
 (g/ml)  (nm)    TG  Cholesterol  PL 
Chylomicron  0.95  75 – 1200  AI, AII, AIV, B48, CI, CII,  80 – 95  2 – 7  3 – 9 
      CIII,  E     
VLDL  0.95 – 1.006  30 – 80  B100, CI, CII, CIII, E  55 – 80  5 – 15  10 – 20  10 – 20 
IDL  IDL  1.006 – 1.019  1.006 – 1.019  25 – 35  25 – 35  B100, CI, CII, CIII, E  B100, CI, CII, CIII, E  20 – 50  20 – 50  20 – 40  20 – 40  15 – 25  15 – 25 
LDL  LDL  1.019 – 1.063  1.019 – 1.063  18 – 25  18 – 25  B100  B100  5 – 15  5 – 15  40 – 50  40 – 50  20 – 25  20 – 25 
HDL  HDL  1.063 – 1.21  1.063 – 1.21  5 – 12  5 – 12  AI, AII, AIV, AV, CI, CII,  AI, AII, AIV, AV, CI, CII,  5 –10  5 –10  12 – 25  12 – 25  20 – 30  20 – 30 
            CIII,  E  CIII,  E           
   
HDL, high density lipoprotein; IDL, intermediate density lipoprotein; LDL, low density lipoprotein; PL, 
phospholipid; TG, triglyceride; VLDL, very low density lipoprotein. 
 
 
Figure 1.4 shows a schematic overview of the lipoprotein fluxes within the body, table 1.4 
summarizes the properties of the lipoproteins that constitute these fluxes. In the enterocytes, 
dietary TGs are incorporated into lipoproteins called chylomicrons. Apolipoprotein B (apoB) 
is the main protein of TG containing lipoproteins (chylomicrons and VLDL). In the surface of 
chylomicrons, a truncated form of apoB is present, consisting only of 48% of the N-terminal 
part of the protein and therefore called apoB48. Editing of the apoB100 into apoB48 is 
regulated by the apoB editing complex-1 (apobec1) (77). The TG content of these particles, 
when present in the circulation, is lipolysed by the action of lipoprotein lipase (LPL) secreted 
by muscle and adipose tissue. ApoCIII inhibits the actions of LPL and apoCII enhances these 
lipolytic actions. The released fatty acids can be taken up and are subsequently reesterified 
into TGs (e.g., in adipocytes) or used as an energy source (e.g., in muscle). When taken up by 
the liver, the fatty acids are re-esterified to form TG and first stored in an intracellular TG 
pool (78). Later on, the TGs stored in this pool can be released to be subsequently secreted in 
VLDL particles. As a result of lipolysis, chylomicrons are depleted of TGs, become smaller 
and are referred to as chylomicron remnants. Both chylomicrons and chylomicron remnants 
are cleared by the liver upon binding to the low density lipoprotein (LDL) receptor, the LDL 
receptor related protein (LRP) or hepatic lipase (HL) (79).  
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For transport from the liver to peripheral tissues, TGs need to be incorporated into VLDL 
particles. VLDL-TGs are lipolyzed by LPL in a similar way as chylomicron-TGs and the fatty 
acids are taken up by the peripheral tissues. Upon depletion of the TG content, the VLDL 
particle size decreases and the relative cholesterol concentration increases. The cholesterol-
dense VLDL remnant particles are called intermediate density lipoprotein (IDL) or LDL 
particles, depending on their size and density. Insulin inhibits assembly and secretion of 
VLDL particles by the liver, as will be discussed later. 
In fasted conditions, FFAs are released from the adipose stores after lipolysis of stored 
TG by two enzymes called triglyceride hydrolase (TGH) or adipose TG lipase (ATGL) and 
hormone sensitive lipase (HSL) (80) and carried by serum albumin to the liver. Insulin 
inhibits lipolysis in peripheral tissues. Thus, upon fasting, when insulin levels are low, the 
insulin-mediated inhibition of lipolysis is absent and FFAs are released into the circulation, 
taken up by the liver and muscle and used in the ß-oxidation process. Part of the FFA not 
directly used for oxidative purposes is stored in the liver, causing the well-established hepatic 
steatosis associated with fasting  (81). 
 
 
Hepatic lipid metabolism and the actions of insulin 
 
As discussed, dietary glucose taken up by the liver is stored as glycogen or broken down in 
the glycolytic pathway to yield carbon-3 compounds such as pyruvate. Pyruvate can be 
converted to citrate in the tricarboxylic acid (TCA) cycle and citrate can be converted to 
acetyl-CoA by ATP citrate lyase (ACL) (figure 1.5). Acetyl-CoA is the moiety from which 
fatty acids are synthesized. Two acetyl-CoA can be covalently linked to each other to form 
malonyl-CoA, a process controlled by acetyl-CoA carboxylase (ACC). Subsequently, via the 
actions of fatty acid synthase (FAS), malonyl-CoA condense to form fatty acids. Fatty acids 
can be incorporated into TG via the actions of acyl-CoA synthase (ACS) and glycerol-3-
phosphate acyltransferase (GPAT). The expression of genes encoding ACL, ACC, FAS, ACS, 
and GPAT is regulated by both SREBP-1c (60) and ChREBP (82,83), whereas expression Pk 
of is regulated by ChREBP but not by SREBP-1c (84). Of notice, the SREBP-1c protein 
activity and gene transcription are regulated by insulin (61); the activity of ChREBP is 
regulated by glucose (83,85). More about these transcription factors can be found in chapter 8 
of this thesis. 
The liver is very well capable to synthesize fatty acids and TG from glucose and thus 
contributes to control of whole-body energy homeostasis. Insulin plays a key role herein, 
mainly via its effects on SREBP-1c expression (61). In the liver, insulin not only stimulates 
de novo lipogenesis but also inhibits VLDL assembly and secretion. How insulin influences 
VLDL assembly and secretion is not exactly known. Insulin might (i) decrease lipidation of 
the pre-VLDL particle via inhibition of microsomal TG transporting protein (MTTP) (86,87), 
(ii) stimulate degradation of the VLDL apolipoprotein apoB (88-90), and/or (iii) inhibit 
supply of substrates needed for VLDL assembly (78), i.e., TG, cholesterol and phospholipids. 
More details about VLDL assembly and secretion and the role of insulin herein are discussed 
in chapter 8 of this thesis. 
Comparable insulin-mediated, energy-conserving effects are found in peripheral 
tissues, especially in adipose tissues where insulin inhibits lipolysis. Of course, both hepatic 
and peripheral lipid-related effects of insulin are consistent with its role in fed conditions. In 
this condition, the liver does not need to add lipids to the total lipoprotein pool via secretion 
of VLDL and adipocytes do not need to deliver FFA to the periphery and the liver. 
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Figure 1.5. Schematic representation of the link between hepatic glucose and lipid metabolism and the role of 
insulin herein. ACC, acetyl-CoA carboxylase; ACL, ATP citrate lyase; ACS, acetyl-CoA synthase; apoB, 
apolipoprotein B; FAS, fatty acid synthase; G6P, glucose-6-phosphate; GLUT2, glucose transporter-2; GK, 
glucokinase; GS, glycogen synthase; GPAT, glycerol-phosphate acyltransferase; MTTP, microsomal triglyceride 
transport protein; PEP, phosphoenolpyruvate; PFK, phosphofructo-1-kinase; PK, pyruvate kinase; SREBP-1c, 
sterol-regulatory element-binding protein-1c; TCA, tricarboxylic acid cycle; VLDL, very low density 
lipoprotein. 
 
 
Hepatic steatosis and insulin resistance: beyond triglycerides 
 
It is important to realize that TGs are inert molecules and therefore not cytotoxic themselves. 
Fatty acids, however, might display direct (adverse) cellular effects. Increased plasma FFA 
concentrations have for long been associated with enhanced hepatic glucose production and 
insulin resistance (reviewed by Boden (91)). Fatty acids are the substrates for hepatic β-
oxidation, a process in which fatty acids are broken down to generate ketone bodies and 
energy for GNG (92). Interestingly, fatty acids stimulate transcription of genes encoding 
proteins involved in β-oxidation via binding to the nuclear peroxisome proliferator actived 
receptor-α (PPARα) (93). Thus, fatty acids might continously stimulate β-oxidation, resulting 
in elevated HGP, even under hyperinsulinemic conditions. The latter is a feature of hepatic 
insulin resistance. On the other hand, because insulin inhibits lipolysis of TG in adipose 
tissue, increased plasma FFA levels could also be the result of insulin resistance and not the 
cause of insulin resistance.  
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Various studies report other direct effects of fatty acids on insulin resistance. For instance, it 
was shown that PPARα  induces transcription of TRB3 (94), a protein that prevents PKB 
phosphorylation and activation (95). In mice, TRB3 seems to promote hyperglycemia by 
increasing glucose production by the liver due to decreased PKB-mediated GSK-3β and 
FoxO1 phosphorylation.  
Apart from their effects via PPARα, fatty acids are also source for other molecules 
suggested to interfere with insulin signaling, for instance ceramide and glycosphingolipids 
(figure 1.6). The major mammalian fatty acid palmitate is a precursor in ceramide synthesis. 
Ceramide is a precursor for numerous different glycosphingolipids (figure 1.6) (96). In 
skeletal muscle from obese insulin resistant individuals, the ceramide concentrations were 2-
fold increased (97). Moreover, in vitro studies showed that excessive ceramide concentrations 
disturb insulin signaling via inhibitory effects on PKB phosphorylation (98). Ceramide is the 
precursor for glycosphingolipids (GSLs), thus the possibility exists that the latter molecules 
might also play an important role in the development of insulin resistance (99). 
Glycosphingolipids are important components of the protein-enriched membrane domains 
called rafts and caveolae (100) and insulin receptors are predominantly found in these 
membrane structures, at least in adipocytes (101). It is therefore speculated that the close 
contact interactions between the insulin receptor and glycosphingolipids result in reduced 
receptor integrity (99). As a consequence, the tissue in which the receptor is located is less 
insulin sensitive. Indeed, it was reported that addition of the glycosphingolipid GM3 to 
cultured adipocytes suppressed phosphorylation of the insulin receptor and IRS1, resulting in 
reduced glucose uptake (102). Compared to their wild-type littermates, mice that are deficient 
for GM3 synthase, an important enzyme in glycosphingolipid synthesis, showed decreased 
glycosphingolipid levels in combination with enhanced peripheral insulin signaling (103). In 
addition, the GM3-synthase deficient mice were protected from high-fat diet induced insulin 
resistance (103).  
In conclusion, fatty acids themselves might induce insulin resistance via continuously 
enhanced GNG due to elevated β-oxidation, via PPARα-induced TRB3 transcription resulting 
in PKB blockade, via ceramide-mediated PKB inactivation, glycosphingolipids interfering 
with insulin receptor integrity, or combinations of these factors. 
 
 
 
O
N
H
R
C
C
C
H
H
H2
HO
 
Figure 1.6. Basic structure of sphingolipids. For ceramide, R is H; for glycosphingolipids, R consists of series of 
glucose, galactose, N-acetyl galactosamine, and M-acetyl neuramic moieties. 
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Animal models of hepatic steatosis 
 
Several animal models have proven to be useful tools in metabolic studies, because whole-
body metabolism is a complex network of various different factors that influence each other. 
Such interplay is necessary to ensure proper regulation of energy homeostasis needed to 
maintain life in under varying conditions.. For instance, one can argue that the main goal of 
whole-body glucose metabolism is to provide glucose to the brain, because this organ needs 
glucose to function. The brain is, however,  not capable to synthesise its alternate energy 
sources, ketone bodies, by oxidation of amino acids or fatty acids without undergoing adverse 
structural and functional damage (104). Thus, the liver is the organ that produces glucose and 
ketone bodies, and secretes VLDL, depending on the overall metabolic condition of the body, 
simply to maintain whole-body energy homeostasis. Factors derived from peripheral tissues, 
such as leptin, adiponectin and fatty acids, and those derived from the liver, such as glucose, 
TGs and ketone bodies, all act together to help maintaining this homeostasis.  
Knowing this, it is easy to imagine that, to study the effects of hepatic steatosis on 
insulin sensitivity, experiments with animals are preferred above those with isolated cells. 
Recently, Den Boer et al. (105) published an overview of the role of animal models of hepatic 
steatosis for research on insulin sensitivity. The authors concluded that complex interactions 
between endocrine, metabolic, and transcriptional pathways are involved in TG-induced 
hepatic insulin resistance. Thus, the liver seems be passively and actively involved in insulin 
resistance associated with hepatic steatosis. More recently, studies from Rossetti’s group 
(106-108) emphasised the role of the brain in the regulation of the actions of insulin on the 
liver. The overall conclusion from these studies is that, in extreme conditions, the insulin-
mediated control of HGP is controlled by the brain. So far, no studies were performed on the 
role of the brain in the other aspects of hepatic insulin sensitivity, e.g. control of VLDL 
production. 
 
 
Objectives and outline of this thesis 
 
From the studies discussed in this introduction, it is clear that animal models of hepatic 
steatose are useful tools. We therefore performed in vivo experiments to study the effect of 
hepatic steatosis on insulin sensitivity in various animal models. In chapters 2, 4 and 5, the 
leptin-deficient ob/ob mice were used. These mice show enhanced de novo lipogenesis (30) 
that is considered a major cause of their hepatic steatosis. In chapter 2, we questioned whether 
the hyperglycemia seen in ob/ob mice was the result of reduced peripheral glucose clearance 
or enhanced HGP. Chapter 4 describes studies in which both hepatic and peripheral insulin 
sensitivity was investigated in more detail. For this, we used the “golden standard” to 
determine insulin sensitivity: the hyperinsulinemic euglycemic clamp technique. In the 
studies described in chapter 5 we used the ob/ob mice to study the effects of a novel inhibitor 
of the glycosphingolipid synthesis, the iminosugar derivative N-(5’-adamantane-1’-yl-
methoxy)-pentyl-1-deoxynojirimycin (AMP-DNM). In these studies, insulin sensitivity was 
tested using the hyperinsulinemic euglycemic clamp technique described in chapter 4.  
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It was shown in previous studies that pharmacological LXR activation results in severe 
hepatic steatosis (109) and we used this model in the studies described in chapters 3 and 4. In 
chapter 3, we questioned whether LXR-induced hepatic steatosis resulted in affected VLDL-
TG production. In chapter 4 we investigated whether hepatic and peripheral insulin sensitivity 
of glucose metabolism was affected due to this hepatic steatosis. In the studies described in 
chapter 6, we studied whether hepatic steatosis due to pharmacological inhibition of the rate-
controlling enzyme in β-oxidation, carnitine palmitoyl transferase-1 (CPT1), affected insulin 
sensitivity of VLDL production. In the studies described in chapter 7, we questioned which 
lipogenic transcription factor (SREBP-1c, LXRα or ChREBP) was responsible for enhanced 
lipogenic gene expression upon pharmacological inhibition of glucose-6-phosphatase. 
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Summary 
 
Aims/hypothesis  Leptin-deficient ob/ob mice are hyperinsulinaemic and hyperglycaemic; 
however, the cause of hyperglycaemia remains largely unknown. Methods  Glucose 
metabolism in vivo in 9-h fasted ob/ob mice and lean littermates was studied by infusing [U-
13C]-glucose, [2-
13C]-glycerol, [1-
2H]-galactose and paracetamol for 6 h, applying mass 
isotopomer distribution analysis on blood glucose and urinary paracetamol-glucuronide. 
Results  When expressed on the basis of body weight, endogenous glucose production (109 ± 
23 vs 152 ± 27 µmol·kg
–1·min
–1, obese versus lean mice, p<0.01) and de novo synthesis of 
glucose-6-phosphate (122 ± 13 vs 160 ± 6 µmol·kg
–1·min
–1, obese versus lean mice, p<0.001) 
were lower in ob/ob mice than in lean littermates. In contrast, glucose cycling was greatly 
increased in obese mice (56 ± 13 vs 26 ± 4  µmol·kg
–1·min
–1, obese versus lean mice, 
p<0.001). As a result, total hepatic glucose output remained unaffected (165 ± 31 vs 178 ± 
28 µmol·kg
–1·min
–1, obese vs lean mice, NS). The metabolic clearance rate of glucose was 
significantly lower in obese mice (8 ± 2 vs 18 ± 2 ml·kg
–1·min
–1, obese versus lean mice, 
p<0.001). Hepatic mRNA levels of genes encoding for glucokinase and pyruvate kinase were 
markedly increased in ob/ob mice. Conclusions/interpretation  Unaffected total hepatic 
glucose output in the presence of hyperinsulinaemia reflects hepatic insulin resistance in 
ob/ob mice, which is associated with markedly increased rates of glucose cycling. 
Hyperglycaemia in ob/ob mice primarily results from a decreased metabolic clearance rate of 
glucose. 
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Introduction 
 
Hyperinsulinaemia and fasting hyperglycaemia are hallmarks of type 2 diabetes. Insulin 
resistance of peripheral organs (muscle and adipocytes), as well as of the liver, may contribute 
to fasting hyperglycaemia. Peripheral insulin resistance reduces the ability of peripheral 
organs to clear glucose from the circulation. Hepatic insulin resistance develops in two stages. 
During the early stages in the development of type 2 diabetes, characterised by 
hyperinsulinaemia and normoglycaemia, hepatic glucose production is still normal under 
fasting conditions. However, during absorptive phases when insulin concentrations are 
elevated, hepatic glucose production remains inappropriately high. At later stages in the 
development of type 2 diabetes in humans, hepatic glucose production starts to increase even 
under fasting conditions (1). 
Both gluconeogenesis and glycogenolysis may contribute to elevated hepatic glucose 
production. Furthermore, data indicates that cycling of glucose, the process of sequential 
glucose uptake and subsequent phosphorylation by glucokinase and dephosphorylation by 
glucose-6-phosphatase (G6Pase), occurs at increased rates in humans with type 2 diabetes 
(2,3). Little is known about the quantitative role of glucose cycling in the increased 
production of hepatic glucose in type 2 diabetes. Depending on the methodologies used for 
quantification of hepatic glucose fluxes, increased glucose cycling may affect the estimation 
of rates of gluconeogenesis and glycogenolysis. 
Leptin-deficient ob/ob mice suffer from severe obesity and diabetes due to leptin 
deficiency, and provide a model for type 2 diabetes. These mice exhibit age-dependent 
hyperglycaemia and hyperinsulinaemia. Quantitative data on the perturbations of glucose 
metabolism in these mice in vivo are scarce. In vitro studies on perfused isolated livers of 
ob/ob mice have shown that glycogen turnover is increased (4). In addition, glucose cycling 
rates have been shown to be greatly increased in hepatocytes isolated from 24-h fasted ob/ob 
mice (5). 
Novel methodologies using multiple stable isotopes in vivo now allow the 
determination of flux rates through the separate metabolic pathways involved in hepatic 
carbohydrate metabolism (6-8). In the current study, we used these methods to evaluate the 
quantitative role of gluconeogenesis, glycogenolysis and glucose cycling in hyperglycaemia 
in modestly fasted ob/ob mice. 
 
 
Experimental procedures 
 
Animals 
Female ob/ob mice (n=7) and lean littermates (n=7), 8 weeks of age and on a C57Bl/6 genetic 
background, were purchased from Harlan (Zeist, The Netherlands). The mice were housed in 
a temperature-controlled (21 °C) room with a dark–light cycle of 12 h each. Experimental 
procedures were approved by the Ethics Committee for Animal Experiments of the State 
University Groningen. Mice were fitted with a permanent catheter in the right atrium via the 
right jugular vein, as described previously (9). Mice were allowed to recover from surgery for 
at least 4 days. 
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Materials 
The following isotopes were used: [2-
13C]-glycerol (99% 
13C atom percent excess), [1-
2H]-
galactose (98% 
2H atom percent excess) (Isotec, Miamisburg, Ohio, USA), [U-
13C]-glucose 
(99% 
13C atom percent excess) (Cambridge Isotope Laboratories, Andover, Mass., USA). All 
chemicals used were reagent pro analysis grade. Blood spots and urine were collected on 
Schleicher and Schuell No. 2992 filter paper (Schleicher and Schuells, ‘s Hertogenbosch, The 
Netherlands). Infusates were freshly prepared and sterilised by the Hospital Pharmacy at the 
day before the experiment. 
 
Animal experiments 
Experiments were performed in awake, chronically catheterised mice, essentially as described 
previously (10). Mice were fasted for 9 h, after which they were placed in metabolic cages to 
allow frequent collection of blood spots and urine. Mice were infused with a sterile solution 
containing [U-
13C]-glucose (13.9 µmol/ml), [2-
13C]-glycerol (160 µmol/ml), [1-
2H]-galactose 
(33 µmol/ml) and paracetamol (1.0 mg/ml) at a rate of 0.6 ml/h. During the experiment, blood 
glucose was measured using EuroFlash test strips (LifeScan Benelux, Beerse, Belgium). 
Blood spots were collected on filter paper before the start of the infusion and hourly 
afterwards until 6 h after the start of the infusion. Blood spots were air-dried and stored at 
room temperature until analysis. Timed urine samples were collected on filter paper strips at 
hourly intervals. Strips were air-dried and stored at room temperature until analysis. At the 
end of the experiment, animals were anaesthetised with isoflurane, and a large blood sample 
was collected in heparin-containing tubes by heart puncture. The sample was centrifuged 
immediately and stored at –20 °C until analysis. The liver was quickly excised, weighed and 
immediately frozen in liquid nitrogen. 
 
Determination of metabolite concentrations 
Plasma was isolated from blood by centrifugation, and liver tissue was homogenised. 
Commercially available kits were use to determine plasma levels of ß-hydroxybutyrate, 
lactate (Roche Diagnostics, Mannheim, Germany) and NEFA (Wako Chemicals, Neuss, 
Germany). Plasma insulin levels were determined by RIA (RI-13K; Linco Research, St. 
Charles, Mo., USA). Total liver protein content was determined according to the method of 
Lowry et al. (11). Hepatic glycogen was determined by sonication after extraction with 1 
mol/l KOH. The extract was incubated at 90 °C for 30 min, cooled and then adjusted to pH 
4.5 by the addition of 3 mol/l acetic acid. Precipitated protein was removed by centrifugation. 
Glycogen was converted to glucose by treating the samples with amyloglucosidase. A glucose 
assay was then performed at pH 7.4 with ATP, NADP
+, hexokinase and G6P dehydrogenase. 
Liver samples for the determination of G6P were treated by sonication in a 5% (w/v) 
HClO4 solution. Precipitated protein was removed by rapid centrifugation at 20000 g for 1 
min in a cold microcentrifuge, and the supernatant was neutralised to pH 7 by the addition of 
small amounts of a solution containing 2 mol/l KOH and 0.3 mol/l MOPS. Levels of G6P 
were determined fluorimetrically with NADP
+ and G6P dehydrogenase.  
 
Hepatic mRNA levels 
Total RNA was isolated from liver tissue using the Trizol method (Invitrogen, Paisley, UK). 
Using random primers, RNA was converted to cDNA with M-Mulv-RT (Roche Diagnostics) 
according to the manufacturer’s protocol. The cDNA levels of the genes of interest were 
measured by RT-PCR using the ABI Prism 7700 Sequence Detection System (Applied 
Biosystems, Foster City, Calif., USA). An amount of cDNA equivalent to 20 ng of total RNA 
was amplified using the qPCR core kit (Eurogentec, Seraing, Belgium) according to the 
manufacturer’s protocol with the appropriate forward and reverse primers (Invitrogen) and a 
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template-specific 3’-TAMRA, 5’-FAM-labelled Double Dye Oligonucleotide probe 
(Eurogentec). Calibration curves were run on serial dilutions of pooled cDNA solutions as 
used in the assay. The data were processed using the ABI Sequence Detector v.1.6.3 (Applied 
Biosystems). Quantified expression levels were within the linear part of the calibration 
curves. PCR results were normalised by 18S-rRNA levels. The sequences of the primers and 
probes used in this study are listed in table 2.1.  
 
 
 
 
Table 2.1. Sequences of the primers and probes used in PCR measurements 
 
Gene Sense  Sequence  GeneBank  no. 
β-actin  Forward ACCCACACTGTGCCCATCTAC NM_007393 
  Reverse GCTCGGTCAGGATCTTCATGA   
  Probe AGGGCTATGCTCTCCCTCACGCCA  
18S-rRNA  Forward CGGCTACCACATCCAAGGA X00686 
  Reverse CCAATTACAGGGCCTCGAAA   
  Probe CGCGCAAATTACCCACTCCCGA   
G6ph  Forward CTGCAAGGGAGAACTCAGCAA  NM_008061 
  Reverse GAGGACCAAGGAAGCCACAAT   
  Probe TGCTCCCATTCCGCTTCGCCT   
G6Pt  Forward GAGGCCTTGTAGGAAGCATTG  NM_008063 
  Reverse CCATCCCAGCCATCATGAGTA   
  Probe CTCTGTATGGGAACCCTCGCCACG  
Gk  Forward CCTGGGCTTCACCTTCTCCTT  NM_010292 
  Reverse GAGGCCTTGAAGCCCTTGGT   
  Probe CACGAAGACATAGACAAGGGCATCCTGCTC  
Gp  Forward GAAGGAGGCAAACGGATCAAC  NM_133198 
  Reverse TCACGATGTCCGAGTGGATCT   
  Probe CCTCTGCATCGTGGGCTGCCA   
Gs  Forward GCTCTCCAGACGATTCTTGCA  NM_145572 
  Reverse GTGCGGTTCCTCTGAATGATC   
  Probe CCTCTACGGGTTTTGTAAACAGTCACGCC   
Pk  Forward CGTTTGTGCCACACAGATGCT  NM_013631 
  Reverse CATTGGCCACATCGCTTGTCT   
  Probe AGCATGATCACTAAGGCTCGACCAACTCGG   
Pepck  Forward GTGTCATCCGCAAGCTGAAG  NM_011044 
  Reverse CTTTCGATCCTGGCCACATC   
 Probe  CAACTGTTGGCTGGCTCTCACTGACCC  
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Figure 2.1. Schematic model of calculated hepatic carbohydrate fluxes. The major metabolic pathways and 
enzymatic reactions involved in hepatic carbohydrate metabolism that share G6P as a metabolite are shown, 
apart from glycolysis, which cannot be assessed in this model. These pathways are as follows: (i) de novo 
synthesis of G6P; (ii) glycogenolysis; (iii) glucokinase; (iv) glucose-6-phosphatase; and (v) glycogen synthesis. 
Gluconeogenesis is represented by (i) and (iv). 
 
 
Mass isotopomer distribution analysis 
Glucose and paracetamol-glucuronic acid (Par-GlcUA) were extracted from blood spot and 
urine filter paper strips respectively, derivatised, and measured by GC-MS, essentially as 
described previously (8,10). The fractional isotopomer distribution according to GC-MS (m0–
m6) was corrected for the fractional distribution due to the natural abundance of 
13C by 
multiple linear regression, as described by Lee et al. (6) to obtain the excess mole fraction of 
mass isotopomers M0–M6 due to incorporation of infused labelled compounds, i.e. [2-
13C]-
glycerol, [U-
13C]-glucose and [1-
2H]-galactose. 
Figure 2.1 shows a graphical representation of the isotopic model applied in which the 
following metabolic pathways are considered: (i) de novo synthesis of G6P; (ii) 
glycogenolysis; (iii) glucokinase; (iv) glucose-6-phosphatase; and (v) glycogen synthesis. 
Gluconeogenesis is represented by the combination of the pathways (i) and (iv). Glycolysis is 
not considered in this model. Paracetamol, [2-
13C]-glycerol, [U-
13C]-glucose and [1-
2H]-
galactose were used to calculate flux rates through the pathways mentioned above. 
Paracetamol, as its glycoconjugate Par-GlcUA, was used to sample UDP-glucose. 
Incorporation of [2-
13C]-glycerol into blood glucose and urinary Par-GlcUA was used to 
estimated the fractional contributions of de novo synthesis of G6P to blood glucose and UDP-
glucose (via Par-GlcUA) respectively. These fractional contributions were subsequently 
converted into absolute rates of gluconeogenic flux into each of the compounds by 
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multiplying by the rate of appearance of blood glucose and UDP-glucose (via Par-GlcUA) 
respectively. The rates of appearance of blood glucose and UDP-glucose were calculated from 
the isotopic dilution of [U-
13C]-glucose and [1-
2H]-galactose in blood glucose and urinary 
Par-GlcUA respectively. 
The whole-body blood glucose production rate [Ra(glc;whole body)], equal to blood 
glucose disposal [Rd(glc)] at isotopic steady-state, was calculated according to:  
 
  Ra(glc;whole body) = Rd(glc) = M6(glc)infuse/M6(glc)blood x infusion(glc;M6)      (1) 
 
in which M6(glc)infuse is the excess mole fraction of infused [U-
13C]-glucose, M6(glc)blood is 
the excess mole fraction of blood [U-
13C]-glucose, and infusion(glc;M6) is the infusion rate of 
uniformly labeled [U-
13C]-glucose. 
Metabolic clearance rate of blood glucose [MCR(glc)] was calculated according to:  
 
  MCR(glc) = Rd(glc)/[glc]          (2) 
 
where [glc] is the blood glucose concentration in mmol/l. 
The rates of endogenous glucose production [Ra(glc;endo)] were calculated according to: 
 
Ra(glc;endo) = Ra(glc;whole body) – infusion(glc;M6)        (3) 
 
The rates of whole-body production of UDP-glucose [Ra(UDPglc;whole body)] were 
calculated according to:  
 
  Ra(UDPglc;whole body) = M1(gal)infuse/M1(Par-GlcUA) x infusion (gal;M1)     (4) 
 
in which M1(gal)infuse is the excess mole fraction of infused [1-
2H]-galactose, M1(Par-GlcUA) 
is the excess mole fraction of urinary Par-[1-
2H]-GlcUA, and infusion(gal;M1) is the infusion 
rate of [1-
2H]-galactose. Ra(UDPglc;whole body) was calculated assuming a constant and 
complete entry of infused galactose into the hepatic UDP-glucose pool. Furthermore, it was 
assumed that the fractional isotopomer distribution observed for Par-GlcUA reflects the 
fractional isotopomer distribution for UDP-glucose. 
The rate of appearance of endogenously produced UDP-glucose [Ra(UDPglc;endo)] 
was calculated according to:  
 
  Ra(UDPglc;endo) = Ra(UDPglc;whole body) – infusion(gal;M1)    (5) 
 
In the isotopic model applied, stable isotopically labelled compounds, i.e. [1-
2H]-galactose 
and [U-
13C]-glucose, were used that did not lose their labeled atom(s) upon entering 
metabolism. As a consequence, these compounds can re-enter the circulation (recycling), 
acting as an additional infusion of labeled compounds of unknown magnitude, which add to 
the excess mole fractions observed. This results in an underestimation of the rates of 
appearance of these compounds (12). The contribution of recycling should therefore be added 
to the calculated rates of appearance of endogenous compounds to obtain the total rates of 
appearance of these compounds (12). To calculate the recycling of [U-
13C]-glucose and [1-
2H]-galactose, two exchange factors are introduced: the fractional contribution of blood 
glucose to UDP-glucose formation [c(glc)], and the fractional contribution of UDP-glucose to 
blood glucose [c(UDPglc)]. These two factors are calculated according to:  
 
  c(glc) = M6(Par-GlcUA)/M6(glc)blood        ( 6 )  
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in which M6(Par-GlcUA) is the excess mole fraction of urinary Par-[U-
13C]-GlcUA; and 
 
 c(UDPglc)  =  M1(glc)blood/M1(Par-GlcUA)       (7) 
 
in which M1(glc)blood is the excess mole fraction of blood [1-
2H]-glucose. The associated rates 
of recycling of blood glucose [R(r(glc))] and of UDP-glucose [R(r(UDPglc))] were calculated 
as follows:  
 
  R(r(glc)) = (c(glc)/(1 - c(glC))) x Ra(glc;endo)            (8) 
  R(r(UDPglc)) = (c(UDPglc)/(1 - c(UDPglc)))  x  Ra(UDPglc;endo)    (9) 
 
Total rates of endogenous glucose production [total Ra(glc;endo)] and endogenous UDP-
glucose [total Ra(UDPglc;endo)] are calculated according to:  
 
  total  Ra(glc;endo)  =  Ra(glc;endo)  +  R(r(glc))       (10) 
  total Ra(UDPglc;endo) = Ra(UDPglc;endo) + R(r(UDPglc))          (11) 
 
The fractional contribution of the de novo synthesis of G6P to the production of glucose 
[f(glc)] and UDP-glucose [f(UDPglc)] was calculated from the incorporation of [2-
13C]-
glycerol into glucose and Par-GlcUA respectively, as described in detail elsewhere (7,8). The 
rates of the gluconeogenic fluxes into blood glucose [GNG(glc)] and into UDP-glucose 
[GNG(UDPglc)] were calculated according to:  
 
  GNG(glc) = f(glc) x (total Ra(glc;endo) + infusion(glc;M6))     (12) 
  GNG(UDPglc) = f(UDPglc) x (total Ra(UDPglc;endo) + infusion(gal;M1)   (13) 
 
The de novo synthesis of G6P [GNG(G6P)] is the sum of GNG(glc) and GNG(UDPglc), 
corrected for the exchange of label between blood glucose and UDP-glucose, calculated 
according to:  
 
  GNG(G6P) = GNG(glc) x (1 - c(UDPglc)) + GNG(UDPglc) x (1 - c(glc))    (14) 
 
The contribution of glycogenolysis to blood glucose formation [GLY(glc)] and UDP-glucose 
formation [GLY(UDPglc)] was calculated according to:  
 
  GLY(glc)  =  total  Ra(glc;endo)  –  GNG(glc)       (15) 
 
in which the contribution of glycogenolysis to the total rate of appearance of glucose in blood 
is equal to the part that is not derived from gluconeogenesis; and  
 
  GLY(UDPglc) = total Ra(UDPglc;endo) – GNG(UDPglc) – glc(UDPglc)    (16) 
 
in which glc(UDPglc) represents the contribution of blood glucose to UDP-glucose, which 
was calculated according to:  
 
  glc(UDPglc) = c(glc) x (total Ra(UDPglc;endo) + infusion(gal;M1))    (17) 
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In contrast to blood glucose, the total rate of appearance of UDP-glucose is determined by: (i) 
gluconeogenic flux from G6P; (ii) glycogenolysis; and (iii) the flux of blood glucose into the 
UDP-glucose pool. The flux of glycogen into UDP-glucose is a measure of glycogen/glucose-
1-phosphate cycling (8). 
The individual isotopic fluxes through the various enzymes involved in hepatic 
glucose metabolism were calculated based on a factorial model by adding the different 
contributions to the flux rates. For the enzymes glucokinase (Gk), glucose-6-phosphatase 
(G6pase), glycogen synthase (Gs) and glycogen phosphorylase (Gp) the flux rates were 
calculated according to:  
 
  Gk  =  glc(UDPglc)  +  R(r(glc))         (18) 
 
in which only two contributions to the flux through Gk are considered (i.e. the flux of blood 
glucose into UDP-glucose and glucose / G6P cycling), whereas glycolysis is not included  
 
  G6pase = total Ra(glc;endo) = GNG(glc)  +  GLY(glc)      (19) 
  Gs  =  Ra(UDPglc;whole  body)         (20) 
  Gp  =  GLY(glc)  +  GLY(UDPglc)         (21) 
 
in which two contributions to the flux through glycogen phosphorylase are considered (i.e. 
glycogenolysis resulting in blood glucose appearance and glycogen/G1P cycling). 
 
Statistical analysis 
All values are means ± SD. Levels of significance of difference of metabolite concentrations, 
gene expression and the values of the individual time points during isotope infusion 
experiments were determined using the non-parametric Mann–Whitney test for unpaired data. 
Levels of significance of differences between the averages of the values of the fluxes at 
individual time points between 3 and 6 h during the experiment were estimated using repeated 
measures ANOVA. A p-value of less than 0.05 was considered statistically significant. 
 
 
Results 
 
Body and liver weights of obese mice were more than double those of lean mice (table 2.2). 
Consequently, normalisation of liver weight to body weight yielded no difference between 
obese and lean mice. Protein contents per gram of liver tissue were not significantly different 
between obese and lean mice. Hepatic glycogen content was mildly elevated in ob/ob mice, 
whereas G6P levels were not significantly different between the two groups. At the end of the 
experiment, plasma NEFA concentrations were almost two-fold higher in the ob/ob mice than 
in the lean mice. Plasma lactate and alanine concentrations were similar in the two groups, 
whereas plasma ß-hydroxybutyrate concentrations were elevated in ob/ob mice.  
Figure 2.2 shows the blood glucose concentrations of the two groups of mice during 
the infusion experiment. Obese mice were clearly hyperglycaemic (8.8 ± 0.5 vs. 13.2 ± 1.9 
mmol/l, lean versus obese mice, p<0.05) and hyperinsulinaemic. Insulin concentrations 
remained constant (45 ± 10 pmol/l at t=0 and 60 ± 45 pmol/l at t=6 h) during the experiment 
in lean mice, but decreased from 900 ± 480 pmol/l at t=0 to 435 ± 270 pmol/l at t=6 h in 
ob/ob mice. 
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Table  2.2. Hepatic and plasma parameters in ob/ob mice and lean littermates 
 
  Lean mice (n=7)  Ob/ob mice (n=7) 
Liver  
 
body weight (g)  22.7 ± 1.2  49.7 ± 3.0 *
 
liver weight (g)  1.1 ± 0.0  2.6 ± 0.4
 *
 
relative liver weight (% body weight)  4.7 ± 0.3  5.0 ± 0.8 
total liver protein (mg)  156 ± 20  325 ± 63 * 
liver protein content (mg/g liver)  144 ± 18  127 ± 18 
G6P (nmol/g liver)  118 ± 56  153 ± 34 
glycogen (µmol glucose/g liver)  179 ± 16  207 ± 11 * 
Plasma    
glucose (mmol/l)  8.8 ± 0.5  13.2 ± 1.9 * 
insulin (pmol/l)  45 ± 10  900 ± 480 * 
NEFA (mmol/l)  0.5 ± 0.1  0.9 ± 0.2 * 
ß-hydroxybutyrate (mmol/l)  0.5 ± 0.4  3.1 ± 1.4 * 
alanine (µmol/l)  133 ± 113  176 ± 33 
lactate (mmol/l)  3.5 ± 1.0  3.5 ± 1.0 
 
Figure 2.3 shows endogenous glucose production [Ra(glc;endo), equation (3)] and the 
metabolic clearance rate of glucose [MCR(glc), equation (2)]. At isotopic steady-state, i.e. 
between 3 h and 6 h after the start of the infusion of labelled compounds, endogenous glucose 
production was significantly decreased in ob/ob mice (152 ± 27 vs. 109 ± 23 µmol·kg
–1·min
–1, 
lean versus obese mice, p<0.001), as was the metabolic clearance rate of glucose (18 ± 2 vs. 8 
± 2 ml·kg
–1·min
–1, lean versus obese mice, p<0.001).  
The rate of de novo synthesis of G6P [GNG(G6P), equation (14)] in obese mice was 
significantly lower than that in lean control mice (160 ± 6 vs. 122 ± 13 µmol·kg
–1·min
–1, lean 
versus obese mice, p<0.001) (figure 2.4a). In obese mice, the partitioning of newly 
synthesised G6P towards plasma glucose or glycogen was similar to that in lean control mice 
(figure 2.4b). In contrast, glucose cycling [R(r(glc)), equation (8)] was greatly enhanced in 
obese mice (56 ± 13 µmol·kg
–1·min
–1 vs. 26 ± 4 µmol·kg
–1·min
–1, obese versus lean mice, 
p<0.001) (figure 2.5a). Consequently, total endogenous glucose production, i.e. the sum of 
endogenous glucose production and glucose cycling, was not significantly different in obese 
and lean mice (178 ± 28 vs. 165 ± 31 µmol·kg
–1·min
–1, lean versus obese mice, NS) (figure 
2.5b). 
Figure 2.6 shows the calculated mean values obtained at steady-state for the individual 
fluxes through the various pathways of hepatic glucose metabolism. As anticipated, the 
calculated isotopic flux through glucokinase [Gk, equation (18)] was strongly increased in 
obese mice. The glucose-6-phosphatase flux [G6pase, equation (19)], equivalent to the total 
endogenous glucose production, was unchanged. The flux through glycogen phosphorylase 
[Gp, equation (21)] was not altered significantly, whereas the glycogen synthase flux [Gs, 
equation (20)] was significantly decreased in obese mice compared with lean littermates. 
Table 2.3 provides a summary of the calculated flux rates, normalised to either body 
weight or amount of liver protein (liver is the major glucose-producing organ). Independent of 
the method of normalisation, the same conclusions can be drawn with respect to the changes 
in glucose metabolism in lean and ob/ob mice. 
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Figure 2.2.  Plasma glucose concentrations during infusion experiments. Blood glucose levels in lean (empty 
circles, n=7) and ob/ob (filled circles, n=7) mice. Values shown are the means ± SD. * p<0.05 vs lean animals. 
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Figure 2.3.  Endogenous glucose production (a) and metabolic clearance (b) during the infusion experiments in 
lean (empty circles, n=7) and ob/ob (filled circles, n=7) mice. Values shown are the means ± SD. * p<0.05 vs 
lean animals. 
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Levels of expression of relevant genes in the liver of lean and ob/ob mice are shown in figure 
2.7. The expression of the genes encoding glucokinase and liver-type pyruvate kinase were 
strongly up-regulated in the liver of ob/ob mice. The mRNA levels of other key enzymes 
involved in carbohydrate metabolism (i.e. phosphoenolpyruvate carboxykinase, G6P 
hydrolase and G6P translocase) did not differ significantly between obese and lean mice. It 
has previously been shown that the expression of the genes encoding sterol regulatory 
element-binding protein-1c (Srebp-1c) and peroxisome proliferator-activated receptor-γ  
(Pparγ), transcription factors involved in control of hepatic glucose and fat metabolism, is 
significantly elevated in the liver of ob/ob mice compared with that of their lean littermates 
(13). Furthermore, mRNA levels of Irs-1, but particularly Irs-2, were observed to be strongly 
repressed in the liver of obese mice (13). 
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Figure 2.4. (a) The rate of de novo synthesis of G6P in lean (empty circles) and ob/ob (filled circles) mice. (b) 
The partitioning of the rates of de novo synthesis of G6P to UDP-glucose (shaded area) and to glucose (white 
area) during the last 3 h of the infusion experiment in lean and ob/ob mice. Values shown are the means ± SD 
(n=7 for each group). * p<0.05 vs. lean animals. 
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Table 2.3. Summary of the calculated values of the various flux rates, using the isotopic model shown in figure 
2.1 normalised to either body weight or liver protein. 
 
  Normalised to body weight  Normalised to liver protein 
  (µmol·kg
–1·min
–1) (µmol·g  protein
–1·min
–1) 
  lean  Ob/ob  lean  Ob/ob 
De novo synthesis of G6P (Pepck)  160 ± 6  122 ± 13 *
  23.6 ± 0.9  18.8 ± 2.0 * 
Endogenous glucose production  157 ± 27  109 ± 23 *  23.1 ± 4.0  16.8 ± 3.5 * 
Glucose cycling  26 ± 4  56 ± 13 *  3.8 ± 0.6  8.6 ± 2.0 * 
Total endogenous glucose production (G6Pase)  178 ± 28  165 ± 31  26.2 ± 4.1  25.4 ± 4.8 
Glucokinase  73 ± 11  82 ± 18 *  6.3 ± 1.6  12.6 ± 2.8 * 
Glycogen synthase  100 ± 35  67 ± 16 *  14.7 ± 5.2  10.3 ± 2.5 * 
Glycogen phosphorylase  40 ± 18  50 ± 15  5.9 ± 2.7  7.7 ± 2.3 
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Figure 2.5. (a)  Rate of cycling between glucose and G6P during the infusion experiment in lean (empty circles) 
and ob/ob (filled circles) mice. (b) The contributions of endogenous glucose production (white area) and glucose 
cycling (shaded area) to the total endogenous glucose production in lean and ob/ob mice during the last 3 h of 
the infusion experiment. Values shown are the means ± SD (n=7 for each group). * p<0.05 vs lean animals. 
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Discussion 
 
The leptin-deficient ob/ob mouse is a commonly used mouse model of type 2 diabetes, but 
quantitative in vivo data on the disturbances that underlie hyperglycaemia in this model are 
sparse. In this study, we determined flux rates through various pathways relevant in hepatic 
carbohydrate metabolism in lean and ob/ob mice. When expressed per unit of body weight or 
liver protein, hepatic glucose metabolism activity was, in general, suppressed in obese mice 
compared with that in their lean littermates. However, glucose cycling was an exception to 
this, and was observed to be greatly increase d  i n  o b e s e  m i c e .  I n terestingly, the newly 
produced G6P was not preferentially directed towards plasma glucose in ob/ob mice, but 
instead was partitioned to glycogen stores to a similar extent as that observed in lean mice. 
Furthermore, the expression of genes of key enzymes involved in glucose metabolism were 
similar in livers of ob/ob and lean mice, apart from the expression of glucokinase and liver-
type pyruvate kinase which was increased in the liver of ob/ob mice. 
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Figure 2.6.   Separate fluxes through the relevant metabolic pathways involved in hepatic carbohydrate 
metabolism during the last 3 h of the infusion experiment in lean and ob/ob mice. Values shown are the means ± 
SD (n=7 for each group). * p<0.05 vs lean animals. 
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Figure 2.7.  Gene expression of enzymes involved in glucose metabolism at the end of the infusion experiment in 
lean (n=3) and ob/ob (n=3) mice. Levels of cDNA were measured by RT-PCR as described in the Materials and 
methods section. Data are expressed relative to 18S-rRNA and the results of the lean animals are set equal to 1. 
Expression of genes was normalised to 18S-rRNA, since the level of ß-actin mRNA in livers of obese mice was 
increased by ~30% when normalised by liver weight. In contrast, 18S-rRNA levels were similar in livers of 
obese and lean mice. * p<0.05 vs lean animals. G6ph, G6P hydrolase; G6pt, G6P translocase; Gk, glucokinase; 
Gp, glycogen phosphorylase; Gs, glycogen synthase; Pepck, phosphoenolpyruvate carboxykinase; Pk, pyruvate 
kinase. 
 
Before discussing the results, some methodological issues have to be addressed. In this study, 
a multiple isotope infusion protocol was used to calculate the relevant fluxes of glucose 
metabolism (7). The validity of the isotope model, with the application of glycoconjugates, 
and the mass isotopomer distribution analysis (MIDA) approach has been substantiated in 
various studies, although some controversy still remains (14,15). Since the contribution of 
glycolysis to intracellular G6P metabolism has not been included in this model, the calculated 
flux rate through glucokinase represents a minimal estimate. We have validated the 
application of MIDA in 9-h fasted C57Bl/6 mice in a separate study (10). In 24-h fasted mice, 
no stable isotopic steady-state could be obtained (10). In the current study, we compared 
hepatic glucose metabolism in groups of mice with strongly different body compositions. Our 
data show that, with respect to hepatic glucose metabolism, normalisation to body weight 
appeared to be appropriate, since the same conclusions could be drawn regardless of whether 
the data was normalised to body weight or liver protein. 
Irrespective of hyperinsulinaemia and hyperglycaemia, total glucose output (glucose-
6-phosphatase flux) was not affected, while endogenous glucose production was only 
modestly inhibited in ob/ob mice. This points to hepatic insulin resistance. Previously 
reported values of endogenous glucose production in C57Bl/6 mice are almost identical to 
those reported in this study in lean littermates of ob/ob mice (16,17). Furthermore, 
endogenous glucose production in C57Bl/6 mice could be suppressed almost completely 
during hyperinsulinaemic clamp at normal or increased glucose concentrations (16-18). The 
impaired suppression of endogenous glucose production was mainly due to the blunted 
response of de novo synthesis of G6P to the combined hyperinsulinaemia and hyperglycaemia 
in ob/ob mice. This indicates that, in the absence of leptin, insulin appears to be largely 
ineffective in suppressing hepatic de novo synthesis of G6P by an as yet unknown 
mechanism. 
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In the liver of ob/ob mice, the decreased contribution of endogenous glucose production to 
total glucose output appeared to be compensated by enhanced glucose cycling. Glucose 
cycling was increased by a factor of ~2.5 in the liver of ob/ob mice, due to an enhanced flux 
through glucokinase. A previous study reported a high rate of glucose cycling in hepatocytes 
isolated from the liver of ob/ob mice fasted for 24 h (5). Similarly, in an earlier publication, 
glucokinase activity was found to remain elevated in the liver of ob/ob mice throughout a 48-
h fast (19). Collectively, these observations indicate that, independent of the duration of 
fasting, the liver of ob/ob mice maintains a high capacity to phosphorylate glucose. 
Besides hepatic insulin resistance, peripheral organs were also found to be insulin 
resistant in ob/ob mice. Metabolic clearance of plasma glucose was decreased by a factor of 
~2 at blood glucose concentrations that were almost double that in lean mice. This indicates 
that net glucose uptake by peripheral tissue was similar in ob/ob and lean mice, irrespective of 
the elevated insulin concentrations in the obese group. Thus, hyperglycaemia in ob/ob mice is 
due to peripheral insulin resistance. This finding is in agreement with an earlier study using 
different means to investigate peripheral insulin resistance in ob/ob mice, which reported that 
uptake of 2-deoxyglucose was severely inhibited in isolated skeletal muscle of obese mice 
compared with that in lean mice (20). 
As discussed, we observed ‘normal’ rates of total glucose output and high rates of 
glucose cycling. In accordance with these observations, ‘normal’ mRNA levels of the 
gluconeogenic enzymes G6P hydrolase and phosphoenolpyruvate carboxykinase were 
observed, while mRNA levels of glucokinase and liver-type pyruvate kinase were 
significantly increased in the liver of obese mice compared to those in liver of lean 
littermates. Significant increases in mRNA levels of Srebp-1c and its target genes in 
lipogenesis, i.e. Fas and Acc1, in livers of fasted ob/ob mice have previously been reported 
(13,21). This indicates an enhanced glycolytic flux into lipogenesis. It should be realised that 
the glycolytic flux as part of the glucokinase flux cannot be assessed in the isotopic model 
applied. Recent data indicate that hyperglycaemia could directly induce increased expression 
of the genes encoding Srebp-1c and pyruvate kinase in an insulin-independent way (22). 
In humans with type 2 diabetes, there is evidence for enhanced gluconeogenesis and 
glycogenolysis after an overnight fast, particularly in patients with severe fasting 
hyperglycaemia (1,23-28). Although liver was insulin resistant in ob/ob mice, this did not 
result in enhanced hepatic glucose production. In the present study, only a moderate fasting 
hyperglycaemia was observed in ob/ob mice at 8 weeks of age. Apparently, in these mice the 
disease had not yet progressed to a more severe stage with (very) high fasting blood glucose 
concentrations. Furthermore, in most studies on (often obese) diabetic subjects, the data was 
normalised to lean body mass instead of body weight, which might have led to seemingly 
elevated values for gluconeogenic and glycogenolytic fluxes in these individuals compared 
with those in non-diabetic subjects. Until now, only very few studies have considered the role 
of glucose cycling in hepatic glucose production. There are indications that hepatic cycling of 
glucose is elevated in humans with type 2 diabetes (2,3). 
In conclusion, this study demonstrates that in ob/ob mice, de novo synthesis of G6P is 
diminished while glucose cycling is increased, resulting in an unaffected total glucose output 
by the liver. However, these observations were made where there was a background of 
hyperglycaemia and hyperinsulinaemia. This points to a co-existence of hepatic and 
peripheral insulin resistance, with peripheral insulin resistance as the cause of 
hyperglycaemia. 
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Abstract 
 
The oxysterol-activated liver X receptor (LXR) provides a link between sterol and fatty acid 
metabolism; activation of LXR induces transcription of lipogenic genes. This study shows 
that induction of the lipogenic genes Srebp-1c, Fas, and Acc1 upon administration of the 
synthetic LXR agonist T0901317 to C57BL/6J mice (10 mg/kg/day, 4 days) is associated with 
massive hepatic steatosis along the entire liver lobule and a 2.5-fold increase in very low 
density lipoprotein-triglyceride (VLDL-TG) secretion. The increased VLDL-TG secretion 
was fully accounted for by formation of larger (129 ± 9 nm versus 94 ± 12 nm, a 2.5-fold 
increase of particle volume) TG-rich particles. Stimulation of VLDL-TG secretion did not 
lead to elevated plasma TG levels in C57BL/6J mice, indicating efficient particle metabolism 
and clearance. However, T0901317 treatment did lead to severe hypertriglyceridemia in 
mouse models of defective TG-rich lipoprotein clearance, i.e. APOE*3-Leiden transgenic 
mice (3.2-fold increase) and apoE -/- LDLr -/- double knockouts (12-fold increase). 
Incubation of rat hepatoma McA-RH7777 cells with T0901317 also resulted in intracellular 
TG accumulation and enhanced TG secretion. We conclude that, in addition to raising high 
density lipoprotein cholesterol concentrations, pharmacological LXR activation in mice leads 
to development of hepatic steatosis and secretion of atherogenic, large TG-rich VLDL 
particles. 
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Introduction 
 
The nuclear liver X receptor α (LXRα; NR1H3) and LXRβ (NR1H2) are involved in the 
control of cholesterol and fatty acid metabolism. LXRα is expressed mainly in the liver 
whereas LXRβ is ubiquitously expressed (1,2). Activated LXRs heterodimerize with the 
retinoid X receptor (NR2B1) and bind to a LXR response element, consisting of two 
hexameric nucleotide direct repeats separated by four nucleotides, to induce gene 
transcription (1,2). Oxysterols constitute the physiological ligands for LXR. The most potent 
LXR-activating oxysterols are 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, and 
24(S),25-epoxycholesterol (3). Activation of LXR in macrophages results in increased 
expression of genes encoding ATP-binding cassette (ABC) cholesterol transporters ABCA1 
(4-7) and ABCG1 (8,9) and apolipoprotein E (apoE) (9). ABCA1, ABCG1, and apoE are 
involved in cholesterol efflux from macrophages toward high density lipoproteins (HDL), 
which is considered the critical first step of reverse cholesterol transport. In the liver, LXR is 
involved in transcriptional control of Cyp7A1, encoding a critical enzyme in the conversion of 
cholesterol into bile acids (3, 10), as well as in transcriptional control of ABCG5/ABCG8 
(11,12), ABC transporters implicated in biliary cholesterol excretion. Induction of intestinal 
Abca1, Abcg5, and Abcg8 expression upon LXR activation is thought to reduce the efficiency 
of cholesterol absorption and hence to accelerate fecal cholesterol disposal (4). The 
physiological role of LXR in the control of cholesterol metabolism and the possibility of 
pharmacological interventions aimed at prevention of atherosclerosis via this regulatory 
system have recently been reviewed extensively (13-17).  
In addition to cholesterol transport genes, LXR has been reported to control genes that 
encode proteins involved in de novo lipogenesis. Induced transcription has been reported for 
the gene encoding the sterol-regulatory element-binding protein-1c (SREBP-1c) (18-20), the 
transcription factor that regulates expression of various lipogenic genes, including those 
encoding acetyl-CoA carboxylase (ACC) and fatty acid synthase (21). Apart from indirect 
actions through SREBP-1c, LXR also directly influences transcription of Fas (22) and of 
genes encoding lipoprotein lipase (23), cholesterol ester transfer protein (24), and stearoyl-
CoA desaturase-1 (25).  
Recently, the availability of synthetic LXR agonists, e.g. T0901317, has provided 
more insight into metabolic consequences of LXR activation. Oral administration of 
T0901317 to C57BL/6 mice increased HDL cholesterol concentrations in plasma, probably 
related to induction of the Abca1 and Abcg1 expression (18). In addition to this potentially 
beneficial effect, treatment with LXR agonists also led to a marked increase in hepatic 
triglyceride (TG) content (18). In Lxrα/Lxrβ double knockout mice, hepatic steatosis did not 
occur upon treatment with high doses of the agonist (18). In wild type mice, but not in Lxrα  
knockout mice, hepatic TG accumulation was also observed upon feeding a high cholesterol 
diet (10). Hepatic steatosis is thought to be a result of increased fatty acid synthesis caused by 
induction of lipogenic genes. De novo lipogenesis, in turn, is thought to contribute to 
regulation of hepatic very low density lipoprotein (VLDL) production (26), but data on VLDL 
production upon LXR activation are not available. In this study, we examined the effects of 
T0901317 treatment on VLDL-TG production rates in relation to steady state plasma TG 
levels in mice. Our results demonstrate that administration of the synthetic LXR agonist 
resulted in an increased hepatic production rate of VLDL-TG, caused by formation of large 
TG-rich particles. In wild type mice, increased VLDL-TG production was compensated for by 
efficient metabolism and clearance, and no effects on fasting TG levels were seen. However, 
in mice with impaired particle clearance (apoE -/- LDLr -/- double knockouts, APOE*3-
Leiden transgenics) treatment with the LXR agonist resulted in a marked 
hypertriglyceridemia.  
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Experimental procedures 
 
Animals 
Male C57BL/6J mice (Harlan, Horst, The Netherlands), were housed in a light- and 
temperature-controlled facility. The animals were fed a commercially available lab chow 
(RMH-B, Hope Farms BV, Woerden, The Netherlands), containing 6.2% fat and ~0.01% 
cholesterol (w/w), and water ad libitum. Male transgenic mice expressing the human 
APOE*3-Leiden gene (27,28) and apoE -/- LDLr -/- double knockout mice (29) were bred at 
the animal facility of the Gaubius Laboratory (Leiden, The Netherlands) and were fed the 
same standard diet. The mice received humane care, and experimental procedures were in 
accordance with local guidelines for use of experimental animals.  
 
Plasma and liver tissue sampling 
C57BL/6J mice received 10 mg/kg LXR agonist T0901317 (kindly donated by Organon 
Laboratories, Lanarkshire, United Kingdom) or its solvent by gavage daily for 4 days. 
T0901317 was dissolved in Me2SO and Chremophor (both from Sigma) in 5% 
mannitol/water, to a final concentration of 2.5 mg/ml. On the morning of the fifth day, a large 
blood sample was collected by cardiac puncture and centrifuged. The obtained plasma was 
stored at  20 °C until analyzed. The liver was quickly removed, weighed, and frozen in 
separate portions for RNA isolation and lipid analysis. Parts of the liver were frozen in 
isopentane and used for microscopic examination.  
ApoE -/- LDLr -/- double knockout mice and APOE*3-Leiden transgenic mice were 
treated for 4 days with T0901317 (10 mg/kg/day) or its solvent as described. Before onset of 
treatment (day 0) and on day 2 of treatment, a small EDTA blood sample was collected by tail 
bleeding and plasma was obtained for measurement of triglyceride concentrations. On day 4 
of treatment, a large blood sample was obtained by cardiac puncture.  
 
In vivo VLDL triglyceride production rate 
C57BL/6J wild type mice received T0901317 or the solvent only exactly as described. On the 
fifth day, after a fasting period of 10 h, mice received an injection of 12.5 mg of Triton WR-
1339 in 100 µl of phosphate-buffered saline via the penile vein. Tail blood samples were 
taken under light halothane anesthesia before and 1, 2, and 3 h after the injection of Triton 
WR-1339. At 4 h after Triton WR-1339, a large blood sample was collected by cardiac 
puncture. The collected blood samples were used for triglyceride measurements. VLDL 
triglyceride production rate was calculated from the slope of the triglyceride concentration 
versus time curve (30). The large blood sample was used for isolation of VLDL.  
 
Hepatic RNA isolation and measurement of mRNA levels by real-time PCR (Taqman) 
Total RNA was isolated from ~30 mg of liver tissue with the TRIzol method (Invitrogen, 
Paisley, United Kingdom). RNA was converted to single stranded cDNA by a reverse 
transcription procedure with Moloney murine leukemia virus-RT (Roche Diagnostics, 
Mannheim, Germany) according to the protocol of the manufacturer using random primers. 
cDNA levels were measured by real-time PCR using the ABI Prism 7700 sequence detection 
system (Applied Biosystems, Foster City, CA).  
For the PCR amplification studies, an amount of cDNA corresponding to 20 ng of 
total RNA was amplified using the qPCR core kit (Eurogentec, Seraing, Belgium) essentially 
according to the protocol of the manufacturer and optimized for amplification of the particular 
gene using the appropriate forward and reverse primers (Invitrogen) and a template-specific 
3'-TAMRA (6-carboxytetramethylrhodamine)/5'-FAM (6-carboxyfluorescein)-labeled double 
dye oligonucleotide probe (Eurogentec). In the same experiments, calibration curves were run 
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on serial dilutions of pooled 8× concentrated cDNA solution as used in the assay, resulting in 
series containing 4, 2, 1, 0.5, 0.25, 0.125, 0.062, and 0.031 × cDNA present in the assay 
incubation. The data obtained were processed using the software program ABI Sequence 
Detector (version 1.6.3; System Applied Biosystems, Foster City, CA). All quantified 
expression levels were within the linear part of the calibration curves and were calculated by 
using these curves. PCR results were normalized to  β-Actin mRNA levels. The sequences of 
the primers and probes used in this study are listed in table 3.1.  
 
Hepatic lipid and protein analyses 
Livers were homogenized and hepatic concentrations of triglycerides, free cholesterol and 
total cholesterol were measured using commercial kits (Roche Diagnostics and Wako 
Chemicals, Neuss, Germany) after lipid extraction according to Bligh and Dyer (31) and 
redissolving the lipids in 2% Triton X-100 in water. Phospholipid content of the liver was 
determined according to Böttcher et al. (32) after lipid extraction. Protein concentrations in 
livers were determined according to Lowry et al. (33) using bovine serum albumin as 
standard (Pierce). Fatty acid composition was determined by gas chromatography after 
methylation as described previously (34).  
 
Histology 
Liver histology was examined on frozen liver sections after Oil-Red-O staining for neutral 
lipids by standard procedures.  
 
Plasma lipid analyses 
Plasma triglycerides, phospholipids, free fatty acids, HDL cholesterol, free cholesterol, and 
total cholesterol were determined using commercially available kits (Roche Diagnostics and 
Wako Chemicals). Lipoproteins of C57BL/6J mice, apoE -/- LDLr -/- double knockout mice 
and APOE*3-Leiden transgenic mice were separated using fast protein liquid chromatography 
(FPLC) on a Superose 6B 10/30 column (Amersham Biosciences). The contents of apoB100, 
apoB48, and apoA-I in the fractions were visualized by Western blotting. Proteins in the 
fractions were separated by SDS-PAGE using 4-15% gradient gels (Ready Gels, Bio-Rad) 
and transferred to nitrocellulose membranes (Hyperbound, Amersham Biosciences, 
Roosendaal, The Netherlands). The membranes were incubated with sheep anti-human apoB 
(Roche Diagnostics) or rabbit anti-human apoA-I (Calbiochem, San Diego, CA), followed by 
incubation with donkey anti-sheep IgG horseradish peroxidase or donkey anti-rabbit IgG 
horseradish peroxidase and visualized by ECL detection (all three from Amersham 
Biosciences, Uppsala, Sweden) according to the instructions from the manufacturer.  
 
VLDL isolation and analyses 
Plasma VLDL/IDL (d < 1.019 g/ml) was isolated by density gradient ultracentrifugation. For 
this, 300 µl of plasma was adjusted to 800 µl with a NaCl/KBr solution with a density of 
1.019 g/ml, containing 1 mM EDTA and NaN3, and centrifuged at 120,000 rpm in a Optima 
TM LX tabletop ultracentrifuge (Beckman Instruments, Inc., Palo Alto, CA). VLDL was 
isolated by tube slicing, and the volume was recorded by weight. ApoB100 and apoB48 were 
determined by Western blotting, using antibodies against human apoB raised in sheep. 
Triglyceride and cholesterol content were determined as described for plasma. Phospholipids 
were determined using a commercial kit (Wako Chemicals). Fatty acid composition was 
determined as described previously (34).  
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Table 3.1. Primers and probes used for Real Time PCR analysis of hepatic gene expression. 
 
Gene   Sequences (5’ to 3’) GenBank
TM accession no.
β-Actin  forward AGCCATGTACGTAGCCATCCA NM_007393 (mouse)
  reverse TCTCCGGAGTCCATCACAATG  NM_031144  (rat) 
  probe TGTCCCTGTATGCCTCTGGTCGTACCAC  
Srebp-1c  forward GGAGCCATGGATTGCACATT  AF286470  (mouse) 
 reverse  CCTGTCTCACCCCCAGCATA  Ref.  (50)  (rat) 
  probe CAGCTCATCAACAACCAAGACAGTGACTTCC  
Srebp-1a  forward GAGGCGGCTCTGGAACAGA  Ref.  (50) 
  reverse TGTCTTCGATGTCGTTCAAAACC   
  probe TGTGTCCAGTTCGCACATCTCGGC   
Acc1  forward GCCATTGGTATTGGGGCTTAC AF374170  (mouse) 
 reverse  CCCGACCAAGGACTTTGTTG  NM_022193  (rat) 
  probe CTCAACCTGGATGGTTCTTTGTCCCAGC   
Fas  forward GGCATCATTGGGCACTCCTT  AF127033  (mouse) 
 reverse  GCTGCAAGCACAGCCTCTCT  NM_017332  (rat) 
  probe CCATCTGCATAGCCACAGGCAACCTC   
Apob  forward GCCCATTGTGGACAAGTTGATC AW012827 
  reverse CCAGGACTTGGAGGTCTTGGA   
  probe AAGCCAGGGCCTATCTCCGCATCC   
Apobec-1  forward TCGTCCGAACACCAGATGCT NM_031159 
  reverse GGTGTCGGCTCAGAAACTCTGT   
  probe CCTGGTTCCTGTCCTGGAGTCCCTG   
Mttp  forward CAAGCTCACGTACTCCACTGAAG NM_008642 
  reverse TCATCATCACCATCAGGATTCCT   
  probe ACCGCAAGACAGCGTGGGCTACA   
Apoe  forward CCTGAACCGCTTCTGGGATT  NM_009696 
  reverse GCTCTTCCTGGACCTGGTCA   
  probe AAAGCGTCTGCACCCAGCGCAGG   
Hl  forward ACTGCAGGAGTGTGGCTTCAAC  NM_008280 
  reverse TGGGACTGTCGGGACTTCAG   
  probe CAAGCCATCCACCGACCACCCG   
Lpl  forward AAGGTCAGAGCCAAGAGAAGCA  NM_008509 
  reverse CCAGAAAAGTGAATCTTGACTTGGT   
  probe CCTGAAGACTCGCTCTCAGATGCCCTACA   
Pltp  forward TCAGTCTGCGCTGGAGTCTCT  NM_011125 
  reverse AAGGCATCACTCCGATTTGC   
  probe TCCCACTGCAGGCCCCACTGAA   
Vldlr  forward CCACAGCAGTATCAGAAGTCAGTGT  NM_013703 
  reverse CACCTACTGCTGCCATCACTAAGA   
  probe CAGCTGCCTGGGCCATCCTTCC   
Ldlr  forward GCATCAGCTTGGACAAGGTGT  X64414 
  reverse GGGAACAGCCACCATTGTTG   
  probe CACTCCTTGATGGGCTCATCCGACC   
Lxrα  forward GCTCTGCTCATTGCCATCAG  AF085745 
  reverse TGTTGCAGCCTCTCTACTTGGA   
  probe TCTGCAGACCGGCCCAACGTG   
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VLDL size determination 
VLDL size and volume distribution profiles were analyzed by dynamic scattering using a 
Nicomp model 370 submicron particle analyzer (Nicomp Particle Sizing Systems, Santa 
Barbara, CA). Particle diameters were calculated from the volume distribution patterns 
provided by the analyzer.  
 
Cell culture experiments 
McA-RH7777 (rat hepatoma) cells were plated in 35-mm six-well plastic dishes (Costar 
Corp., Cambridge, MA) in 2 ml of Dulbecco's modified Eagle's medium containing 10% fetal 
calf serum, 10% natural horse serum, penicillin/streptomycin, and geneticin. At a confluence 
of ~30%, the medium was removed and cells were washed with Hanks' balanced salt solution 
(HBSS) and subsequently incubated with Dulbecco's modified Eagle's medium + 10% fetal 
calf serum + 10% natural horse serum containing either 0 or 10 µM T0901317 and the above 
mentioned antibiotics. After 24 h, the medium was removed and half of the wells were 
incubated with the same medium for another 41 h. The other half of the wells were incubated 
with the same medium to which was added 25 µM [
3H]glycerol (4.4 µCi/well) for 41 h. The 
medium was then collected, centrifuged to remove debris, and stored at 4 °C until further 
analysis. Cells were washed with ice-cold HBSS and either used for RNA isolation or scraped 
into 2 ml of HBSS for lipid extraction ([
3H]glycerol- labeled cells).  
 
Lipid analyses of cells and medium 
Lipids secreted by McA-RH7777 cells into medium and cellular lipids were extracted as 
described previously (35). [
3H]TG was separated from the other lipids by thin layer 
chromatography with hexane/diethyl ether/acetic acid (80/20/1 v/v/v) as developing solvent. 
After iodine staining, the spots containing [
3H]TG (as a measure for VLDL-TG secretion) 
were scraped into vials and assayed for radioactivity by scintillation counting. Part of the 
extracted lipids was dissolved in chloroform containing 2% Triton X-100. The chloroform 
was replaced by the same volume of water after evaporation of the chloroform, the lipids were 
resuspended, and total cellular TG concentration was determined using the commercially 
available triglyceride assay kit (Roche Diagnostics).  
 
Western blotting of apoB in medium 
Secreted apoB in medium of McA-RH7777 cells was concentrated with fumed silica 
according to the methods described by Vance et al. (36). ApoB was separated by SDS-PAGE 
using 4-15% gradient gels as described.  
 
Protein measurements of cells 
Protein concentrations of cell suspensions were determined according to Lowry et al. (33) 
using bovine serum albumin as standard (Pierce).  
 
mRNA expression levels in cells 
Total RNA from McA-RH7777 cells was isolated by using the SV Total RNA Isolation 
System (Promega RNA, Madison, WI) according to the instructions from the manufacturer. 
RNA was processed for real-time PCR as described under "Hepatic RNA isolation and 
measurement of mRNA levels by real-time PCR (Taqman)."  
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Statistics 
All values represent mean ± standard deviation for the number of animals, wells, or 
experiments indicated. Statistical analysis of two groups was assessed by Mann-Whitney U 
test. Level of significance was set at p < 0.05. Analyses were performed using SPSS for 
Windows software (SPSS, Chicago, IL).  
 
 
Table 3.2. Comparison of hepatic lipid parameters of mice treated with T0901317 or its solvent. Male C57BL/6J 
mice were treated with 10 mg/kg of the synthetic LXR agonist T0901317, or its solvent (control) during four 
days. Livers were weighed and concentrations of lipids were measured as described under “Experimental 
Procedures”. Each value represents the mean ± S.D.; n=10. *, p < 0.05. 
 
 control  T0901317 
liver weight (% of body weight)  4.6 ± 0.6  6.6 ± 0.3 *
 
protein (mg/g liver)  225 ± 17  225 ± 17 
triglycerides (nmol/mg liver)  6.92 ± 2.65  57.74 ± 16.61 *
 
free cholesterol (nmol/mg liver)  4.21 ± 0.50  3.83 ± 0.71 *
 
cholesterylester (nmol/mg liver)  1.44 ± 0.52  0.98 ± 0.40 *
 
phospholipids (nmol/mg liver)  35.74 ± 3.48  36.43 ± 3.63 
 
 
 
 
 
Figure 3.1. Uniform Oil-Red-O (ORO) staining for neutral fat in livers of T0901317-treated mice. No staining 
was observed in liver sections from male C57BL/6J mice receiving the solvent (A). Massive staining was found 
in liver sections from mice treated four days with 10 mg/kg of the LXR agonist T0901317 (B). V, central vein; 
P, portal vein. Original magnification 50x. 
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Results 
 
Effects of T0901317 on hepatic and plasma lipids in C57BL/6J Mice 
Livers from mice that had received T0901317 were clearly heavier than those in the control 
group (table 3.2). The hepatic TG content in treated mice was ~10 times higher than in 
controls. There were no differences in protein, phospholipid, and free cholesterol contents, 
whereas the cholesteryl ester content was slightly decreased after treatment (table 3.2). Oil-
Red-O staining for neutral lipids on frozen liver sections showed massive lipid accumulation 
in periportal (zone 1) as well as in perivenous (zone 3) hepatocytes in mice receiving 
T0901317 (figure 3.1). The hepatic fatty acid composition was changed upon treatment: the 
relative amount of oleate (C18:1) was sharply increased (figure 3.2), whereas the relative 
amounts of palmitate (C16:0), linoleate (C18:2), and arachidonate (C20:4) were markedly 
decreased upon LXR activation.  
Hepatic expression of Lxrα was slightly reduced upon treatment with the agonist 
(figure 3.3A), but expression of genes involved in de novo lipogenesis was clearly increased 
(figure 3.3B). Expression of Srebp-1c was more than doubled after LXR activation, whereas 
mRNA levels of Acc1 and Fas were 3.5-4.5 times higher than in controls. Acc1 encodes the 
cytosolic isoform of ACC. No induction of mRNA levels of Srebp-1a was observed. 
The plasma concentrations of free cholesterol, cholesteryl esters, phospholipids, and 
free fatty acids (FFA) were significantly elevated in the treated group as compared with 
controls (table 3.3). As expected, HDL cholesterol was increased by ~60%, but the TG 
concentration was not affected by LXR activation in these experiments. Upon FPLC 
separation of plasma lipoproteins, distribution of TG appeared to be unaffected after LXR 
activation (figure 3.4A). Cholesterol contents of fractions 25-29 were higher in the group 
treated with T0901317 (figure 3.4B). Figure 3.4C shows that apoA-I was present in these 
earlier fractions after LXR activation, indicating that the "shoulder" in the cholesterol profile 
could be attributed to the presence of large HDL particles.  
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Figure 3.2. Changes in relative hepatic concentrations of major fatty acid species upon LXR activation.  Fatty 
acid composition was determined in ~15 mg liver tissue by gas chromatography after methylation, with 
heptadecanoic acid (C17:0) as internal standard. Open bars: livers from male C57BL/6J mice receiving the 
solvent (control). Closed bars: livers from mice treated four days with 10 mg/kg of the LXR agonist T0901317. 
Values represent the mean percentage ± S.D.; n=10; *, p < 0.05. 
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Figure 3.3. Changes in relative hepatic gene expression upon LXR activation, determined by Real Time PCR. 
RNA was isolated from ~30 mg liver tissue of male C57BL/6J mice and converted to cDNA. Levels of cDNA 
were measured by Real Time PCR as described in “Experimental Procedures”. Results were normalized to β-
Actin mRNA levels. (A) Expression of the gene encoding LXRα. (B) Expressions of genes encoding proteins 
involved in de novo lipogenesis. Open bars, mice receiving the solvent (control), arbitrarily defined as 1. Closed 
bars, mice treated four days with 10 mg/kg of the LXR agonist T0901317. Lxra, liver X receptor α; Srebp-1c: 
sterol-regulatory element-binding protein-1c; Acc1, acetylCoA carboxylase-1; Fas, fatty acid synthase.Values 
represent the mean ± S.D.; n=4; *, p < 0.05. 
 
 
 
LXR activation leads to stimulation of VLDL-TG secretion through formation of larger 
particles 
Figure 3.5 shows the plasma TG concentration versus time curve after injection of Triton 
WR-1339 in control and T0901317-treated mice. The VLDL-TG production rates were 
calculated from these curves. Upon LXR activation, the production rate was 2.56 times higher 
than control values: 201.9 ± 36.4 versus 78.8 ± 18.7 µmol/kg/h (figure 3.5, inset). The 
concentrations of free cholesterol, cholesteryl esters, phospholipids, and TG in nascent VLDL 
particles isolated from plasma obtained at 4 h after Triton WR-1339 injection are summarized 
in table 3.4. The mol% of surface lipids (free cholesterol and phospholipids) was reduced 
relative to that of core lipids (TG and cholesteryl esters), leading to an increase of the 
core:surface ratio by 14.4%. Accordingly, direct measurement of particle sizes revealed that 
after LXR activation the mean diameter of the VLDL particles was increased by 48% (129 ± 
9 versus 94 ± 12 nm, p < 0.001). The diameter was used to calculate the particle volume. The 
increase in mean particle volume (factor 2.54) was virtually identical to the increase in 
VLDL-TG production (factor 2.56), indicating that the latter increase was caused by the 
production of larger particles rather than by the production of more particles. In accordance 
with this notion, no differences in apoB contents were found in isolated VLDL fractions by 
Western blotting (figure 3.6).  
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Figure 3.4. Effect of LXR activation on distribution of triglycerides and cholesterol in plasma lipoprotein 
fractions. Lipoproteins were separated using FPLC (fast protein liquid chromatography) on a Pharmacia 
Superose 6B 10/30 column. Plasma of 10 male C57BL/6J mice per group was pooled, and 0.2 ml was applied to 
the column and eluted with phosphate-buffered saline at a flow of 0.5 ml/min. Triglycerides and cholesterol were 
measured as described under “Experimental Procedures”. (A) Profiles of triglycerides. (B) Profiles of 
cholesterol. (○) Mice receiving the solvent (control). (●) Mice treated four days with 10 mg/kg of the LXR 
agonist T0901317. (C) SDS-polyacrylamide gel electrophoresis followed by Western blotting of ApoA-I in the 
indicated FPLC fractions. Top panel, mice treated four days with 10 mg/kg of the LXR agonist T0901317; 
Bottom panel, mice receiving the solvent (control). 
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Table 3.3. Comparison of plasma lipid parameters of mice treated with T0901317 or its solvent. Male C57BL/6J 
mice were treated with 10 mg/kg of the synthetic LXR agonist T0901317 or its solvent (control) during four 
days. Blood was collected by cardiac puncture, and plasma obtained by centrifugation. Concentrations of lipids 
were measured as described under “Experimental Procedures”. Each value represents the mean ± S.D.; n=10. *, 
p < 0.05. 
 
  control T0901317 
free cholesterol (mM)  0.60 ± 0.07  0.87 ± 0.05 * 
cholesterylester (mM)  1.36 ± 0.31  2.27 ± 0.21 * 
HDL cholesterol (mM)  1.35 ± 0.27  2.15 ± 0.14 * 
phospholipids (mM)  2.55 ± 0.41  3.94 ± 0.21 * 
triglycerides (mM)  0.46 ± 0.16  0.49 ± 0.21 
free fatty acids (mM)  0.34 ± 0.07  0.47 ± 0.08 * 
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Figure 3.5. Plasma triglyceride concentrations in T0901317-treated and control mice after injection of Triton 
WR-1339. Male C57BL/6J mice received at t=0 an injection of 12 mg Triton WR-1339 in 100 µl PBS via the 
penile vein. Triglyceride concentration was measured in the plasma samples collected at indicated time points as 
described under “Experimental Procedures”. (○) Plasma from mice receiving the solvent (control). (●) Plasma 
from mice treated four days with 10 mg/kg of the LXR agonist T0901317. The inset shows the VLDL-TG 
production rate in µmol/kg/hr, calculated from the plasma TG vs. time curve. Open bar, mice receiving the 
solvent (control). Closed bar, mice treated four days with 10 mg/kg of the LXR agonist T0901317; Values 
represent the mean ± S.D.; n=6 (T0901317), n=7 (control); *, p < 0.05. 
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Figure 3.6. Apolipoprotein B contents in nascent VLDL particles of control and T0901317-treated mice. Plasma 
was obtained by cardiac puncture at 4 hours after injection of Triton WR1339. 300 µl plasma was adjusted to 
800 µl with a NaCl/KBr solution (d = 1.019 g/ml), containing 1 mM EDTA and NaN3, and centrifuged at 
120.000 rpm. VLDL was isolated by tube slicing and this fraction was applied to SDS-polyacrylamide gel 
electrophoresis followed by Western blotting. Each lane represents VLDL from an individual mouse. Left panel, 
mice receiving the solvent (control). Right panel, mice treated four days with 10 mg/kg of the LXR agonist 
T0901317.  
  
Figure 3.7. Changes in relative concentrations of major fatty acid species in VLDL fractions upon LXR 
activation. VLDL fractions were isolated from plasma obtained by cardiac puncture at 4 hours after injection of 
Triton WR1339. Fatty acids were determined by gas chromatography after methylation, with heptadecanoic acid 
(C17:0) as internal standard. Open bars: VLDL from mice receiving the solvent (control). Closed bars: VLDL 
from mice treated four days with 10 mg/kg of the LXR agonist T0901317. Values represent the mean percentage 
± S.D.; n=10; *, p < 0.05. 
 
 
The fatty acid composition of the VLDL fraction was changed upon treatment, resulting in 
changes similar as seen for the hepatic fatty acids (figure 3.7). The relative amount of VLDL-
associated oleate (C18:1) was increased, and relative amounts of palmitate (C16:0), linoleate 
(C18:2), and arachidonate (C20:4) were decreased upon LXR activation.  
To gain further insight into the molecular background of LXR-induced stimulation of 
VLDL-TG secretion, the expression of genes involved in the control of this process was 
investigated. Figure 3.8A shows that expression of the Apob gene was slightly but 
significantly reduced upon LXR activation. No changes in expression of Mttp and Apoe were 
noted. Likewise, expression of Apobec-1, encoding the apoB mRNA-editing protein, was not 
affected. In contrast, a marked induction of Lpl and Pltp mRNA levels was found (figure 
3.8B), the latter encoding the phospholipid transfer protein. Expression of Ldlr, encoding the 
low density lipoprotein receptor involved in the clearance of TG-rich lipoproteins, was 
slightly induced. 
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Figure 3.8. Changes in relative hepatic gene expression upon LXR activation, determined by Real Time PCR. 
RNA was isolated from ~30 mg liver tissue of male C57BL/6J mice and converted to cDNA. Levels of cDNA 
were measured by Real Time PCR as described in “Experimental Procedures”. Results were normalized to β-
Actin mRNA levels. (A) Expressions of the genes encoding proteins involved in VLDL assembly and secretion. 
(B) Expressions of genes encoding proteins involved in VLDL metabolism and clearance. Open bars, mice 
receiving the solvent (control), arbitrarily defined as 1. Closed bars, mice treated four days with 10 mg/kg of the 
LXR agonist T0901317. Apob, apolipoprotein B; Apobec-1, apolipoprotein B editing complex-1; Mttp, 
microsomal triglyceride transfer protein; Apoe, apolipoprotein E; Hl, hepatic lipase; Lpl, lipoprotein lipase; Pltp, 
phospholipid transfer protein. Values represent the mean ± S.D.; n=4; *, p < 0.05. 
 
 
Table 3.4. Comparison of composition and size of nascent VLDL particles of mice treated with T0901317 or its 
solvent. Male C57BL/6J mice were treated with 10 mg/kg of the synthetic LXR agonist T0901317 or its solvent 
(control) during four days. Mice were injected with Triton WR-1339 on the fifth day. At 4 hours after injection, 
blood was collected by cardiac puncture and VLDL was isolated from plasma by density gradient 
ultracentrifugation. Concentrations of lipids were measured as described under “Experimental Procedures” and 
particle diameter using a particle sizer. Particle volume was calculated  using  the  equation                          
Volume = 4/3·π·(½diameter)
3. Each value represents the mean ± S.D.; n=7 (control); n=6 (T0901317); *, p < 
0.05. 
 
  control T0901317 
free cholesterol (mM)  1.50 ± 0.31  2.01 ± 0.31 *
 
cholesterylester (mM)  0.63 ± 0.10  1.34 ± 0.19 *
 
phospholipids (mM)  2.95 ± 0.62  4.47 ± 0.45 *
 
triglycerides (mM)  28.53 ± 5.86  47.10 ± 8.66 *
 
core:surface lipids  6.55 ± 0.35  7.49 ± 1.10 
diameter (nm)  94 ± 12  129 ± 9 *
 
volume (10
5 nm
3 )  4.5 ± 1.7  11.3 ± 2.3 *
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Figure 3.9. Plasma triglyceride concentrations in apoE-/- LDLr-/- mice and APOE*3-Leiden transgenic mice 
upon LXR activation. Male apoE-/- LDLr-/- mice and APOE*3-Leiden transgenic mice were treated for 4 days 
with T0901317 or its solvent. Before onset of treatment (day 0) and on the second day of treatment, a small 
EDTA-bloodsample was collected by tail bleeding. On the fourth day, blood was obtained by cardiac puncture. 
Triglyceride concentration was measured in plasma as described under “Experimental Procedures”. (A) Plasma 
triglyceride concentrations in APOE*3-Leiden transgenic mice. (B) Plasma triglyceride concentrations in         
apoE -/- LDLr-/- double knockout mice. Open bars: mice receiving the solvent (control). Closed bars: mice 
treated with 10 mg/kg of the LXR agonist T0901317; Values represent the mean ± S.D.; n=4 (ApoE*3-Leiden); 
n=3 (apoE-/- LDLr-/- double knockouts); *, p < 0.05 for treated vs. control; #, p < 0.05 compared to 
concentration at t=0. 
 
 
 
LXR Activation leads to hypertriglyceridemia in apoE-/- LDLr- /-  double knockout and 
APOE*3-Leiden transgenic mice 
Increased VLDL-TG production in C57BL/6J mice was not accompanied by elevated fasting 
TG levels (table 3.3), possibly as a result of efficient particle metabolism and clearance. To 
test this option, effects of LXR activation on plasma TG levels were also studied in mouse 
models with defective particle clearance, i.e. apoE -/- LDLr -/- double knockout and 
APOE*3-Leiden transgenic mice. Figure 3.9 shows that, in both apoE -/- LDLr -/- mice and 
in APOE*3-Leiden transgenic mice, treatment with T0901317 resulted in a very strong, 
progressive increase in plasma TG concentrations. As expected, TG was almost exclusively 
present in VLDL-sized lipoprotein fractions in T0901317-treated apoE -/- LDLr -/- double 
knockouts and in APOE*3-Leiden transgenics upon FPLC separation of plasma lipoproteins 
(data not shown). 
 
61 Insulin sensitivity of hepatic glucose and lipid metabolism in animal models of hepatic steatosis 
 
 
 
 
 
0
1
2
3
4
5
6
7
8
Apob Srebp-1c Acc1 Fas Lxra
Control
T0901317
*
*
* *
*
0
1
2
3
4
5
6
7
8
Apob Srebp-1c Acc1 Fas Lxra
Control
T0901317
*
*
* *
*
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10. Changes in relative hepatic gene expression, determined by Real Time PCR, upon LXR activation 
in McA-RH7777 cells. RNA was isolated from McA-RH7777 cells exposed to T0901317-containing medium or 
control medium and converted to cDNA. Levels of cDNA were measured by Real Time PCR as described in 
“Experimental Procedures”. Results were normalized to β-Actin mRNA levels. Open bars: cells without 
T0901317 (control), arbitrarily defined as 1. Closed bars: cells incubated with 10 µM of the LXR agonist 
T0901317 during 65 hour. Apob, apolipoprotein B; Srebp-1c, sterol-regulatory element-binding protein-1c; 
Acc1, acetylCoA carboxylase-1; Fas, fatty acid synthase; Lxra, liver X receptor α. Values represent the mean ± 
S.D.; n=6; *, p < 0.05. 
 
 
Effects of LXR Activation on VLDL-TG Production in Cultured Liver Cells 
To determine whether LXR effects on VLDL production can be achieved via direct actions on 
liver cells, the rat hepatoma cell line McA-RH7777 was exposed to the LXR agonist 
T0901317 for 65 h. Figure 3.10 shows the effects of LXR activation on mRNA expression of 
genes involved in VLDL assembly and fatty acid synthesis. After incubation with T0901317, 
a 7-fold increase in Srebp-1c mRNA levels was observed as well as a 2-fold increase in both 
Acc1 and Fas mRNA levels. Similar to the in vivo situation, a 20% decrease in Apob and a 
slight decrease in Lxrα  mRNA levels were observed after exposure of the cells to the LXR 
agonist. 
After 24 h of incubation with T0901317 alone, the medium was replaced by medium 
also containing [
3H]glycerol. After another 41-h incubation, lipids were isolated from cells 
and media to determine the amount and secretion of newly synthesized VLDL-TG. Incubation 
with T0901317 resulted in a 2.6-fold induction of VLDL-TG secretion and a 3.4-fold 
induction of TG synthesis (figure 3.11A). Intracellular total TG mass was also increased upon 
incubation with T0901317 (1.4-fold compared with control situation). The amount of apoB 
isolated from medium after incubation with T0901317 was compared with that in the control 
medium. No significant differences in apoB100 or apoB48 were detected (figure 3.11B).  
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Discussion 
 
Pharmacological activation of LXR leading to accelerated reverse cholesterol transport has 
been advocated as a potential novel treatment or prevention of atherosclerosis (17). This study 
shows that the beneficial raise of HDL levels is accompanied by potentially adverse effects on 
triglyceride metabolism. In mice, an increased VLDL-TG production was seen upon LXR 
activation by the LXR agonist T0901317, caused by the formation of large, TG-rich particles. 
Large VLDL particles, also known as VLDL1 particles, are considered pro-atherogenic and 
are metabolized to small dense low density lipoprotein. Increased production of VLDL1 is a 
hallmark of diabetes type 2-related hyperlipidemia (37). 
 
 
 
0
1
2
3
4
3H-TG
secretion
3H-TG
synthesis
TG
mass
*
*
*
F
o
l
d
 
i
n
d
u
c
t
i
o
n Control
T0901317
A
B
0
1
2
3
4
3H-TG
secretion
3H-TG
synthesis
TG
mass
*
*
*
F
o
l
d
 
i
n
d
u
c
t
i
o
n Control
T0901317
A
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11. Triglyceride synthesis and VLDL-triglyceride secretion in the rat hepatoma cell line McA-RH7777. 
McA-RH7777 cells were incubated with or without 10 µM T0901317 for 24 h. After 24 h the medium was 
removed and replaced by medium containing 
3H-glycerol with or without 10 µM T0901317. After 41 h medium 
was collected and cells were harvested. Lipids were extracted from medium and cell suspensions and 
3H-TG was 
separated from other lipids by TLC. 
3H-TG spots were assayed for radioactivity by scintillation counting. The 
intracellular TG mass was enzymatically determined as described under “Experimental Procedures”. Secreted 
ApoB in the medium was concentrated with fumed silica and separated from other proteins on a 4-15% gradient 
gel by SDS PAGE followed by Western blotting. (A) Fold induction of  
3H-TG secretion, 
3H-TG synthesis and 
intracellular TG mass after a 65-h incubation with 10 µM T0901317 (closed bars) compared to the control 
situation (open bars). Values represent mean fold induction from three independent experiments ± S.D., * 
significantly different from control, p < 0.05. (B) Secreted apoB100 and apoB48 after a 65-h-incubation with or 
without 10 µM T0901317. The ApoB blot is representative for the results from three independent experiments. 
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The development of a severe hepatic steatosis, also reported previously (18), is likely related 
to increased de novo lipogenesis in combination with an increased FFA flux toward the liver. 
Slight quantitative differences in T0901317-induced gene expression patterns between our 
and other studies (18,22,25) are probably the result of differences in treatment protocols. For 
instance, Liang et al. (25) supplied T0901317 via the food during 12 h, which may have 
resulted in a more constant exposure of the liver to the agonist. Livers were removed 
immediately after this 12-h period. In our study mice received T0901317 daily for 4 days, and 
livers were taken out ~20 h after the last administration. Second, effects of the agonist may be 
transient because Joseph et al. (22) showed that hepatic expression of Fas and Scd-1 was 
higher after 3 days of LXR activation than after 7 days. 
The accumulated neutral lipids were distributed uniformly across the liver lobule, in 
contrast to most models of steatosis, e.g. the ob/ob mice (38), in which fat accumulates 
mainly in perivenous (zone 3) hepatocytes. After LXR activation, TG accumulated both in 
perivenous (zone 3) hepatocytes, which may reflect increased de novo lipogenesis (39), and in 
periportal (zone 1) hepatocytes. The fatty acid profile showed a specific increase in 18:1 fatty 
acids, in accordance with increased expression of Scd-1 after LXR activation (25). The fatty 
acid composition of VLDL was comparable with that of liver homogenates, indicating that 
TG containing specific fatty acids are not preferentially recruited for VLDL assembly.  
The increase of HDL cholesterol was mainly the result of the presence of larger 
particles in the circulation. Elevated HDL levels are probably caused by increased cholesterol 
efflux from peripheral and/or liver cells caused by induction of ABCA1 and ABCG1. The 
HDL elevating action of the LXR agonist may be, in part, counteracted by the LXR-induced 
expression of Pltp, because overexpression of Pltp is shown to reduce HDL in mice (40). 
However, induction of Pltp expression might also contribute to the presence of large HDL 
particles, as PLTP is a main factor in the regulation of the size and composition of HDL. 
PLTP has been proposed to catalyze conversion of two HDL particles to yield one larger 
HDL particle and a small lipid-poor apoA-I particle, pre-β-HDL (41,42). These latter particles 
are efficient acceptors of cholesterol from peripheral cells.  
The induced VLDL-TG production rate upon LXR activation was found to be the 
result exclusively of formation of larger particles. The increase in VLDL-TG production 
exactly matched the increased mean VLDL particle volume. The apoB content of isolated 
VLDL fractions was not affected upon treatment, strengthening our conclusion that LXR 
activation leads to formation of larger instead of more VLDL particles. The increased TG 
production by the liver did not lead to a raise in plasma TG levels in CL57BL/6J mice, but 
defective clearance in apoE -/- LDLr -/- double knockout and APOE*3-Leiden transgenic 
mice clearly unmasked the hypertriglyceridemic actions of LXR activation. Plasma TG levels 
markedly and progressively increased upon treatment with the agonist in these mice. 
Interestingly, Schultz et al. (18) showed that treatment of wild type C57BL/6 mice with 
T0901317 during 7 days did lead to elevated plasma TG levels. The discrepancy with our 
results may be caused by a difference in duration of treatment. Possibly, net effects of 
T0901317-treatment on plasma lipid levels are determined by time-dependent effects on gene 
expression levels and their metabolic consequences.  
It is tempting to speculate that LXR-stimulated de novo lipogenesis is the primary 
cause of the raised VLDL-TG secretion. The increased VLDL-TG production together with 
the induced transcription of hepatic Lpl might account for the elevated plasma FFA levels 
observed upon treatment (table 3.2). Lipoprotein lipase hydrolyzes TG and thereby catalyzes 
the conversion of VLDL into IDL, and subsequently of IDL into low density lipoprotein. Both 
conversions result in the release of FFAs into the bloodstream (43) and these FFAs will to 
large extent be taken up again by the liver. Increased supply of FFAs to liver cells stimulates 
VLDL-TG production (44); part of the observed stimulation of VLDL-TG production may 
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therefore occur via this indirect mechanism. To investigate whether LXR activation stimulates 
the VLDL-TG secretion by liver cells directly, we performed a limited series of experiments 
with McA-RH7777 cells kept under fixed FA concentrations. In these in vitro studies, we also 
found a gene expression profile consistent with increased de novo lipogenesis and stimulated 
cellular TG secretion, again without changes in apoB production. Administration of 
T0901317 to C57BL/6 mice also results in induction of Srebp-1 and Scd-1 mRNA levels in 
intestine and kidney (18). A recent study from Mak et al. (45) showed that incubation of 
murine macrophages with T0901317 resulted in increased Srebp-1 and Fas mRNA levels. 
Nevertheless, actions of the LXR agonist in hepatocytes may be responsible for the observed 
increased VLDL-TG production rate in vivo because these cells are primarily involved in this 
process. It should be stressed that increased hepatic de novo lipogenesis is not always 
associated with increased VLDL-TG secretion. For instance, the strong induction of de novo 
lipogenesis upon inhibition of glucose-6-phosphatase activity in rats is not associated with 
increased VLDL production (46). Apparently, different regulatory factors dominate under 
different metabolic conditions.  
Genes encoding proteins involved in assembly and secretion of VLDL, i.e., Apoe and 
Mttp, were not affected upon treatment. The production of larger VLDL particles might be 
accounted for by an intracellular action of PLTP. Jiang et al. (47) reported that PLTP-
deficient mice show a decreased secretion of apoB-containing particles. Because this 
decreased apoB production rate was observed both in vivo and in hepatocytes in vitro, it was 
concluded that PLTP must also be active within the cells. This suggestion is supported by the 
fact that mice overexpressing the human PLTP show increased VLDL-TG production (48). 
However, neither of these studies provided information about the size of the particles 
produced in the presence or absence of PLTP. Alternatively, induction of Cyp7A1 expression 
and activity may contribute to increased VLDL-TG production, as mice overexpressing the 
human  Cyp7A1 gene also show this feature (49). Thus, various mechanisms may be 
responsible for the production of larger VLDL particles after LXR activation, but the exact 
mode of action is currently not known.  
In conclusion, pharmacological activation of LXR is associated with development of 
hepatic steatosis and strongly affects the VLDL production process in mice, leading to 
formation of large, TG-rich particles. This combination of hepatic fat accumulation and 
overproduction of large VLDL strikingly resembles that observed in human diabetic states.  
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Abstract 
 
Liver X receptor (LXR) agonists have been proposed to act as anti-diabetic drugs. However, 
pharmacological LXR activation leads to severe hepatic steatosis, a condition usually 
associated with insulin resistance and type 2 diabetes mellitus. To address this apparent 
contradiction, lean and ob/ob mice were treated with the LXR agonist GW-3965 for 10 days. 
Insulin sensitivity was assessed by hyperinsulinemic-euglycemic clamp studies. Hepatic 
glucose production (HGP) and metabolic clearance rate (MCR) of glucose were determined 
with stable isotope techniques. Blood glucose and hepatic and whole body insulin sensitivity 
remained unaffected upon treatment in lean mice, despite increased hepatic triglyceride 
contents (61.7 ± 7.2 vs. 12.1 ± 2.0 nmol/mg liver, P < 0.05). In ob/ob mice, LXR activation 
resulted in lower blood glucose levels and significantly improved whole body insulin 
sensitivity. GW-3965 treatment did not affect HGP under normo- and hyperinsulinemic 
conditions, despite increased hepatic triglyceride contents (221 ± 13 vs. 176 ± 19 nmol/mg 
liver, P < 0.05). Clamped MCR increased upon GW-3965 treatment (18.2 ± 1.0 vs. 14.3 ± 1.4 
ml·kg
–1·min
–1, P = 0.05). LXR activation increased white adipose tissue mRNA levels of 
Glut4, Acc1 and Fas in ob/ob mice only. In conclusion, LXR-induced blood glucose lowering 
in  ob/ob mice was attributable to increased peripheral glucose uptake and metabolism, 
physiologically reflected in a slightly improved insulin sensitivity. Remarkably, steatosis 
associated with LXR activation did not affect hepatic insulin sensitivity.  
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Introduction 
 
Nuclear receptors act as cellular sensors of endogenous and exogenous compounds. When 
activated by their ligands, these receptors modulate transcription of their target genes to allow 
the cell to adapt adequately to changing conditions. The liver X receptor (LXR; NR1H3) has 
been identified as an oxysterol-activated nuclear receptor (26,40,47). After ligand binding, 
LXR forms a heterodimer with the retinoid X receptor (RXR; NR2B1). This complex binds to 
LXR response elements in promoter regions of genes, resulting in adaptation of gene 
transcription by attracting coactivator or corepressor complexes (13). LXR is well known to 
induce transcription of genes encoding proteins involved in reverse cholesterol transport, i.e., 
ATP-binding cassette transporter (ABC) A1 (10,34,36,38,44), ABCG1 (24,45), ABCG5, 
ABCG8 (4,35,48), and Cyp7A1 (15,26,33). Pharmacological LXR activation increases high-
density lipoprotein (HDL) cholesterol levels and stimulates fecal cholesterol excretion in mice 
(30,34,38,44). Treatment with agonists such as T-0901317 or GW-3965 attenuated 
development of atherosclerosis in apolipoprotein E-deficient (Apoe –/–) and low-density 
lipoprotein (LDL) receptor-deficient (Ldlr –/–) mice (11,41). Thus synthetic LXR agonists 
were considered as potential anti-atherosclerotic agents. Application of LXR agonists, 
however, was found to be associated with a number of undesirable side effects. LXR also 
controls expression of various genes involved in lipogenesis and triglyceride (TG) 
metabolism, and severe hepatic steatosis developed in mice upon LXR agonist treatment 
(14,37). We have previously shown that pharmacological activation of LXR is associated with 
production of large, TG-rich very low density lipoprotein (VLDL) particles, leading to 
hypertriglyceridemia in a mouse model with a humanized lipid profile (14).  
Hepatic steatosis is associated with hepatic insulin resistance and type 2 diabetes 
mellitus (2,22). Counterintuitively, despite induction of hepatic steatosis, treatment with the 
LXR agonist GW-3965 improved the response to a glucose tolerance test in C57BL/6J mice 
on a high-fat diet (23) but not in chow-fed mice. Cao et al. (8) showed that LXR activation 
reduced blood glucose levels in diabetic rodents, which was associated with decreased hepatic 
expression of the gene encoding phosphoenolpyruvate carboxykinase (PEPCK), supposedly 
rate controlling in gluconeogenesis (GNG). Moreover, treatment of db/db  mice  with             
T-0901317 markedly lowered hepatic Pepck gene expression in combination with more 
severe hepatic TG accumulation (9), suggesting that suppressed hepatic Pepck expression 
might result in a shift from GNG toward lipogenesis.  
So far, no quantitative data have been reported concerning the effects of LXR 
activation on hepatic and peripheral insulin sensitivity and on hepatic glucose metabolism. 
Moreover, the commonly used animal model for type 2 diabetes mellitus, the obese, leptin-
deficient  ob/ob mouse, has not been used to evaluate the anti-diabetic effects of LXR 
activation. Therefore, we quantified the effects of LXR activation by GW-3965 on whole 
body and hepatic insulin sensitivity in lean and obese (ob/ob) mice.  
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Materials and methods 
 
Animals 
Male lean and obese (ob/ob) C57BL/6J mice (Harlan, Horst, The Netherlands) were housed in 
a light- and temperature-controlled facility and were fed commercially available laboratory 
chow (RMH-B; Hope Farms, Woerden, The Netherlands) containing 6.2% fat and 0.01% 
cholesterol (wt/wt). For 10 days, the animals were fed the same diet with or without the 
synthetic LXR agonist GW-3965 (0.03% wt/wt; kindly provided by GlaxoSmithKline 
Pharmaceuticals, Stevenage, UK). On the 11th day, mice were subjected to one of the 
experiments described below. Experimental procedures were approved by the Ethics 
Committee for Animal Experiments of the State University Groningen.  
 
Plasma and tissue sampling and analyses 
Lean and ob/ob mice were killed under isoflurane anesthesia on the 11th day of treatment. A 
large blood sample was collected by cardiac puncture and centrifuged. Plasma was stored at   
-20°C until analyzed. The liver was quickly removed, weighed, and frozen in separate 
portions for RNA isolation and lipid analyses. Abdominal white adipose tissue (WAT) and 
backlimb muscle tissue were collected and frozen for RNA isolation.  
Plasma TGs, phospholipids, nonesterified fatty acid (NEFA), HDL cholesterol, free 
cholesterol, and total cholesterol were determined using commercially available kits (Roche 
Diagnostics, Mannheim, Germany, and Wako Chemicals, Neuss, Germany). Plasma insulin 
concentrations were determined using RIA RI-13K (Linco Research, St. Charles, MO). 
Hepatic concentrations of TGs, free cholesterol, and total cholesterol were measured using 
commercial kits (Roche Diagnostics and Wako Chemicals) after lipid extraction according to 
Bligh and Dyer (6). Phospholipid content of the liver was determined according to Böttcher et 
al. (7) after lipid extraction. Protein concentrations in livers were determined according to 
Lowry  et al. (28) using BSA (Pierce, Rockford, IL) as standard. Hepatic glycogen and 
glucose 6-phosphate (G6P) levels were determined as described before (17,19). Fatty acid 
composition was determined by gas chromatography after methylation, as described 
previously (27).  
 
Hyperinsulinemic euglycemic clamps 
Lean and ob/ob mice were equipped with a permanent catheter in the right atrium via the 
jugular vein (21). The two-way entrance of the catheter was attached to the skull with acrylic 
glue. The mice were allowed a resting period of at least 5 days during which the treatment 
period was completed. Before the start of the experiment (9 h), food was withdrawn, but mice 
still had free access to water. They were kept in metabolic cages during the experiment, 
allowing frequent collection of blood spots from the mice without anesthesia (42).  
The mice were infused for 6 h with two solutions. The first one (insulin solution) was 
a 1% BSA solution containing 40 µg/ml somatostatin (UCB, Breda, The Netherlands). This 
solution contained insulin (Actrapid; Novo Nordisk, Bagsvaerd, Denmark), leading to an 
insulin infusion rate of 10 mU·kg
–1·min
–1. To prevent high total infusion rates leading to 
possible higher morbidity, this solution contained 200 mg/ml glucose, from which 2% was 
[U-
13C]glucose (99% 
13C atom %excess; Cambridge Isotope Laboratories, Andover, MA). 
The solution was infused at a constant flow rate of 0.135 ml/h. The second infusate (glucose 
solution) was a 30% glucose solution, from which 3% was [U-
13C]glucose. Its infusion rate 
was adjusted according to measured blood glucose levels to maintain euglycemic conditions. 
Just before the start of the experiment, a small blood sample was obtained by tail bleeding. 
Blood glucose levels were measured with a Lifescan EuroFlash glucose meter (Lifescan 
Benelux, Beerse, Belgium) in a small tail blood sample that was taken every 15 min. For gas 
72 Liver X receptor activation and insulin sensitivity 
chromatography/mass spectrometry (GC-MS) measurements, a blood spot was obtained by 
tail bleeding every hour. After the clamp, animals were killed by cardiac puncture under 
anesthesia. Blood samples were centrifuged, and the obtained plasma was stored at –20°C 
until analyzed.  
 
Hepatic carbohydrate flux measurements 
After 10 days of treatment, hepatic carbohydrate fluxes were determined using infusion of 
stable isotopes, as previously described by van Dijk et al. (42). The mice were allowed a 
resting period after surgery of at least 5 days during which the treatment period was 
completed. Before the start of infusion (9 h), food was withdrawn, but mice still had free 
access to water. They were infused at a rate of 0.3 ml/h (lean mice) or 0.6 ml/h (ob/ob mice) 
with a solution containing 13.9 µmol/ml [U-
13C]glucose, 160 µmol/ml [2-
13C]glycerol, 33 
µmol/ml [1-
2H]galactose, and 1.0 mg/ml paracetamol. Blood and urine spots were collected at 
hourly intervals on filter papers.  
 
Measurement of mass isotopomer distribution by GC-MS 
Analytical procedures for extraction of glucose from blood spots filter paper 
(hyperinsulinemic-euglycemic clamp and hepatic carbohydrate flux experiment) and 
paracetamol-glucuronide from urine filter paper (hepatic carbohydrate flux experiment), 
derivatization of the extracted compounds, and GC-MS measurements of derivatives were 
essentially, according to van Dijk and colleagues (42,43).  
 
Mass isotopomer distribution analysis for hepatic carbohydrate fluxes 
The measured fractional isotopomer distribution by GC-MS (m0-m6) was corrected for the 
fractional distribution resulting from natural abundance of 
13C by multiple linear regression as 
described by Lee et al. (25) to obtain the excess mole fraction of mass isotopomers M0-M6 
due to incorporation of infused labeled compounds. For the determination of the hepatic 
carbohydrate fluxes, this distribution was used in mass isotopomer distribution analysis 
algorithms of isotope incorporation and dilution according to Hellerstein et al. (16) and as 
described by van Dijk and colleagues (42, 43).  
 
Calculation of endogenous glucose production and metabolic clearance rate under clamped 
conditions 
Two solutions with [U-
13C]glucose were infused with different rates. Therefore, the total rate 
of appearance of glucose into plasma [Ra(Glc;whole body)] was calculated as follows:  
 
Ra(glc;whole body) = (M6(glc)glucose x infusion(glc;M6)glucose + M6(glc)insulin  
             x infusion(glc;M6)insulin)/M6(glc)blood   (1)  
 
in which M6(Glc)glucose and M6(Glc)insulin are the excess mole fractions of infused [U-
13C]glucose in the glucose and insulin solution, respectively, and infusion(Glc;M6)glucose and 
infusion(Glc;M6)insulin are the infusion rates of [U-
13C]glucose of the glucose and insulin 
solution, respectively. M6(Glc)blood is the excess mole fraction of infused [U-
13C]glucose in 
blood.  
The rate of endogenous plasma glucose [Ra(Glc;endo)] was calculated as follows:  
 
Ra(glc;endo) = Ra(glc;whole body) - infusion(glc;M6)glucose - infusion(glc;M6)insulin    (2) 
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Table 4.1.Primers and probes used for realtime-PCR analysis. 
 
Gene   Sequences (5’ to 3’) GenBank
TM accession no.
β-Actin  Forward AGCCATGTACGTAGCCATCCA NM_007393   
  Reverse TCTCCGGAGTCCATCACAATG   
  Probe TGTCCCTGTATGCCTCTGGTCGTACCAC  
18S rRNA  Forward CGGCTACCACATCCAAGGA X00686 
  Reverse CCAATTACAGGGCCTCGAAA   
  Probe CGCGCAAATTACCCACTCCCGA   
Srebp-1c  Forward GGAGCCATGGATTGCACATT  AF286470   
 Reverse  CCTGTCTCACCCCCAGCATA   
  Probe CAGCTCATCAACAACCAAGACAGTGACTTCC  
Fas  Forward GGCATCATTGGGCACTCCTT  NM_007988   
 Reverse  GCTGCAAGCACAGCCTCTCT   
  Probe CCATCTGCATAGCCACAGGCAACCTC   
Acc1  Forward GCCATTGGTATTGGGGCTTAC XM_109883/ 
 Reverse  CCCGACCAAGGACTTTGTTG   
  Probe CTCAACCTGGATGGTTCTTTGTCCCAGC  
Acc2  Forward CATACACAGAGCTGGTGTTGGACT  NM_133904 
 Reverse  CACCATGCCCACCTCGTTAC   
  Probe CAGGAAGCCGGTTCATCTCCACCAG   
Lxrα  Forward GCTCTGCTCATTGCCATCAG  AF085745 
  Reverse TGTTGCAGCCTCTCTACTTGGA   
  Probe TCTGCAGACCGGCCCAACGTG   
Gk  Forward CCTGGGCTTCACCTTCTCCTT  NM_010292 
  Reverse GAGGCCTTGAAGCCCTTGGT   
  Probe CACGAAGACATAGACAAGGGCATCCTGCTC   
G6pt  Forward GAGGCCTTGTAGGAAGCATTG  NM_008063 
 Reverse  CCATCCCAGCCATCATGAGTA   
  Probe CTCTGTATGGGAACCCTCGCCACG  
G6ph  Forward CTGCAAGGGAGAACTCAGCAA  NM_008061 
  Reverse GAGGACCAAGGAAGCCACAAT   
  Probe TCGTTCCCATTCCGCTTCGCCT   
Gp  Forward GAAGGAGGCAAACGGATCAAC  NM_133198 
 Reverse  TCACGATGTCCGAGTGGATCT   
  Probe CCTCTGCATCGTGGGCTGCCA   
Gs  Forward GCTCTCCAGACGATTCTTGCA  AA537291 
 Reverse  GTGCGGTTCCTCTGAATGATC   
  Probe CCTCTACGGGTTTTGTAAACAGTCACGCC   
Pepck  Forward GTGTCATCCGCAAGCTGAAG  NM_011044 
  Reverse CTTTCGATCCTGGCCACATC   
  Probe CAACTGTTGGCTGGCTCTCACTGACCC  
Pk  Forward CGTTTGTGCCACACAGATGCT  NM_013631 
  Reverse CATTGGCCACATCGCTTGTCT   
  Probe AGCATGATCACTAAGGCTCGACCAACTCGG   
Glut4  Forward CTCATGGGCCTAGCCAATG  NM_009204 
  Reverse GGGCGATTTCTCCCACATAC   
  Probe CATTGGCGCCTACTCAGGGCTAACATC   
Hk1  Forward CACCGGCAGATTGAGGAAAC  NM_010438 
  Reverse CTCAGCCCCATTTCCATCTCT   
  Probe TCCCACTTCCGCCTCAGCAAGC   
Hk2  Forward GGAACCCAGCTGTTTGACCA  NM_013820 
  Reverse CAGGGGAACGAGAAGGTGAAA   
  Probe TGCCTGGCCAACTTCATGGACAAGC   
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The metabolic clearance rate of glucose (MCR) was calculated according to: 
 
MCR = Ra(glc;whole body)/[glc]  (3) 
 
where [Glc] is the blood glucose concentration (mM).  
 
RNA isolation and measurement of mRNA levels by real-time PCR (Taqman) 
mRNA expression levels in liver, WAT, and skeletal muscle were measured by real-time 
PCR, as described previously (14). PCR results were normalized to β-actin (hepatic tissue) or 
18S (WAT, skeletal muscle) mRNA levels. The sequences of the primers and probes used are 
listed in table 4.1.  
 
Statistics 
All values represent means ± SE for the number of animals or experiments indicated. 
Statistical analysis of two groups was assessed by Mann-Whitney U-test (plasma and hepatic 
parameters) or ANOVA for repeated measurement (flux and clamp experiment). Level of 
significance was set at P < 0.05. Analyses were performed using SPSS for Windows software 
(SPSS, Chicago, IL).  
 
 
Results 
 
LXR activation increased hepatic TG content in both lean and ob/ob mice 
Feeding the synthetic LXR agonist GW-3965 (0.03% wt/wt) for 10 days did not affect body 
weights of either lean or ob/ob mice (table 4.2). Lean mice developed increased liver weights 
and a fivefold increase in hepatic TG content upon GW-3965 treatment (table 4.2). Although 
ob/ob mice already showed severe hepatic steatosis on the control diet, LXR activation 
resulted in a further 25% increase in hepatic TG content. LXR activation resulted in a clearly 
altered hepatic fatty acid composition in lean mice (figure 4.1). GW-3965 treatment 
significantly reduced the relative amount of hepatic saturated fatty acids and polyunsaturated 
fatty acids from 37.8 ± 0.7 to 28.7 ± 0.6% and from 42.3 ± 2.8 to 27.5 ± 1.4%, respectively. 
In contrast, the relative amount of monounsaturated fatty acids significantly increased from 
19.9 ± 3.4 to 43.8 ± 1.9% upon LXR activation. In ob/ob mice, LXR activation did not 
significantly affect hepatic fatty acid composition. Glycogen and G6P levels were higher in 
ob/ob mice than in lean mice. GW-3965 treatment did not affect glycogen and G6P levels of 
lean mice. In ob/ob mice, in contrast, LXR activation reduced glycogen to levels comparable 
to those of lean mice, whereas G6P levels remained unchanged (table 4.2).  
LXR activation resulted in elevated plasma cholesterol levels in lean mice (table 4.2), 
mainly because of increased HDL cholesterol levels. Plasma TG and NEFA levels were not 
affected by the agonist in lean mice. Blood glucose levels were not affected by the treatment 
in lean mice (figure 4.2), but insulin levels were somewhat increased in the treated mice (table 
4.2). In ob/ob mice, LXR activation had no significant effect on plasma lipid levels, but the 
treatment resulted in reduced lower blood glucose (figure 4.2) and plasma insulin levels (table 
4.2). 
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Figure 4.1. Hepatic fatty acid composition in lean and ob/ob mice fed a diet with or without the synthetic LXR 
agonist GW3965 for 10 days. Relative amounts of saturated (SAFA, white bars), monounsaturated (MUFA, 
striped bars) and polyunsaturated (PUFA, black bars) fatty acids; n=6; *, p<0.05 treated vs. untreated. 
 
 
 
 
Table 4.2. Hepatic and plasma parameters in lean and ob/ob mice fed a diet with or without the synthetic LXR 
agonist GW3965 for 10 days. Values are means ± S.E.M.; n = 6; *, p<0.05 treated vs. untreated; 
†, p<0.05 ob/ob 
vs. lean untreated. G6P, glucose-6-phosphate. 
 
 Lean  ob/ob 
 Control  GW3965  Control  GW3965 
Body weight (gram)  25.5 ± 1.0  25.0 ± 0.5  47.0 ± 1.3 
† 47.4 ± 0.7 
†
Liver weight (% of bodyweight)  5.3 ± 0.1  6.3 ± 0.1 *  8.5 ± 0.4 
† 8.4 ± 0.2 
†
Liver proteins (mg/g
 liver)  229.5 ± 4.2  223.6 ± 9.5  292.4 ± 14.5 
† 296.9 ± 18.9 
†
Liver triglycerides (nmol/mg
 liver)  12.1 ± 2.0  61.7 ± 7.2 *  176.2 ± 18.8 
† 220.8 ± 13.2 *
†
Liver glycogen (nmol/mg
 liver)  166 ± 9  152 ± 17  309 ± 23 
† 209 ± 18 * 
Liver G6P (nmol/g
 liver)  645 ± 30  692 ± 35  762 ± 22 
† 929 ± 67 
†
Plasma triglycerides (mM)  0.79 ± 0.06  1.10 ± 0.30  0.96 ± 0.11  0.59 ± 0.08 
†
Plasma free cholesterol (mM)  0.80 ± 0.03  1.21 ± 0.04 *  1.12 ± 0.09  1.17 ± 0.06 
†
Plasma cholesterylester (mM)  1.88 ± 0.07  2.73 ± 0.05 *  4.64 ± 0.34 
† 5.18 ± 0.25 
†
Plasma HDL cholesterol (mM)  1.76 ± 0.44  2.88 ± 0.13  2.90 ± 0.33  3.51 ± 0.26 
†
Plasma NEFA (mM)  0.22 ± 0.02  0.21 ± 0.03  0.58 ± 0.03 
† 0.51 ± 0.05 
†
Plasma insulin (ng/ml)  0.25 ± 0.06  0.48 ± 0.06 *  1.26 ± 0.49 
† 0.47 ± 0.22 
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Figure 4.2. Blood glucose levels (mM) in lean and ob/ob mice before and after 3 or 10 days diet with or without 
the synthetic LXR agonist GW3965. N=6; *, p<0.05 treated vs. untreated; †, p<0.05  vs. before treatment. 
 
 
Improved insulin sensitivity in ob/ob mice upon LXR activation 
To test whether insulin sensitivity was influenced by LXR activation, we performed 
hyperinsulinemic-euglycemic clamp studies in conscious mice for 6 h. The total glucose 
infusion rate (GIR) was adjusted such that euglycemic conditions were maintained throughout 
the infusion period (figure 4.3A). In all four groups of mice, GIR reached constant values 
after 3 h of infusion (figure 4.3B). In lean mice, GIR did not differ significantly between the 
treated and nontreated group. Calculated for the last 3 h of the experiment, GIR was 593 ± 13 
and 564 ± 14 µmol·kg
–1·min
–1 for untreated and treated lean mice, respectively. In untreated 
ob/ob mice, GIR was markedly lower than in lean mice, i.e., 95 ± 5 µmol·kg
–1·min
–1. After the 
10-day treatment period, insulin sensitivity was improved significantly, as is evident from the 
50% increase in GIR to a value of 141 ± 5 µmol·kg
–1·min
–1. 
 
Hyperinsulinemia reduced hepatic glucose production irrespective of GW-3965 treatment. 
LXR agonist treatment (10 days) did not affect any of the measurable fluxes in lean mice, but 
resulted in a tendency toward increased GNG and significantly increased fluxes through 
glycogen phosphorylase (GP), glucose-6-phosphatase (G6Pase), and glucokinase (GK) in 
ob/ob mice (table 4.3). The ob/ob mice showed slightly higher glucose cycling rates upon 
LXR activation (table 4.3), confirming recent findings from our laboratory (3). Most 
importantly, endogenous glucose production [Ra(Glc;endo), hepatic glucose production 
(HGP)] did not differ between untreated and treated lean and ob/ob mice (table 4.3). 
In lean mice, steady-state HGP during the last 3 h of the clamp was strongly reduced 
and not affected by administration of the agonist: 11 ± 18 vs. 23 ± 15 µmol·kg
–1·min
–1, 
untreated  vs. treated (figure 4.3A). Thus HGP was almost completely inhibited in both 
groups, i.e., by 94 and 86%, respectively. Steady-state HGP under clamped conditions was 
higher in ob/ob mice compared with lean mice, indicating hepatic insulin resistance, without 
significant differences between untreated and treated ob/ob mice, i.e., 79 ± 7 vs. 64 ± 16 
µmol·kg
–1·min
–1, respectively (figure 4.4A). The insulin-mediated suppression of HGP was 
similar in untreated and GW-3965-treated ob/ob mice, i.e., 48 and 61% respectively. 
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Figure 4.3. Blood glucose level and glucose infusion rate during hyperinsulinemic euglycemic clamps in lean 
and ob/ob mice fed a diet with (dotted line) or without (solid line) the synthetic LXR agonist GW3965 for 10 
days. a) Blood glucose levels (mM); b) glucose infusion rates (µmol/kg/min) during clamping; n=6, n=5 (treated 
ob/ob mice); *, p<0.05 treated vs. untreated. 
 
Table 4.3. Hepatic carbohydrate fluxes in lean and ob/ob mice fed a diet with or without the synthetic LXR 
agonist GW3965 for 10 days. Values are means ± S.E.M.; n=5; *, p<0.05 treated vs. untreated; 
†, p<0.05 ob/ob 
vs. lean untreated. 
 
  Lean  ob/ob 
  Control GW3965  Control  GW3965 
Total gluconeogenic flux (µmol/kg/min)  144 ± 8  131 ± 6  143 ± 10  185 ± 4 
Glycogen synthase flux (µmol/kg/min)  111 ± 7  96 ± 7  56 ± 7 
† 70 ± 12 
†
Glycogen phosphorylase flux (µmol/kg/min)  97 ± 7  84 ± 8  85 ± 7  114 ± 3 * 
Glucose-6-phosphatase flux (µmol/kg/min)  228 ± 16  191 ± 10  232 ± 12  289 ± 14 *
†
Glucokinase flux (µmol/kg/min)  82 ± 10  60 ± 7  101 ± 17  148 ± 17 *
†
Hepatic glucose production (µmol/kg/min)  173 ± 9  152 ± 8  153 ± 9  169 ± 2 
Cycling glucose – glucose-6-phospate (%)  23 ± 2  20 ± 2  34 ± 4  40 ± 4 
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Slightly improved metabolic clearance of glucose under clamped conditions in GW-3965-
treated ob/ob mice 
From the data available, it is possible to calculate the MCR under both basal and clamped 
conditions (figure 4.4B). In lean mice, basal MCR was not affected by LXR activation. 
During the clamp, values of MCR increased 5.5-fold and 5.7-fold in untreated and treated 
C57BL/6J mice, respectively. In contrast, MCR did not change upon hyperinsulinemia in 
untreated ob/ob mice, but clamping increased MCR by 80% in treated ob/ob mice. Thus 
clamped MCR values were 18.2 ± 1.0 and 14.3 ± 1.4 ml·kg
–1·min
–1 (P = 0.05) in treated and 
untreated ob/ob mice, respectively.  
 
Effects of LXR activation on hepatic gene expression in lean and ob/ob mice 
As expected, hepatic mRNA levels of genes encoding sterol-regulatory element-binding 
protein-1c (SREBP-1c) and fatty acid synthetase (FAS) increased upon LXR activation in the 
lean mice (table 4.4). Expression of Fas was higher in ob/ob mice than in lean mice but was 
not affected by LXR activation. Expression of Lxrα, the major LXR isoform, was not affected 
by LXR activation.  
From the genes encoding relevant enzymes in hepatic carbohydrate metabolism, only 
expression of Gk, encoding for glucokinase, was significantly increased by 54% upon GW-
3965 treatment in the lean mice (table 4.4). Data suggest a tendency toward lower expression 
of  Pepck and higher expression of the pyruvate kinase gene (Pk) in treated lean mice. 
Compared with lean mice, ob/ob mice showed significantly higher expression of Gk and 
G6pt. The latter gene encodes for G6P translocase, which is part of the G6Pase complex that 
controls the flux of G6P toward glucose. Upon LXR activation, expression of the genes 
encoding for both subunits of the G6Pase complex, G6pt and G6ph, was markedly reduced in 
ob/ob mice.  
 
Normalization of Glut4, Acc1, and Fas WAT mRNA levels in ob/ob mice upon LXR activation 
Because previous studies reported effects of LXR agonists on adipose and muscle mRNA 
expression profiles (23,39), we determined WAT in skeletal muscle mRNA levels of several 
genes encoding proteins involved in glucose or lipogenesis (figure 4.5). LXR activation 
resulted in a threefold increase of Srebp-1c in adipose tissue of the lean mice, but Fas and 
Acc1 (encoding for acetyl-CoA carboxylase-1) mRNA levels were not affected. Expression of 
these lipogenic genes was lower in untreated ob/ob mice compared with untreated lean mice. 
Yet, LXR activation resulted in a fourfold increased expression of Srebp-1c, whereas Fas and 
Acc1 expression were increased 2.6- and 2.3-fold, respectively. Untreated ob/ob mice showed 
lower adipose mRNA levels of Glut4 than untreated lean mice, but Glut4 expression 
normalized upon LXR activation in ob/ob mice. Expression of the genes encoding for 
hexokinase-1 (Hk1) and hexokinase-2 (Hk2) was not different between the two strains and not 
affected by LXR activation. In muscle tissue, LXR activation led a 8.6- and 3.5-fold increase 
of  Srebp-1c  mRNA levels in lean and ob/ob mice, respectively. Neither Fas,  Acc2 (the 
isoform of ACC predominantly expressed in muscle; see Ref. 1), nor Glut4 muscle mRNA 
levels in lean and ob/ob mice were affected upon LXR activation. In ob/ob mice only, LXR 
activation slightly reduced muscle mRNA levels of Hk1 and Hk2. WAT and muscle Lxrα 
expression was not affected upon GW-3965 activation in either lean or ob/ob mice.  
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Table 4.4. Hepatic gene expression in lean and ob/ob mice fed a diet with or without the synthetic LXR agonist 
GW3965 for 10 days. Values are means ± S.E.M.; results normalized to β-Actin mRNA levels; data from 
untreated lean mice defined as 1; n=4 (lean), n=6 (ob/ob); *, p<0.05 treated vs. untreated; 
†, p<0.05 ob/ob vs. 
lean untreated. Srebp-1c, sterol-regulatory element-binding protein-1c; Fas, fatty acid synthetase; Lxrα, liver x 
receptor α; Gk, glucokinase; G6ph, glucose-6-phosphate hydrolase; G6pt, glucose-6-phosphate translocase; Gs, 
glycogen synthase; Gp, glycogen phosphorylase; Pepck, phosphoenolpyruvate carboxykinase; Pk, pyruvate 
kinase. 
 
  Lean  ob/ob 
  Control GW3965  Control  GW3965 
Srebp-1c  1.00 ± 0.18  2.61 ± 0.53 *  1.27 ± 0.20  1.84 ± 0.18 
†
Fas  1.00 ± 0.16  3.76 ± 1.27 *  3.15 ± 0.31 
† 2.96 ± 0.38 
†
Lxrα  1.00 ± 0.15  0.71 ± 0.05  1.46 ± 0.17  1.52 ± 0.25 
Gk  1.00 ± 0.12  1.54 ± 0.18 *  2.21 ± 0.07 
† 2.45 ± 0.24 
†
G6ph  1.00 ± 0.20  1.05 ± 0.41  1.07 ± 0.15  0.41 ± 0.08 * 
†
G6pt  1.00 ± 0.21  1.08 ± 0.11  1.56 ± 0.08 
† 0.86 ± 0.09 * 
Gs  1.00 ± 0.19  0.94 ± 0.19  1.11 ± 0.15  0.99 ± 0.12 
Gp  1.00 ± 0.14  1.26 ± 0.36  1.11 ± 0.11  0.74 ± 0.11 
Pepck  1.00 ± 0.16  0.78 ± 0.23  0.96 ± 0.12  0.71 ± 0.07 
Pk  1.00 ± 0.15  1.35 ± 0.20  1.02 ± 0.24  0.60 ± 0.08 
†
 
 
 
 
Discussion 
 
This study documents that pharmacological LXR activation improves glucose metabolism in 
ob/ob mice by increased peripheral glucose uptake and slightly increased peripheral insulin 
sensitivity. Remarkably, HGP and hepatic insulin sensitivity remained unaffected although 
LXR activation increased hepatic TG content dramatically. These observations indicate 
tissue-specific effects of LXR activation on fat and glucose metabolism. Treatment with the 
LXR agonist resulted in reduced blood glucose concentrations in ob/ob mice but had no effect 
whatsoever in lean mice (figure 4.2), in accordance with previous studies (8,9,23). Laffitte et 
al. (23) showed that obese, but not lean, C57BL/6 mice had improved glucose tolerance after 
1 week of GW-3965 treatment. The LXR agonist T-0901317 lowered blood glucose in male 
db/db mice and male Zucker diabetic fatty rats but not in their nondiabetic controls (8,9).  
Previous studies (8,9,23) suggested that reduced GNG might, at least in part, account 
for the anti-diabetic effect of LXR agonists. However, this conclusion was based merely on 
the finding of reduced Pepck mRNA levels. To assess the actual effects of LXR activation on 
GNG flux and HGP, we quantified hepatic carbohydrate fluxes using stable isotope 
techniques (42,43). From these data (table 4.3) it is evident that neither GNG nor HGP was 
affected upon LXR activation in lean or ob/ob mice. We found reduced blood glucose levels 
in ob/ob mice upon GW-3965 treatment, but our data clearly indicate that this effect of LXR 
activation is not the result of reduced GNG. We found hepatic Pepck expression to be slightly 
reduced in both strains of mice upon GW-3965 treatment. Previous reports (8,23) showed 
more drastic effects on Pepck expression. The type of agonist (T-0901317 vs. GW-3965), 
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mode and dose of administration, and the diabetic animal model could account for the 
differences in this respect between these studies and our results. For Gk expression, we found 
a 54% increase in lean mice and no change in ob/ob mice upon LXR activation, whereas 
others found a more than threefold induction in 12-h fasted female C57BL/6J mice (23). 
Changes in Gk mRNA levels could, at least in part, be the result of Srebp-1c induction (20). 
Nonetheless, our study demonstrates that changes in hepatic gene expression do not fully 
translate into changes in the metabolic fluxes. The slight reduction of Pepck gene expression 
was not reflected in the GNG flux (table 4.3). Recently, is was pointed out that only severe 
reductions (–90%) or drastic increases (+300%) of Pepck expression are associated with 
changes in GNG in mice (29). Consequently, relatively small alterations in Pepck mRNA 
levels per se do not predict changes in gluconeogenic flux.  
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Figure 4.4. Hepatic glucose production and metabolic clearance rate under basal (stable isotope infusion) and 
clamped conditions in lean and ob/ob mice fed a diet with or without the synthetic LXR agonist GW3965 for 10 
days. a) Hepatic glucose production (µmol/kg/min); b) metabolic clearance rate (ml/kg/min); n=6, n=5 (clamped 
treated ob/ob and basal lean); *, p<0.05 ob/ob vs. lean untreated; †, p<0.05 clamped vs. basal, same mice and 
treatment. 
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Figure 4.5. White adipose tissue (WAT) and skeletal muscle gene expression in mice fed a diet with (black bars) 
or without (white bars) the synthetic LXR agonist GW3965 for 10 days. a) WAT mRNA levels; b) skeletal 
muscle mRNA levels; results normalized to 18S mRNA levels; data from untreated lean mice defined as 1; n=3 
(untreated), n=5 (treated); *, p<0.05 treated vs. untreated; †, p<0.05 ob/ob vs. lean untreated. Srebp-1c, sterol-
regulatory element-binding protein-1c, Fas, fatty acid synthetase; Acc1, acetyl-CoA carboxylase-1; Glut4, 
glucosetransporter-4; Hk, hexokinase; Lxrα, liver X receptor α. 
 
 
Cao et al. (8) suggested that LXR activation improves insulin sensitivity. In contrast, we 
found a slight increase of plasma insulin levels in lean mice upon LXR activation (table 4.2), 
which might suggest worsening of insulin sensitivity. The best possible technique to 
determine insulin sensitivity in vivo is the hyperinsulinemic-euglycemic clamp. Hence, to 
determine whether insulin sensitivity was actually affected, we used this technique in 
conscious, unrestrained mice to mimic the normal, physiological situation. Insulin-mediated 
glucose uptake did not differ between treated and untreated lean mice (figure 4.4A), 
indicating that LXR activation did not affect whole body insulin sensitivity. In addition, 
insulin-mediated suppression of HGP in lean mice was not affected by treatment with the 
LXR agonist (figure 4.4B), indicative for unaffected hepatic insulin sensitivity. In ob/ob mice, 
82 Liver X receptor activation and insulin sensitivity 
LXR activation resulted in a 50% increase of the GIR required to maintain euglycemia (figure 
4.3, A and B). HGP was not significantly affected (figure 4.4A), indicating that the agonist 
had no measurable effect on hepatic insulin sensitivity. Yet, MCR was slightly increased upon 
clamping (figure 4.4B), indicating a positive, albeit only marginal, effect of the agonist on 
peripheral insulin sensitivity. Overall, insulin sensitivity of the treated ob/ob mice was still 
poor, since the effects on GIR, insulin-mediated suppression of HGP, and stimulation of MCR 
by no means yielded values for these parameters observed in lean C57BL/6J mice.  
LXR activation induced a considerable increase in hepatic TG content. Steatosis is 
usually associated with hepatic insulin resistance, which means that the liver is less sensitive 
to the suppressive effects of insulin on hepatic glucose and VLDL-TG production. There are 
multiple endocrine, metabolic, and transcriptionally active factors involved in the interaction 
between hepatic TG metabolism and hepatic insulin sensitivity. The hierarchy between these 
different factors in modulating hepatic insulin sensitivity is at present unclear (12). In the 
present study, however, we report the striking observation that LXR-induced hepatic steatosis 
lacks the association with insulin resistance, at least with respect to insulin-mediated 
suppression of HGP. This might be a result of potential counteracting antidiabetic effects of 
the LXR agonist. In previous reports, it was already noticed that beneficial effects of LXR 
agonists on carbohydrate metabolism were only present in diabetic animal models (8,9,23). In 
these animals, insulin resistance associated with hepatic steatosis probably failed to overrule 
the effects of LXR on glucose homeostasis. Changes in hepatic fatty acid profile upon LXR 
activation may contribute in this respect (figure 4.1). LXR activation enhances transcription 
of the gene encoding stearoyl-CoA desaturase-1, Scd1, an enzyme involved in the conversion 
of saturated fatty acid into monounsaturated fatty acids (31). An increase in dietary 
monounsaturated fatty acids resulted in improved insulin sensitivity in healthy men and 
women (46), but had no effect on insulin secretion. Therefore, hepatic steatosis in which TG 
contain relatively more monounsaturated fatty acids, as observed in GW-3965-treated lean 
mice, might be "healthier" than steatosis with predominantly saturated fatty acids containing 
TG.  
The LXR agonist increased expression of lipogenic genes Acc1 and Fas in WAT of 
ob/ob mice, but not in lean mice (figure 4,5A). A similar pattern was found for Glut4. Being 
aware of the discrepancy between mRNA expression and real enzyme activity and hence 
fluxes of substrates, it is tempting to speculate that LXR activation leads to increased uptake 
of glucose by adipocytes in ob/ob mice. The observation that GW-3965 treatment did not 
affect expression of Acc2, Fas, and Glut4 in muscle tissue of lean and ob/ob mice (figure 
4.5B) suggests that LXR activation specifically improved glucose uptake by adipocytes and 
not of muscle tissue, suggestive for a fat-specific mechanism for improved peripheral insulin 
sensitivity. After uptake in adipocytes, glucose is metabolized into acetyl-CoA, which serves 
as substrate for lipogenesis. Juvet et al. (18) already reported that LXR agonists increased the 
lipid content of 3T3-L1 adipocytes in culture. Therefore, in the long turn, LXR activation may 
lead to a further increase in adipose tissue mass in the already obese ob/ob mice. The fact that 
GW-3965 treatment failed to increase Acc1, Fas, and Glut4 expression in WAT of lean mice 
might be attributable to circulating leptin. Orci et al. (32) reported that adenovirus-induced 
hyperleptinemia led to transformation of adipocytes to fat-oxidizing cells in wild-type Zucker 
diabetic fatty rats. Moreover, WAT lipogenic gene expression was decreased in these rats. In 
our study, normal plasma leptin levels in the lean mice were apparently still able to suppress 
lipogenic gene expression, but the ob/ob mice lack this capability. As a result, the WAT 
lipogenic mRNA levels were increased in ob/ob mice but not in lean mice.  
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This study unequivocally demonstrates that antidiabetic effects of LXR agonists in ob/ob 
mice are exclusively the result of increased glucose uptake by peripheral tissues, i.e., probably 
by WAT. Moreover, LXR activation had no effect whatsoever on hepatic carbohydrate 
metabolism in lean or ob/ob mice. In adipose tissue, glucose might be more rapidly used as 
substrate for de novo lipogenesis. Because effects of general LXR activation on (peripheral) 
insulin sensitivity are limited in ob/ob mice and coincide with undesirable side effects as 
hepatic steatosis and hypertriglyceridemia, potential application of LXR modulators in 
diabetes treatment will require the development of gene- and/or organ-specific compounds.  
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Abstract 
 
A growing body of evidence implicates ceramide and/or its glycosphingolipid metabolites in 
the pathogenesis of insulin resistance. We have developed a highly specific small molecule 
inhibitor of glucosylceramide synthase, an enzyme which catalyses a necessary step in the 
conversion of ceramide to glycosphingolipids. In cultured adipocytes the iminosugar 
derivative N-(5’-adamantane-1’-ylmethoxy)-pentyl-1-deoxynojirimycin (AMP-DNM), 
enhanced insulin-stimulated glucose uptake and reversed TNF-alpha induced abnormalities in 
insulin signal transduction. When administered to mice, AMP-DNM significantly reduced 
glycosphingolipid but not ceramide concentrations in various tissues. Treatment of ob/ob 
mice with AMP-DNM for 7 days normalised their elevated tissue glucosylceramide levels, 
markedly lowered circulating glucose levels, improved oral glucose tolerance, improved 
insulin sensitivity in muscle and liver, reduced hepatic fat deposition and increased cell 
surface expression of GLUT4 on adipocytes. These findings provide evidence that 
metabolites of ceramide, rather than ceramide itself, may be involved in mediating the link 
between obesity and insulin resistance and that interference with glycosphingolipid 
biosynthesis might present a novel approach to the therapy of states of impaired insulin action 
such as type 2 diabetes. 
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Introduction 
 
Impaired responsiveness to insulin is reflected by increased glucose synthesis by the liver and 
reduced glucose uptake by skeletal muscle and adipose tissue (1-3). In insulin-resistant 
individuals the translocation of the glucose transporter GLUT4 to the plasma membrane of 
myocytes and adipocytes is impaired. Obesity is strongly associated with insulin resistance 
but the underlying pathogenic mechanism is still an enigma. The strong correlation between 
insulin resistance and intramyocellular lipid levels suggests that excessive exposure to lipids 
or their metabolites, so called lipotoxicity, may play a crucial role (1-7). The rapid induction 
of insulin resistance in rodents by infusions with palmitate, and in cultured cells by supplying 
this fatty acid, has directed attention to the sphingolipid ceramide as a potential mediator of 
insulin resistance (1,4-7). Palmitate is a critical precursor in the synthesis of ceramide and its 
enhanced supply inevitably increases sphingolipid formation in tissues (8,9). Increased 
ceramide concentrations (two-fold) were indeed recently reported for skeletal muscle from 
obese insulin-resistant individuals4. The well-established induction of insulin resistance by 
the cytokine TNFα may also be attributed to its ability to promote sphingolipid biosynthesis, 
as has been demonstrated at both mRNA and cellular lipid levels (10-12). In addition, 
investigations with cultured cells have linked excessive ceramide concentrations to disturbed 
insulin signalling (6,13-15). Manipulation of ceramide levels in cultured cells was 
consistently found to affect the insulin signalling pathway downstream at the level of AKT, 
but conflicting reports exist regarding effects on the insulin receptor, IRS-1 and associated PI 
3-kinase activity (6,13-15). Surprisingly, in most studies it has been overlooked that 
metabolites of ceramide, such as glycosphingolipids, might also play an important role in the 
development of insulin resistance. Glycosphingolipids are found in specific (detergent-
resistant) membrane microdomains in close physical proximity to the insulin receptor, as well 
as other tyrosine kinase receptors such as the epidermal growth factor (EGF) receptor (5). A 
regulatory role for glycosphingolipids in hormone sensitivity was first proposed by Bremer 
and coworkers who showed that EGF-mediated signalling is inhibited by GM3, the simplest 
ganglioside (16). More recently, Tagami et al. reported that addition of GM3 to cultured 
adipocytes also suppresses phosphorylation of the insulin receptor and its down-stream 
substrate IRS-1, resulting in reduced glucose uptake (17).  
Other observations further substantiate the role of the gangliosides GM3 in 
responsiveness to insulin. Mutant mice lacking GM3 show an enhanced phosphorylation of 
the skeletal muscle insulin receptor after ligand binding and are protected from high-fat diet 
induced insulin resistance (18). Conversely, GM3 levels are elevated in the muscle of certain 
obese, insulin resistant mouse and rat models (17). Inokuchi and coworkers employed the 
ceramide-analogue 1-phenyl-2-decanoylamino-3-morpholinopropanol (PDMP), an inhibitor 
of glucosylceramide synthase, to reduce glycosphingolipids in cultured adipocytes. They 
noted that PDMP counteracted the inhibitory effects of TNF-alpha on IR and IRS-1 
phosphorylation (17). Very recently it was reported by the same researchers that high GM3 
levels diminished IR accumulation in detergent-resistant membrane microdomains and 
insulin-dependent IR internalization (19). Again glycosphingolipid depletion by incubation of 
cells with PDMP prevented these abnormalities. However, the observations made with PDMP 
are difficult to interpret since this compound not only inhibits conversion of ceramide to 
glucosylceramide but also its transacylation to 1-O-acylceramide and consequently increases 
cellular levels of ceramide (20). Based on the present information it may be therefore 
conceived that not ceramide itself but rather its glycosphingolipid metabolites are 
instrumental in the development of insulin resistance. To discriminate between these 
possibilities we examined in obese mice the effect of reduction of glycosphingolipids by N-
(5’-adamantane-1’-yl-methoxy)-pentyl-1-deoxynojirimycin (AMP-DNM), a specific inhibitor 
89 Insulin sensitivity of hepatic glucose and lipid metabolism in animal models of hepatic steatosis 
 
of glucosylceramide synthase (21). Here we show that pharmacological lowering of 
glycosphingolipids, without significant reduction of ceramide, dramatically reverses insulin 
resistance in in vitro and in vivo models. 
 
 
Materials and methods 
 
Mice 
Experimental procedures were all approved by the appropriate Ethics Committee for Animal 
Experiments. C57Bl/6J and ob/ob mice (C57Bl/6J background) were obtained from Harlan 
(Horst, The Netherlands) and housed in a light- and temperature controlled facility. The 
animals were fed a commercially available lab chow (RMH-B, Hope Farms BV, Woerden, 
The Netherlands) containing about 6% fat and ~0.01% cholesterol (w/w). The iminosugar 
AMP-DNM was mixed in the food for most experiments. In indicated experiments animals 
were used to which the compound had been administered by oral gavage two times daily. 
 
Plasma and tissue sampling 
Animals were sacrificed under isoflurane anaesthesia. A large blood sample was collected by 
cardiac puncture. Tissues were quickly removed and frozen for further analysis. 
 
Cells 
Human adipocytes and appropriate cell culture medium were obtained from Zen-Bio Inc. 
(Chapel Hill, USA). 3T3-L1 pre-adipocytes were obtained from the ATCC (Manassas, USA). 
They were propagated and differentiated as previously described (22). Primary adipocytes 
were prepared from epididymal fat pads as described earlier (23). 
 
Iminosugar 
AMP-DNM (N-(5’-adamantane-1’-yl-methoxy)-pentyl-1-deoxynojirimycin) was synthesized 
as described previously (24). Plasma levels of AMP-DNM were determined by mass 
spectrometry following high pressure liquid chromatography (Xendo, Groningen, The 
Netherlands). 
 
Analysis of lipids and measurement of enzyme activities 
Lipids were extracted according to Folch et al (25). Ceramide and glucosylceramide collected 
from the chloroform phase were determined by HPLC analysis of orthophtaldehyde-
conjugated lipids according to a procedure described previously with some modifications 
(26). The chloroform layer was thoroughly dried and deacylation of lipids was performed in 
0.5 ml 0.1 M NaOH in methanol in a microwave oven (CEM microwave Solids/Moisture 
System SAM-155). After deacylation 0.5 ml methanol and 2 ml chloroform were added and 
phase separation was performed. The chloroform layer was dried under N2 and the deacylated 
lipids were taken up in 250 µl methanol. Deacylated glycolipids were derivatised on line for 
30 min with Ophtalaldehyde. Analysis was performed using an HPLC system (Waters 
Associates, Milford, MA) and a Hypersil BDS C18 3µ, 150 x 4.6 mm reverse phase column 
(Alltech). Chromotographic profiles were analysed using Waters Millenium software. All 
samples were run in duplicate and in every run a reference sample was included.  
Ganglioside composition was determined by HPTLC analysis of the acidic glycolipid 
fraction obtained after Folch extraction using chloroform/methanol/water (65:25:4) as solvent. 
Gangliosides were visualized by spraying resorcinol reagent followed by heating at 105 °C 
for 10 min and quantified by densitometry. Total sphingolipids biosynthesis by cultured cells 
was quantified by exposing cells to [
3H]serine or [
3H]palmitate as described previously (9). 
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Palmitate was administered as 1:1 complex with bovine serum albumin. Activity of 
glucosylceramide synthase and glucocerebrosidase in living cells was determined using as 
substrates fluorescently labelled NBD-ceramide and NBD-glucosylceramide, respectively 
(27). Briefly, NBD-ceramide or NBD-glucosylceramide was complexed to fatty acid-free 
bovine serum albumin in a molar ratio of 1:1. Cells were incubated with 150 µM lipid and 
harvested at different time points. Lipids were extracted, separated by thin layer 
chromatography and NBD-ceramide and NBD-glucosylceramide were quantified (27). 
IC50 values of AMP-DNM for various enzyme activities were determined by 
exposing cells or enzyme preparations to an appropriate range of iminosugar concentrations. 
IC50 values for glucosylceramide synthase and glucocerebrosidase activities were measured 
using living cells with NBD-ceramide and NBD-glucosylceramide as respective substrates. 
Lactase, maltase and sucrase were determined with homogenates of freshly isolated rat 
intestine using assay conditions described earlier (28). Debranching enzyme (alpha-1,6-
glucosidase) was measured with an erythrocyte preparation as enzyme source as described 
previously (29). 
 
2-[
3H]deoxyglucose uptake 
Cultured adipocytes were deprived of serum for 1 h prior to exposure to 0.1 mM 2-
[
3H]deoxyglucose (0.4 mCi/ml). 2-[
3H]deoxyglucose uptake measurements were made in 
triplicate under conditions when hexose uptake was linear (29). Non-specific absorption of 2-
[
3H]deoxyglucose, as determined by cell-associated counts in the presence of 5 µM 
cytochalasin B, was always less than 10% of the total uptake. 
 
Analysis of insulin signalling in 3T3L1 adipocytes 
Fully differentiated 3T3-L1 adipocytes were serum deprived, by incubation in DMEM + 1% 
BSA, and simultaneously pre-treated with or without AMP-DNM (50 µM) and/or TNF alpha 
(0.6 nM) for 24hrs. Following insulin stimulation (5 min with 100 nM) cells were washed 
with ice-cold PBS, and lysed in modified RIPA buffer (50 mM Tris-HCL pH 7.4, 1% NP-40, 
0.25% sodium deoxycholate, 150 mM sodium chloride, 1mM EDTA, 50 mM β-glycerol-2-
phosphate, 5 µM AEBSF, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin A, 1 mM 
sodium pervanadate, 1 mM sodium fluoride, 50 nM okadaic acid). Cell lysates were clarified 
by centrifugation (13,000 rpm for 10 min) and the supernatant collected. Protein 
concentrations were determined using the BioRad DC protein assay kit. Equal amounts of 
whole cell lysates were separated by SDS-PAGE and immunoblots performed in parallel 
using anti-phosphotyrosine antibody (4G10), anti-IRS-1- Upstate Biotech. US), anti-IR (K. 
Siddle), anti-pSer473 AKT, Anti-AKT (Cell Signalling Technology Inc., US), appropriate 
HRP-linked secondary Ab (DAKO, US) and an enzymelinked chemiluminescent kit 
(Amersham, UK). 
 
Measurement of whole-body insulin sensitivity 
Whole-body insulin sensitivity of ob/ob  mice was determined using hyperinsulinemic 
euglycaemic clamps as described previously (31,32). Male ob/ob mice were treated for 7 days 
with a diet with or without MZ21 (25 mg/kg BW). At the start of the diet, mice were equipped 
with a permanent catheter in the right atrium via the jugular vein. Nine hours before the start 
of the clamp experiment, food was withdrawn but mice still had free access to water. Mice 
were kept in metabolic cages during the experiment, allowing frequent collection of 
bloodspots from the tail under conscious and unrestrained conditions. The mice were infused 
for six hours with two solutions. The first infusate contained 220 mU/ml insulin (Actrapid, 
Novo Nordisk., Bagsvaerd, Denmark), 40 µg/ml somatostatin (UCB, Breda, The 
Netherlands), 10 mg/ml BSA (Sigma, St. Louis, MO). To prevent high infusion rates leading 
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to higher morbidity, this solution contained, when given to treated mice, 100 mg/ml glucose, 
from which 3% was [U-
13C]-glucose (99% 
13C APE) (Cambridge Isotope Laboratories Inc., 
Andover, MA). The solution was infused at a rate of 0.3 ml/h. The second infusate was a 30% 
(treated mice) or 15% (untreated mice) glucose solution, from which 3% was [U-
13C]-
glucose. Its infusion rate was adjusted according to measured blood glucose levels to maintain 
euglycemic conditions. Blood glucose levels were measured with a Lifescan EuroFlash 
glucose meter (Lifescan Benelux, Beerse, Belgium) in a small tail blood sample that was 
drawn every 15 minutes. Just before the start of the experiment, a small blood sample was 
obtained by tail bleeding. Blood samples were centrifuged and the obtained plasma was stored 
at -20°C until analysed. Every hour, a bloodspot was obtained by tail bleeding. After the 
clamp, animals were sacrificed by cardiac puncture under anaesthesia. Plasma was obtained 
by centrifugation. The liver was removed, weighed and frozen in liquid N2 until further 
analysis. 
 
Calculation of endogenous glucose production and metabolic clearance rate under clamped 
conditions 
Analytical procedures for extraction of glucose from bloodspots from filterpaper, 
derivatization glucose to its aldonitril pentaacetate derivative and GC-MS were essential 
according to Van Dijk et al. (31,32). The measured fractional isotopomer distribution by 
GCMS (m0-m6) was corrected for the fractional distribution due to natural abundance of 
13C, 
by multiple linear regression to obtain the excess mole fraction of mass isotopomers M0-M6 
due to isotope dilution of infused labelled glucose. Two solutions with [U-
13C]-glucose were 
infused with different rates. Therefore, the total rate of appearance of glucose into plasma 
(Ra(glc;whole body)) was calculated as follows: 
 
Ra(glc;whole body) = (M6(glc)glucose x infusion(glc;M6)glucose + M6(glc)insulin x  
           infusion(glc;M6)insulin)/M6(glc)blood 
 
in which M6(glc)glucose and M6(glc)insulin are the excess mole fractions of infused [U-
13C]-
glucose in the glucose and insulin solution, respectively, and infusion(glc;M6)glucose and 
infusion(glc;M6)insulin are the infusion rates of [U-
13C]-glucose of the glucose and insulin 
solution, respectively. The rate of endogenous plasma glucose (Ra(glc;endo)) was calculated 
as follows: 
 
Ra(glc;endo) = Ra(glc;whole body) - infusion(glc;M6)glucose - infusion(glc;M6)insulin.  
 
The metabolic clearance rate of glucose (MCR) was calculated according to:  
 
MCR = Ra(glc;whole body)/[glc], 
 
where [glc] is the blood glucose concentration (mM).  
 
Glucose tolerance test 
The tolerance test was performed in fasted mice (13–15 h) with oral gavage of glucose (2 g of 
glucose per kg of body weight). Blood glucose values were measured immediately before and 
10, 20, 30, 60, 90 and 120 min after glucose injection. AUCs (areas under the curve) were 
determined for individual mice. 
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Cell surface expression of GM3 and GLUT4 
Flow cytometry using monoclonal anti-GM3 antibody (Seikagu, Japan) or monoclonal anti-
GLUT4 antibody (Abcam, USA) and FITC-or Alexa 488-conjugated rabbit anti-mouse 
secondary antibody were employed according to the procedure described earlier (17). 
 
Statistical testing 
Values presented in figures represent mean +/- SEM. Statistical analysis of two groups was 
assessed by Student’s t-test (one-tailed) or ANOVA for repeated measurement (clamp 
experiment). Level of significance was set at p <0.05. 
 
 
Results 
 
Modulation of glycosphingolipids with AMP-DNM 
N- (5’-adamantane-1’-yl-methoxy)-pentyl-1-deoxynojirimycin (AMP-DNM) is a very potent 
inhibitor of glucosylceramide synthase activity in all cell types tested. As measured using 
fluorescently labelled C6-NBD-ceramide as substrate, exposure of cells to AMP-DNM results 
in swift and marked inhibition of synthesis of glucosylceramide. As determined in this 
manner, IC50 values in cultured macrophages, myoblasts, melanoma cells, HepG2 cells and 
skin fibroblasts are about 150, 220, 200, 150 and 220 nM, respectively. Cellular levels of 
glucosylceramide and its metabolites lactosylceramide and gangliosides are gradually reduced 
by AMP-DNM, reaching equilibrium within 36 hours. Ceramide levels however remain 
constant upon exposure to AMP-DNM. Figure 5.1 shows an illustrative response in lipid 
levels of cultured macrophages and melanoma cells after exposure to 200 nM AMP-DNM. 
 
 
0
20
40
60
80
100
120
140
02 0 4 0 6 0
hours AMP-DNM
r
e
l
a
t
i
v
e
l
i
p
i
d
c
o
n
c
e
n
t
r
a
t
i
o
n
(
%
)
8 0
0
20
40
60
80
100
120
140
02 0 4 0 6 0
hours AMP-DNM
r
e
l
a
t
i
v
e
l
i
p
i
d
c
o
n
c
e
n
t
r
a
t
i
o
n
(
%
)
8 0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Effect of AMP-DNM on ceramide and glucosylceramide concentrations in cultured cells. 
Macrophages derived from peripheral blood monocytes and melanoma cells were cultured in the absence or 
presence of 250 nM AMP-DNM. At different time points, cells were harvested and ceramide and 
glucosylceramide content were determined. Lipid levels are expressed as percentage of those of cells not 
exposed to AMP-DNM. Macrophages: glucosylceramide (closed squares), ceramide (open squares); melanoma 
cells: glucosylceramide (closed diamonds), ceramide (open diamonds). Error bars indicate standard deviation. 
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Figure 5.2. AMP-DNM reverses TNF-alpha induced insulin resistance (A) and surface expression of GM3 (B) in 
3T3-L1 adipocytes. Serum starved 3T3-L1 adipocytes were treated with either vehicle control, AMP-DNM (50 
µM) and/or TNF-alpha (0.6 nM) for 24hrs prior to stimulation with or without insulin (100nM for 5 min.) (A) 
Immunoblots of whole cell lysates were performed in parallel as described in materials and methods. 
Representative blots are shown from one of 3 independent experiments. (B) Cell surface expression of GM3 was 
determined on basal adipocytes (not stimulated with insulin) by FACS analysis. Values represent mean (± SE) % 
of viable cells that stained positive for GM3. * indicates statistical significance (p<0.05) and was observed in 
four independent experiments. 
 
 
Table 5.1. 2-[
3H]deoxyglucose uptake by cultured human adipocytes in the presence and absence of insulin. 
 
  Uptake in cpm/µg protein 
  10
-7 M insulin  10
-8 M insulin  No insulin 
0 µM AMP-DNM  27.6 ± 3.0  23.4 ± 2.9  24.3 ± 2.8 
10 µM AMP-DNM  50.7 ± 4.5  46.4 ± 6.8  29.7 ± 3.1 
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Reduction of glycosphingolipids in normal mice by AMP-DNM 
Normal, six week old C57Bl/6J mice (n=4) were treated with or without AMP-DNM at a dose 
of 25 mg/kg body weight/day for 14 days. The plasma concentration of AMP-DNM was 108 
± 6 nM and remained stable during the period of treatment. Exposure to AMP-DNM was well 
tolerated by the animals as reflected by unchanged body weight gain. After two weeks 
treatment, liver ceramide and glucosylceramide concentrations were analysed by HPLC 
following microwave-mediated deacylation. The hepatic ceramide content of C57Bl/6J mice 
was not changed by the AMP-DNM diet, being 0.24 ± 0.02 and 0.26 ± 0.05 µmol/liver of 
treated and untreated animals. In sharp contrast, liver glucosylceramide (85 ± 15 nmol/liver) 
was reduced by 41 ± 5 % by the AMP-DNM diet. Analysis by HPTLC showed that the 
ganglioside GM2 was concomitantly reduced by ~30%. Similar effects on sphingolipids were 
observed in muscle tissue of treated animals (not shown). The pronounced reduction by AMP-
DNM of glycosphingolipids levels in mouse tissues without concomitant change in ceramide 
concentrations is comparable to the observed effect of the iminosugar in cultured cells. 
 
Effect of AMP-DNM on insulin sensitivity of cultured adipocytes 
In order to study the effect of AMP-DNM on insulin sensitivity in normal cells, we examined 
basal and insulin-stimulated glucose uptake in cultured human adipocytes. Basal uptake of 2-
[
3H]deoxyglucose glucose was not significantly affected by AMP-DNM treatment. However 
uptake of 2-[
3H]deoxyglucose in the presence of 10
-7 M insulin was increased by 84 ± 12 % 
after 16 h exposure to 10 µM AMP-DNM (table 5.1). Glucosylceramide levels in the treated 
cells were reduced to 63 ± 8 % of basal but ceramide levels were unaffected (not shown). In 
order to study the effects of AMP-DNM on insulin signalling in an insulin-resistant cellular 
model we examined 3T3-L1 adipocytes exposed to TNF-alpha. As expected TNF-alpha 
impaired insulin receptor autophosphorylation, IRS-1 tyrosine phosphorylation and the serine 
phosphorylation of AKT at residue 473. All of these abnormalities were significantly 
ameliorated by the simultaneous exposure to AMP-DNM (figure 5.2a). TNF-alpha increased 
cell surface levels of GM3 gangliosides and this was blocked by AMP-DNM (figure 5.2b). 
 
Ceramide and glycosphingolipids in ob/ob mice before and after treatment with AMP-DNM 
In  ob/ob  mice, the hepatic concentration of glucosylceramide was higher (115 ± 16 
nmol/liver) compared to wild types animals (85 ± 15 nmol/liver; p=0.045). Increased 
concentrations of gangliosides were also noted upon HPTLC separation of lipids and charring 
densitometry. The ganglioside GM2 content was 36 ± 12 % increased, a finding consistent 
with previous studies in other tissues of ob/ob mice (17). The ceramide content of liver of 
ob/ob mice was also higher than that in wild type animals (3.15 ± 0.72 and 0.24 ± 0.02 
µmol/liver, respectively). In muscle tissue of ob/ob mice glucosylceramide was again elevated 
compared to wild type mice (2.5 ± 0.5 vs. 1.5 ± 0.4 nmol/mg protein, p=0.031), however 
ceramide concentrations were similar (1.2 ± 0.4 and 1.4 ± 0.6 nmol/mg protein respectively, 
n.s.). 
Two weeks treatment with AMP-DNM did not result in any significant changes in 
ceramide levels in muscle or liver from ob/ob  mice (figure 5.3). In sharp contrast, 
glucosylceramide content of muscle and liver from ob/ob mice decreased by 45 ± 23 % and 
45 ± 11% with AMP-DNM, reaching values similar to those in wild-type animals (figure 5.3). 
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Figure 5.3. Ceramide and glucosylceramide levels in liver and muscle of normal and ob/ob mice treated with 
AMP-DNM. Animals were fed for two weeks with or without 25 mg AMP-DNM/kg. Liver (upper panel) and 
muscle tissue (lower panel) was collected and analysed on ceramide and glucosylceramide content. *, P < 0.05 
by Student's t test. 
 
Beneficial effects of AMP-DNM on metabolism in ob/ob mice 
Prominent effects of AMP-DNM on glucose homeostasis were noted when six week old 
C57Bl/6J mice (n=4) were treated at a dose of 25 mg/kg body weight/day. AMP-DNM had no 
significant effect on body weight or food intake (figure 5.4a). Concomitantly, ob/ob mice 
treated with AMP-DNM showed a dramatic reduction in blood glucose levels (p=0.008) 
(figure 5.4b). Hyperinsulinemic euglycemic clamp studies demonstrated that this was 
associated with a marked improvement in whole body insulin sensitivity (p=0.003) (figure 
5.4c). This was due in part to a significant (~26%) decrease in hepatic glucose production 
(Ra) (p=0.035) as well as a significant (~29%) increase in glucose disposal (Rd) (p=0.0028) 
(figure 5.4d). 
The beneficial effect of AMP-DNM was also revealed by glucose tolerance tests. 
Animals fed with 25 mg/kg AMP-DNM for 8 days showed a better response to oral glucose 
administration as compared to untreated mice. The AUCs of blood glucose levels were 
significantly lower (p=0.023) in AMP-DNM treated mice (see insert figure 5.5). 
Hepatic fat accumulation was apparent in untreated ob/ob mice and this was visibly 
reduced by AMP-DNM therapy. This was confirmed by direct measurement of triglyceride 
levels in livers of AMP-DNM fed ob/ob mice which significantly decreased from 107 ± 13 to 
80 ± 11 nmol/mg liver (p = 0.035). 
Adipocytes were isolated from epididymal fat pads of ob/ob  mice treated with or 
without 25 mg AMP-DNM/kg for 2 weeks. GLUT 4 cell surface expression was examined 
using FACS analysis. Cell surface levels of GLUT4 protein were on average 3.2 fold 
increased in adipocytes from AMP-DNM treated mice as compared to those of controls (not 
shown). 
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Figure 5.4. Beneficial effects of iminosugar feeding on glucose metabolism in ob/ob mice. Ob/ob mice were fed 
either with control chow (open circles and white bars) or with chow providing a dose of 25 mg AMP-DNM per 
kg bodyweight/day (closed circles and grey bars). Body weight (panel a), blood glucose level (panel b), were 
determined at indicated time points. During the clamp, glucose infusion rate (GIR) was monitored (panel c), the 
rate of glucose disposal (Rd(glc) and the rate of endogenous hepatic glucose production (Ra(glc;endo)) were 
calculated (panel d). Data presented are means +/- SD. Significant differences between both groups (*) are 
indicated. Statistical significance of differences were determined using Student’s t test, except in calculations 
over time where ANOVA with repeated measurements was used; p < 0.05 was considered as statistically 
significant. 
 
 
Discussion 
 
In these studies we have demonstrated that AMP-DNM, a potent inhibitor of 
glucosylceramide synthase, enhances insulin stimulated glucose uptake in normal adipocytes 
studies ex vivo and reverses the insulin signalling defect produced by exposure of adipocytes 
to TNF-alpha. More importantly, AMP-DNM has dramatic beneficial effects on the insulin 
resistance and hyperglycaemia seen in ob/ob mice, via a mechanism that does not require a 
reduction in food intake or loss of body weight. 
A key question that arises relates to the specificity of AMP-DNM as an inhibitor of 
glucosylceramide synthase. At a concentration <1 µM, AMP-DNM causes no significant 
inhibition of activity of the lysosomal enzymes glucocerebrosidase and acid α-glucosidase or 
the ER trimming α-glucosidases. The cytosolic debranching enzyme and glycogen synthase 
are also unaffected at such concentrations (data not shown). AMP-DNM was originally 
developed as an inhibitor of a non-lysosomal glucosylceramidase (24). The molecular identity 
of the latter enzyme and its physiological function has still not been established. The enzyme 
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activity is already inhibited by AMP-DNM in the picomolar range (IC50 ~1 nM). Cultured 
adipocytes or ob/ob  mice exposed to low nanomolar concentrations of AMP-DNM that 
completely inhibit the non-lysosomal glucosylceramidase activity but do not effectively 
reduce glucosylceramide synthase activity, do not show improved responsiveness to insulin. It 
therefore can be concluded that inhibition of the non-lysosomal glucosylceramidase by AMP-
DNM is not sufficient, and possibly even not needed, to increase insulin sensitivity. 
Iminosugars can also significantly inhibit intestinal glycosidases, thus reducing the rate of 
digestion and absorption of oligo- and polysaccharides. This may additionally contribute to 
the beneficial effects of AMP-DNM on glucose homeostasis in ob/ob mice. However, AMP-
DNM is only a low affinity inhibitor of sucrase and maltase, with of IC50 values for these 
enzymes of 4.5 µM and 18 µM, respectively (personal observations). Therefore it appears 
highly unlikely that at the dose used AMP-DNM would have significant impact on intestinal 
glycosidases. Finally, it is unlikely that AMP-DNM had significant non-specific toxic effects 
as food intake remained unchanged in treated ob/ob mice and no abnormalities were noted 
upon histological examination of liver, kidney and brain of ob/ob or wild-type mice fed for up 
to 4 weeks with 25 mg/kg body weight/day AMP-DNM. Only modest (30-50%) increases of 
liver glycogen were observed during the first week of feeding of ob/ob mice with AMP-DNM 
diet. Subsequently, glycogen levels remained stable in the normal range of C57Bl/6J animals, 
suggesting that there was no marked inhibition of debranching enzyme. 
 
 
 
 
 
Figure 5.5. Improved glucose tolerance in AMP-DNM treated ob/ob mice. Glucose tolerance tests of male ob/ob 
mice, 8 weeks old, treated for 8 days with or without 25 mg AMP-DNM/ kg (n =6 each) administered by gavage 
two times daily. Animals were starved for 16 h prior to test. Values are expressed +/- SD. P =0.023 by ANOVA. 
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Our studies with this pharmacological inhibitor may help to clarify the relationship between 
obesity, ceramides and insulin resistance and suggest a molecular mechanism for “lipotoxic” 
insulin resistance. Firstly, we confirmed previous observations that liver tissue from insulin 
resistant ob/ob mice had elevated levels of ceramide, glucosylceramide and gangliosides and 
demonstrated that muscle tissue from these animals had increased glucosylceramide but 
normal ceramide concentrations. We then demonstrated that AMP-DNM had dramatic 
beneficial effects on insulin sensitivity without any change in ceramide levels but with a 
marked reduction in tissue levels of glucosylceramide. These observations strongly suggest 
that it is unlikely to be the elevation in ceramide itself that mediates the insulin resistance seen 
in ob/ob mice, but that downstream metabolites of ceramide are more likely to be critically 
involved. This explanation is consistent with recent observations by other researchers 
implicating GM3 gangliosides in the pathogenesis of insulin resistance. 
Our studies in cultured adipocytes provide some potential clues to the mechanism 
whereby AMP-DNM enhances insulin sensitivity. Thus, in normal human adipocytes, AMP-
DNM has no effect in basal glucose uptake but significantly enhances insulin stimulated 
glucose uptake, suggesting an effect in insulin signalling. This is supported by the studies of 
TNF-alpha treated murine adipocytes in which AMP-DNM reversed the adverse effects of 
TNF-alpha on several steps in the insulin signal transduction pathway. This effect was 
demonstrable at a proximal step, i.e. insulin receptor autophosphorylation, of interest because 
of the previously reported localisation of GM3 gangliosides in plasma membrane subdomains 
containing the insulin receptor and the effect of genetic depletion of GM3 on insulin receptor 
autophosphorylation. 
The pharmacological manipulation of the cellular levels of ceramide and its 
metabolites seems, at first sight, to be an intrinsically problematic therapeutic avenue since 
these sphingolipids are implicated in many crucial cellular processes. Ceramide analogues 
like PDMP that inhibit glycosphingolipid biosynthesis and concomitantly cause an increase in 
ceramide are known to exert cytotoxic effects. However, our finding that pharmacological 
manipulation of glycosphingolipid levels with AMP-DNM reverses insulin resistance without 
causing changes in ceramide concentrations may hold promise for the treatment of insulin 
resistance. One hydrophobic iminosugar, N-butyldeoxynojirimycin is already registered for 
the treatment of type 1 Gaucher patients suffering from a deficiency in lysosomal degradation 
of glucosylceramide (33). Although this compound inhibits glucosylceramide synthase, 
compared to AMP-DNM, it is neither a potent nor a selective inhibitor. The IC50 value of N-
butyldeoxynojirimycin for glucosylceramide formation is close to 100 µM when measured 
with a fluorescent ceramide-analogue in living cells (21). The relatively poor bioavailability 
of the compound in mice requires oral administration of large quantities (>5 g/kg body 
weight/day) to reach a plasma concentration consistent with the IC50 value. At such high 
dosages intestinal glycosidases are likely to be inhibited given the measured IC50 values of 
0.5 µM and 9 µM for sucrase and maltase, respectively. Intestinal complaints are a relatively 
common side-effects reported by Gaucher patients receiving N-butyldeoxynojirimycin. 
Interestingly, a more hydrophilic iminosugar, N-hydroxyethyldeoxynojirimycin (Miglitol), is 
already registered as an oral agent for treating diabetes (34). The ancient use of iminosugar-
rich mulberry leaves in the Far East to control hyperglycaemia stimulated the development of 
this drug (35). The presumed mode of action of Miglitol is inhibition of intestinal glycosidase 
activities, thereby buffering monosaccharide assimilation (34). We have established that 
Miglitol does not inhibit glucosylceramide synthase in intact cells or homogenates (personal 
observations). However, since Miglitol is well absorbed it is possible that some proportion of 
the compound is metabolized to some structure that is capable of inhibiting glucosylceramide 
synthase. 
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In summary, our investigations indicate that the beneficial effects of hydrophobic iminosugars 
like AMP-DNM on hyperglycaemia are largely mediated by reduction of excessive 
glycosphingolipids in tissues. These findings support the notion that glycosphingolipids may 
play a critical role in the mediation of lipotoxic insulin resistance and should encourage the 
further evaluation of this class of iminosugar-based compounds for the treatment of human 
insulin resistance and diabetes. 
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Abstract 
 
Accumulation of triglycerides (TG) in the liver is generally associated with hepatic insulin 
resistance. We questioned whether acute hepatic steatosis induced by pharmacological 
blockade of β-oxidation affects hepatic insulin sensitivity, i.e., insulin-mediated suppression 
of VLDL production and insulin-induced activation of phosphatidylinositol 3-kinase (PI3-
kinase) and PKB. Tetradecylglycidic acid (TDGA), an inhibitor of carnitine palmitoyl 
transferase-1 (CPT1), was used for this purpose. Male C57BL/6J mice received 30 mg/kg 
TDGA or its solvent intraperitoneally and were subsequently fasted for 12 h. CPT1 inhibition 
resulted in severe microvesicular hepatic steatosis (19.9 ± 8.3 vs. 112.4 ± 25.2 nmol TG/mg 
liver, control vs. treated, P < 0.05) with elevated plasma nonesterified fatty acid (0.68 ± 0.25 
vs. 1.21 ± 0.41 mM, P < 0.05) and plasma TG (0.39 ± 0.16 vs. 0.60 ± 0.10 mM, P < 0.05) 
concentrations. VLDL-TG production rate was not affected on CPT1 inhibition (74.9 ± 15.2 
vs. 79.1 ± 12.8 µmol TG·kg
–1·min
–1, control vs. treated) although treated mice secreted larger 
VLDL particles (59.3 ± 3.6 vs. 66.6 ± 4.5 nm diameter, P < 0.05). Infusion of insulin under 
euglycemic conditions suppressed VLDL production rate in control and treated mice by 43 
and 54%, respectively, with formation of smaller VLDL particles (51.2 ± 2.5 and 53.2 ± 2.8 
nm diameter). Insulin-induced insulin receptor substrate (IRS)1- and IRS2-associated PI3-
kinase activity and PKB-phosphorylation were not affected on TDGA treatment. In 
conclusion, acute hepatic steatosis caused by pharmacological inhibition of β-oxidation is not 
associated with reduced hepatic insulin sensitivity, indicating that hepatocellular fat content 
per se is not causally related to insulin resistance.  
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Introduction 
 
The liver is a key player in the control of whole body energy metabolism by its ability to 
synthesize, oxidize, store, and distribute the major sources of energy, i.e., glucose and fatty 
acids. In fed conditions, when excess glucose is available from the intestine, plasma insulin 
levels are high, and glucose is stored in the liver as glycogen or enters the glycolytic pathway. 
High insulin suppresses hepatic glucose production (HGP), increases hepatic glucose uptake, 
and stimulates de novo lipogenesis (11). In addition, insulin suppresses the secretion of 
VLDL particles by the liver (36). The actions of insulin on the liver, initiated by binding of 
insulin to its receptor, involve signaling pathways that transduce its effects on gene 
transcription, protein metabolism, and, finally, fluxes of substrates. Of relevance for this work 
is insulin signaling through the phosphatidylinositol 3-kinase (PI3-kinase) pathway. On 
insulin binding, the insulin receptor substrate (IRS) is phosphorylated, and, subsequently, PI3-
kinase is activated. PI3-kinase-mediated phosphatidylinositol 3,4,5-trisphophate (PIP3) 
generation and PIP3-mediated phosphorylation of PKB at Ser473 and Thr308 are key 
processes in the insulin signaling cascade (34). Both PI3-kinase and PKB are involved in 
execution of the effects of insulin on hepatic glucose metabolism (34). It has been reported 
that insulin affects VLDL production via accelerated degradation of apolipoprotein B (apoB) 
(10), a process mediated by PI3-kinase (7) but thought to be independent of PKB (2).  
When insulin levels are low, e.g., during fasting, glucose is mobilized from hepatic 
glycogen stores and hepatic gluconeogenesis is facilitated. β-Oxidation of fatty acids is 
considered the primary source of the energy and reducing equivalents (ATP, NADH) needed 
for gluconeogenesis. β-Oxidation disorders in humans and mice are associated with 
hypoglycemia and reduced ketogenesis as well as with hepatic triglyceride (TG) accumulation 
(hepatic steatosis) on fasting (33). For instance, mice deficient for the major regulator of β-
oxidation, peroxisome proliferator-activated receptor-α, showed massively increased hepatic 
TG levels on fasting (3,17). Hepatic steatosis is generally associated with reduced hepatic 
insulin sensitivity (1,9,24,35), and various animal models have been used to study the effects 
of hepatic steatosis on insulin sensitivity with regard to glucose and fatty acid homeostasis 
(9). For instance, the hepatic steatosis in leptin-deficient ob/ob mice is associated of reduced 
insulin sensitivity of both HGP (16a) and VLDL secretion (44). Moreover, mice that lack the 
peripheral fatty acid transporter (CD36–/– mice) showed massive hepatic TG accumulation 
with decreased sensitivity of HGP to insulin (15).  
During the β-oxidation process, fatty acyl-CoAs are broken down into shorter chains 
by a series of dehydrogenases. Long-chain fatty acids are unable to freely pass the 
mitochondrial membrane and their transfer across the outer mitochondrial membrane is 
mediated by carnitine palmitoyltransferase-1 (CPT1). CPT1 facilitates coupling of carnitine to 
fatty acyl-CoA (32,41). The acylcarnitine thus generated can be transferred across the outer 
membrane by CPT1. Acylcarnitines pass the inner mitochondrial membrane with the help of 
carnitine acylcarnitine translocase. Finally, inside the mitochondria, carnitine is removed from 
the acylchain by CPT2. CPT1 activity has been shown to be rate controlling for a major part 
of hepatic β-oxidation (32). Tetradecylglycidic acid (TDGA) is an inhibitor of CPT1 
(22,38,39) and can be used to evaluate the immediate effects of impaired β-oxidation. We 
used TDGA to address the question of whether hepatic steatosis due to impaired β-oxidation 
is associated with impaired hepatic insulin sensitivity, i.e., insulin-mediated suppression of 
VLDL secretion and insulin-stimulated PKB phosphorylation and PI3-kinase activity.  
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Material and methods 
 
Animals and chemicals 
Male C57BL/6J mice (Harlan, Horst, The Netherlands) were housed in a light- and 
temperature-controlled facility and were fed a commercially available lab chow (cat. no. 
RMH-B; Hope Farms, Woerden, The Netherlands). All experiments were approved by the 
Animal Experiments Ethical Committee of the University of Groningen.  
TDGA was a kind gift from Dr. P. J. Voshol (TNO, Leiden, The Netherlands) and was 
suspended in a concentration of 2.0 mg/ml in a vehicle consisting of 90 mg/ml BSA in saline 
(45).  
 
Collection of basal plasma and liver samples 
Mice received either 30 mg/kg TDGA or its solvent by intraperitoneal injection. Food was 
removed, but the mice still had access to water. Blood glucose levels were measured with a 
Lifescan EuroFlash glucose meter (Lifescan Benelux, Beerse, Belgium) in a small tail blood 
sample taken every hour. After 12 h, mice were killed under isoflurane anesthesia. A large 
blood sample was collected by cardiac puncture and centrifuged. Plasma was stored at –20°C 
until analyzed. The liver was quickly removed, weighed, and frozen in separate portions for 
RNA isolation and lipid analyzes. Plasma TG, phospholipid, nonesterified fatty acids 
(NEFAs), and cholesterol were determined using commercially available kits (Roche 
Diagnostics, Mannheim, Germany, and Wako Chemicals, Neuss, Germany).  
Hepatic TG and cholesterol concentrations were measured using commercial kits 
(Roche Diagnostics and Wako Chemicals) after lipid extraction according to Bligh and Dyer 
(5). After lipid extraction, phospholipid content of the liver was determined according to 
Böttcher et al. (6). Protein concentrations in livers were determined according to Lowry et al. 
(26) by using BSA (Pierce, Rockford, IL) as standard. Hepatic glycogen and glucose-6-
phosphate levels were determined as described previously (18,20). Fatty acid composition 
was determined by gas chromatography after methylation as described previously (25). Liver 
histology was examined on 4-µm-thick frozen liver sections after Oil-Red-O staining for 
neutral lipids by standard procedures. mRNA expression levels in liver was measured by real-
time RT-PCR as described previously (16). PCR results were normalized to β-actin and 18S 
mRNA levels. The sequences of the primers and probes used were listed previously (16,31).  
 
In vivo VLDL-TG production rate 
Mice received either 30 mg/kg TDGA or its solvent as described and were subsequently 
fasted for 9 h. After fasting, mice received an orbital injection of 12.5 mg Triton WR-1339 in 
100 µl PBS. Tail blood samples were taken under light isoflurane anesthesia before and every 
30 min after Triton injection. A large blood sample was collected by cardiac puncture, 90 min 
after Triton injection. The collected blood samples were used for TG measurements.  
To determine the VLDL-TG production rate under hyperinsulinemic conditions, mice 
were equipped with a permanent catheter in the right atrium via the jugular vein (23). The 
two-way entrance of the catheter was attached to the skull with acrylic glue. The mice were 
allowed a resting period of at least 5 days. Mice then received either 30 mg/kg TDGA or its 
solvent as described and were subsequently fasted. Mice were kept in metabolic cages during 
the experiment and the preliminary fasting period, allowing frequent collection of small tail 
blood samples under conscious and unrestrained conditions (40). After 9 h of fasting, the mice 
were infused for 3 h with two solutions. The first was a 1% BSA solution containing 40 µg/ml 
somatostatin (UCB, Breda, The Netherlands). This solution contained insulin (Actrapid; Novo 
Nordisk, Bagsvaerd, Denmark), leading to an insulin infusion rate of 20 mU·kg
–1·min
–1. To 
prevent too high total infusion rates, this solution contained 200 mg/ml glucose. The solution 
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was infused at a constant flow rate of 0.135 ml/h. The second infusate was a 30% glucose 
solution and its infusion rate was adjusted according to measured blood glucose levels to 
maintain euglycemic conditions. Blood glucose levels were measured in a small tail blood 
sample taken every 15 min. After 90 min of infusion, mice received an injection of 12.5 mg 
Triton WR-1339 in 100 µl PBS via the orbita under light isoflurane anesthesia. Orbital blood 
samples were taken under light isoflurane anesthesia before and every 30 min after Triton 
WR-1339 injection. A large blood sample was collected by cardiac puncture 90 min after 
Triton WR-1339 injection. The collected blood samples were used for TG measurements. 
VLDL-TG production rate was calculated from the slope of the TG concentration vs. time 
curve (27). The large blood sample was used for isolation of VLDL.  
 
VLDL isolation and analyses 
Plasma VLDL/intermediate-density lipoprotein (IDL) (density < 1.006 g/ml) was isolated by 
density gradient ultracentrifugation. Hereto, 300 µl plasma was adjusted to 1,000 µl with a 
NaCl/KBr solution of density = 1.006 g/ml and centrifuged at 120,000 rpm in a Optima LX 
tabletop ultracentrifuge (Beckman Instruments, Palo Alto, CA). VLDL was isolated by tube 
slicing, and the volume was recorded by weight. ApoB100 and apoB48 were determined by 
Western blot analysis, using antibodies against human apoB raised in rabbit. TG and 
cholesterol content were determined as described for plasma. Phospholipid content was 
determined using a commercially available kit (Wako Chemicals), and fatty acid composition 
as described previously (25).  
VLDL size and volume distribution profiles were analyzed by dynamic scattering 
using a Nicomp model 370 submicron particle analyzer (Nicomp Particle Sizing Systems, 
Santa Barbara, CA). Particle diameters were calculated from the volume distribution patterns 
provided by the analyzer.  
 
Hepatic insulin signaling pathways 
Mice received either 30 mg/kg TDGA or its solvent as described. After 9 h of fasting, the 
mice were anesthetized and equipped with an infusion line in the vena cava inferior. During 
30 min, mice were infused with saline or a 1% BSA solution containing 13.3 µg/ml 
somatostatin and 100 mg/ml glucose. The latter solution contained insulin resulting in an 
insulin infusion rate of 10 mU·kg
–1·min
–1. The solutions were infused at a flow rate of 0.405 
ml/h. After 30 min of infusion, the liver was quickly removed and frozen in liquid nitrogen.  
Hepatic lysates were made in buffer [in mM: 30 Tris·Cl, pH 7.4, 2.5 EDTA, pH 8.0, 
150 NaCl, 0.5 Na3VO4, 5 NaF, 5 MgCl2, and 1.3 M glycerol and protease inhibitors 
(Complete; Roche Diagnostics)] and cleared by centrifugation. Protein content was 
determined using BCA-kit (Pierce), and equal amounts of protein were used to determine 
PKB-Ser473 and PKB-Thr308 phosphorylation by Western blotting, using antibodies against 
PKB-Ser473P and PKB-Thr308P raised in rabbit (Cell Signaling, Beverly, MA). For PI3-
kinase activity, the lysates were immunoprecipitated overnight with antibodies against IRS1 
(29) or IRS2 (37) raised in rabbits. Following extensive washing, PI3-kinase activity was 
determined as described previously (29). The incorporated radioactivity was quantified using 
a phosphorimager.  
 
Statistics 
All values represent means ± SD for the number of animals indicated. Statistical analysis was 
assessed by the Mann-Whitney U-test. The level of significance was set at P < 0.05. Analyses 
were performed using SPSS for Windows software (SPSS, Chicago, IL).  
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Results 
 
Severe hepatic steatosis on treatment with CPT1 inhibitor TDGA 
To determine the acute effects of β-oxidation inhibition during fasting, i.e., when the body 
strongly depends on fatty acid oxidation for its energy, we treated male C57BL/6J mice with 
the CPT1 inhibitor TDGA and fasted them for 12 h. From 3 h fasting onward, the blood 
glucose levels in TDGA-treated mice were statistically significantly lower than in the control 
mice (figure 6.1). Plasma NEFAs, TG, and free cholesterol levels were increased on TDGA 
treatment (table 6.1). Relative liver weight was increased by 18% on treatment, probably 
related to a marked increase in TG content (table 6.1). In contrast, liver glucose-6-phosphate 
levels were lower in the treated mice. Oil-Red-O staining for neutral lipids on frozen liver 
sections showed massive microvesicular lipid accumulation in periportal (zone 1) as well as 
in perivenous (zone 3) hepatocytes in mice receiving TDGA (figure 6.2). TDGA treatment 
lead to significant changes in the hepatic fatty acid composition (figure 6.3). Relative amounts 
of saturated fatty acids (SAFAs) and polyunsaturated fatty acids (PUFAs) decreased in favor 
of monounsaturated fatty acids (MUFAs).  
 
Insulin sensitivity of VLDL production is not affected by treatment with CPT1 inhibitor TDGA 
Figure 6.4 shows the plasma TG concentration vs. time curve after injection of Triton WR-
1339 in control and TDGA-treated mice, with and without infusion of insulin. From these 
curves, the VLDL-TG production rates were calculated. TDGA treatment did not affect 
VLDL-TG production rate and insulin suppressed the production rate in control and treated 
mice by 43 and 54%, respectively. The concentrations of cholesterol, phospholipids, and TG 
in nascent VLDL particles isolated from plasma obtained at 90 min after Triton WR-1339 
injection are summarized in table 6.2. Under basal conditions, the VLDL TG-to-phospholipid 
ratio tended to increase on TDGA treatment, indicative of the presence of larger particles 
(12). On insulin infusion, this ratio was decreased in both control and treated mice, suggesting 
that insulin-mediated suppression of VLDL-TG secretion was, at least partly, due to the 
secretion of smaller particles. Accordingly, direct measurement of particle sizes revealed that 
the mean diameter of the VLDL particles under basal conditions was increased on TDGA 
treatment (67 ± 5 vs. 59 ± 4 nm, P < 0.05). The diameters were smaller in both control and 
treated mice on insulin infusion (51 ± 3 and 53 ± 3 nm, control and treated, respectively). In 
accordance with these data, apoB100 and apoB48 contents in isolated VLDL fractions were 
increased on insulin infusion, but no significant difference was seen between control and 
TDGA treatment, as determined by Western blot analysis (figure 6.5). The fatty acid 
composition of the VLDL fraction was changed on treatment, resulting in changes similar to 
those seen for the hepatic fatty acids, i.e., increased MUFAs and decreased SAFAs and 
PUFAs (figure 6.6). The hepatic expression of genes encoding enzymes involved in VLDL 
secretion was investigated with real-time RT-PCR (figure 6.7). Expression of Apob and Mttp, 
the latter encoding microsomal TG transfer protein, was slightly increased on TDGA 
treatment. Expression of lipoprotein lipase (Lpl) was slightly reduced in livers of TDGA-
treated mice. 
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Table 6.1. Plasma and hepatic parameters after 12 h of fasting in mice treated with or without CPT1 inhibitor 
TDGA. Values are means ± SD; n = 6 mice. CPT1, carnitine palmytoyl transferase-1; TDGA, tetradecylglycidic 
acid.  *P < 0.05, TDGA vs. control. 
 
 Control  TDGA 
Plasma triglycerides (mM)  0.39 ± 0.16  0.60 ± 0.10 * 
Plasma free cholesterol (mM)  0.61 ± 0.35  0.86 ± 0.36 
Plasma cholesterylester (mM)  1.06 ± 0.54  1.07 ± 0.53 
Plasma NEFA (mM)  0.68 ± 0.26  1.21 ± 0.41 * 
Liver weight (% of bodyweight)  4.26 ± 0.66  5.03 ± 0.39 * 
Liver proteins (mg/g liver)  228 ± 44  211 ± 39 
Liver triglycerides (nmol/mg liver)  19.9 ± 8.3  112.4 ± 25.2 * 
Liver cholesterol (nmol/mg liver)  9.91 ± 1.32  11.13 ± 2.92 * 
Liver phospholipids (nmol/mg liver)  52.65 ± 11.50  49.81 ± 4.61 
Liver glucose-6-phosphate  (nmol/g liver)  50.6 ± 15.6  25.7 ± 2.6 * 
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Figure 6.1. Blood glucose levels during fasting period in mice treated with or without carnitine palmytoyl 
transferase-1 (CPT1)-inhibitor tetradecylglycidic acid (TDGA; 30 mg/kg body wt) (n = 6 mice; *P < 0.05, 
TDGA vs. control). 
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Figure 6.2. Oil-Red-O staining for neutral lipids in livers of mice treated with or without CPT1-inhibitor TDGA. 
V, central vein; P, portal vein.  
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Figure 3. Relative fatty acid profile of livers from mice treated with or without CPT1-inhibitor TDGA. SAFA, 
saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids. N = 6 mice;        
* P < 0.05, TDGA vs. control. 
 
 
Hepatic insulin signaling is not affected on treatment with CPT1 inhibitor TDGA 
To determine whether hepatic steatosis on TDGA treatment affected hepatic insulin signaling, 
we determined PI3-kinase activity and PKB-phosphorylation, both supposedly major steps in 
hepatic insulin signaling. Hereto, TDGA-treated and control mice were subjected to 30-min 
infusion with either saline or insulin. Both IRS1- and IRS2-associated insulin-induced 
increase of PI3-kinase activity did not differ between control and treated mice (figure 6.8). 
Moreover, insulin-induced phosphorylation of PKB, the key mediator of hepatic insulin 
signaling, was not affected by TDGA; insulin-induced PKB phosphorylation on Ser473 and 
Thr308 did not differ between control and TDGA-treated mice (figure 6.9). 
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Figure 6.4. Plasma triglyceride (TG) concentrations and VLDL-TG production rates of mice treated with or 
without CPT1-inhibitor TDGA, under basal and hyperinsulinemic conditions. Inset: VLDL-TG production rate 
in µmol·kg
-1·h
-1 calculated from the plasma TG vs. time curves (n = 6 mice; *P < 0.05, TDGA vs. control). Open 
bars, control mice; closed bars, TDGAtreated mice; open circles, control mice, basal conditions; closed circles, 
TDGA-treated mice, basal conditions; open squares, control mice, hyperinsulinemic conditions; closed squares, 
TDGA-treated mice, hyperinsulinemic conditions. 
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Figure 6.5. Representative apolipoprotein B (apoB) Western blots of VLDL fractions of mice treated with or 
without (Con) CPT1 inhibitor TDGA, under basal and hyperinsulinemic conditions. 
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Figure 6.6. Relative fatty acid profile of VLDL fractions from mice treated with or without (control) CPT1 
inhibitor TDGA (n = 6 mice; * P < 0.05, TDGA vs. control). 
 
 
Table 6.2. Composition and size of nascent VLDL particles of mice treated with or without CPT1 inhibitor 
TDGA under basal and hyperinsulinemic conditions. Values are means ± SD; n = 6 mice; * P < 0.05 TDGA vs. 
control; † P < 0.05 hyperinsulinemic vs. basal. 
 
  Basal Hyperinsulinemic 
  Control TDGA  Control TDGA 
Triglycerides (%)  76.8 ± 1.6  79.1 ± 1.6 *  67.9 ± 1.6 
† 66.8 ± 3.8 
†
Phospholipids (%)  12.2 ± 0.7  11.7 ± 0.8  15.8 ± 0.9 
† 16.2 ± 1.6 
†
Cholesterol (%)  10.9 ± 0.9  9.2 ± 1.1 *  16.4 ± 1.5 
† 17.0 ± 2.3 
†
TG:PL ratio  6.3 ± 0.5  6.8 ± 0.6  4.3 ± 0.3 
† 4.2 ± 0.7 
†
Particle size (nm)  59.3 ± 3.6  66.6 ± 4.5 *  51.2 ± 2.5 
† 53.2 ± 2.8 
†
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Figure 6.7. Changes in hepatic gene expression patterns on TDGA treatment. Results were normalized to β-actin 
and 18S mRNA levels, data from control mice defined as 1. Apob, apolipoprotein B; Apobec1, apolipoprotein B 
editing complex-1; Apoe, apolipoprotein E, Mttp, microsomal triglyceride transfer protein, Lpl, lipoprotein 
lipase. N = 6 mice; * P < 0.05. 
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Figure 6.8. Hepatic phosphatidylinositol 3-kinase (PI3-kinase) activity in mice treated with or without CPT1-
inhibitor TDGA on infusion of saline or insulin. Liver lysates were precipitated with antibodies against Insulin 
receptor substrate (IRS)1 (left) or IRS2 (right). The PI3-kinase activity in acquired pellets was determined by 
incorporation of 32P-ATP into PIP3. The amount of incorporated radioactivity was quantified using a 
phosphorimager. Hepatic PI3-kinase activity in control mice on saline infusion is set as value 100; n = 6 mice;   
# P < 0.05, insulin infusion vs. saline infusion. 
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Figure 6.9. Hepatic PKB-phosphorylation in mice treated with or without CPT1-inhibitor TDGA on infusion of 
saline or insulin. Liver lysates were applied to SDS-PAGE followed by Western blot analysis. Antibody staining 
for PKBphosphorylation at Ser473 (top) and Thr308 (bottom). Each lane represents an individual mouse that 
received infusion of saline or insulin. 
 
 
Discussion 
 
This study demonstrates that pharmacological inhibition of CPT1 by TDGA leads to severe 
hepatic steatosis without affecting insulin sensitivity of hepatic VLDL production. Moreover, 
the PI3-kinase insulin signaling cascade was not affected in the TDGA-induced fatty livers. 
Therefore, this study provides evidence that hepatic fat accumulation per se does not lead to 
insulin resistance in mice and underscores the fact that not all forms of hepatic steatosis are 
associated with insulin resistance.  
In humans, various inherited β-oxidation disorders are associated with increased 
hepatic TG levels, hypoglycemia, and low plasma ketone body levels on fasting (33). The 
TDGA-treated mice showed marked hypoglycemia during fasting. From 3 h of fasting on, 
blood glucose levels were lower in TDGA-treated than controls and showed a steady state. 
Therefore, we performed all subsequent experiments within 9 to 12 h of fasting.  
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Two types of hepatic steatosis are usually discerned, i.e., macrovesicular and microvesicular 
steatosis. The latter type is particularly found in subjects with β-oxidation disorders (8,13); 
TDGA treatment was also associated with microvesicular hepatic steatosis in mice (figure 
6.2). Despite the overabundance of fat in the liver and slightly increased hepatic Apob and 
Mttp gene expression (figure 6.7), basal VLDL-TG production rate was not affected on 
TDGA treatment (figure 6.4). Because this unaffected VLDL-TG production rate was 
accompanied by a 54% increase of plasma TG levels (table 6.1), clearance of TG-rich 
lipoproteins was, by definition, affected in TDGA-treated mice. Slightly reduced hepatic Lpl 
expression (figure 6.7) might contribute to reduced VLDL lipolysis. Moreover, the increased 
NEFA levels on TDGA treatment (table 6.1) might also reduce the capacity of LPL to 
lipolyse VLDL-TG (30). The unaffected VLDL-TG production rate on TDGA treatment may, 
at first sight, seems surprising because VLDL production is one means for the liver to get rid 
of large amounts of TG that accumulate during fasting. A stimulatory effect on VLDL-TG 
production was found in mice with hepatic steatosis due to increased de novo lipogenesis on 
liver X receptor agonist treatment (16). On the other hand, ob/ob mice show severe hepatic 
steatosis and increased de novo lipogenesis, but do not have increased VLDL-TG production 
under basal conditions (44). Furthermore, hepatic steatosis associated with inhibition of 
glucose-6-phosphatase activity was also without effect on VLDL production (4). These 
observations suggest that increased hepatic TG content per se does not stimulate hepatic 
VLDL production. Various factors, apart from the accumulation of TG, might contribute to 
changes in VLDL production. TGs are not the sole components of VLDL; hepatic cholesterol 
and phospholipid availability or synthesis might also influence the secretion and assembly of 
VLDL. In our TDGA-treated mice, hepatic cholesterol levels were slightly higher but 
phospholipid content was not affected. It has been suggested that de novo synthesis of 
cholesterol (19) and phospholipid (42), rather than their concentrations, are determinants of 
VLDL production. Although we have no direct measurements of these parameters, in a 
microarray experiment employing TDGA, we found significantly reduced hepatic gene 
expression of Pemt, encoding phosphatidylethanolamine N-methyltransferase, a key player in 
phospholipid synthesis (F. R. van der Leij, personal communication). Interestingly, PEMT is 
thought to play an important role in providing phospholipid needed for the surface of VLDL 
(28).  
Another explanation for the unaffected VLDL-TG production might be duration of TG 
accumulation. It is reported that fatty acids taken up by the hepatocyte are not directly used 
for VLDL production (14) but are esterified and stored in a cytoplasmic pool. Utilization of 
TGs from this pool for VLDL assembly requires hydrolysis followed by reesterification. Thus 
an TG accumulation over a short period of time, as shown in this study, might not 
immediately lead to increased VLDL-TG production.  
Hepatic steatosis is commonly associated with decreased insulin sensitivity (1,24,35). 
Hepatic insulin sensitivity was tested in a number of ways. First, we checked whether insulin 
would be able to effectively suppress the secretion of VLDL by the liver. Unexpectedly, 
insulin suppressed VLDL-TG production rate equally well in control and TDGA-treated mice 
(figure 6.4). This is in contrast to the situation in ob/ob mice, a commonly used model of 
insulin resistance. Wiegman et al. (44) showed that insulin failed to effectively suppress 
VLDL-TG production in ob/ob mice. Exactly how insulin suppresses VLDL production is not 
entirely clear. It has been suggested that insulin stimulates intracellular degradation of the 
major VLDL apolipoprotein apoB (7) through a mechanism involving PI3-kinase but not 
PKB (2,7,10). Therefore, we determined PI3-kinase activity and PKB phosphorylation in the 
steatotic livers of TDGA-treated mice. Indeed, Western blot analyses revealed that TDGA 
treatment did not affect insulin-induced hepatic PKB-phosphorylation at Ser473 nor at 
Thr308 (figure 6.9). Moreover, IRS1- nor IRS2-associated insulin-stimulated PI3-kinase 
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activities in the liver were affected on TDGA treatment (figure 6.8). Both results strongly 
suggest that hepatic insulin signaling is not affected in the rapidly developed fatty liver of 
TDGA-treated mice. From these data, and from figure 6.4, it cannot be concluded whether 
insulin-mediated suppression of VLDL production is independent from PKB, as suggested 
recently (2). In the study from Au et al. (2), however, it was concluded that PKB was not 
involved in insulin-mediated inhibition of apoB degradation. Other subclasses of PKB and/or 
PKC might be responsible for the effects of insulin on VLDL production. A recent report 
showed that PKC-Θ knockout mice are protected from fat-induced insulin resistance (21), 
suggesting that PKC-Θ is an important component in (skeletal muscle) insulin signaling.  
An aspect that might be involved in the lack of association between hepatic steatosis 
and insulin resistance relates to the difference in the hepatic fatty acid profile between control 
and treated mice (figure 6.3). An increase in dietary MUFAs resulted in improved insulin 
sensitivity in healthy men and women (43), but had no effect on insulin secretion. Therefore, 
hepatic insulin sensitivity might be better preserved in fatty livers that contain relatively more 
MUFAs, as observed in TDGA-treated mice, than fatty livers with predominantly SAFA-
containing TG.  
In conclusion, CPT1 inhibition with TDGA led to the expected microvesicular hepatic 
steatosis in C57BL/6J mice. However, this was not associated with reduced hepatic insulin 
sensitivity because the hepatic insulin signaling cascade was not affected and the inhibitory 
effects of insulin on VLDL production in vivo were not blunted. Therefore, in combination 
with other data (4,16a,44), these observations support the notion that hepatocellular fat 
content per se is not causally related to induction of insulin resistance in mice.  
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Abstract 
 
In mammals, hepatic expression of lipogenic genes is regulated by the coordinate action of 
thetranscription factors sterol-regulatory element-binding protein-1c (SREBP-1c), 
carbohydrate responsive element binding protein (ChREBP) and liver X receptor (LXR). The 
“master-switch” LXR controls not only transcription of Srebp-1c and Chrebp but also 
ChREBP activity. Treatment of mice with S4048, a pharmacological inhibitor of glucose-6-
phosphate translocase, results in increased hepatic triglyceride concentrations associated with 
markedly enhanced transcription of lipogenic genes. We used C57BL/6J OlaHsd mice as well 
as LXRα -/- mice and their wild-type littermates to investigate which lipogenic transcription 
factor is critical for S4048-induced de novo lipogenesis and hepatic steatosis. S4048-treatment 
resulted in similar induction of hepatic steatosis and lipogenic gene expression in all strains of 
mice, i.e., does not require the presence of LXRα. Expression of the ChREBP target gene 
pyruvate kinase was significantly increased, but expression of Srebp-1c and its target gene 
glucokinase was not affected or even decreased by S4048. Nuclear translocation of ChREBP 
was not affected, probably related to concomitantly increased AMPK activity. These data 
strongly indicate involvement of ChREBP but not of SREBP-1c and LXRα in S4048-induced 
de novo lipogenesis and hepatic steatosis. 
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Introduction 
 
In fed conditions, liver and muscle store excess glucose as glycogen, but this storage capacity 
is limited (1). A certain amount of glucose is therefore broken down in the glycolytic pathway 
to yield pyruvate and, after passing the tricarboxylic acid cycle, acetyl-CoA moieties that can 
be used for production of fatty acids and triglycerides (TGs) in a process called de novo 
lipogenesis (DNL). Hepatic transcription of genes encoding for enzymes involved in DNL is 
tightly controlled by three transcription factors, i.e., sterol-regulatory element-binding 
protein-1c (SREBP-1c) (2), carbohydrate responsive element binding protein (ChREBP) 
(3,4), and liver X receptor (LXR) (5,6).  
SREBP-1c, a basic-helix-loop-helix-leucine-zipper transcription factor bound in 
inactive form to the ER membrane, is known to facilitate transcription of many genes 
involved in DNL (2), including acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), 
and acyl-CoA synthase (ACS) upon its activation. Both transcription and activation of 
SREBP-1c itself is tightly regulated by insulin (7). 
ChREBP binds as a heterodimer with Mlx (8) to the carbohydrate response element 
(ChoRE) composed of two E-box (5’-CACGTG-3’) or E-box-like sequences present in 
promoters of target genes. Upon increasing intracellular levels of the glucose metabolite 
xylulose-5-phosphate (Xu5P), protein phosphatase-2A (PP2A) becomes active and 
dephosphorylates ChREBP. Translocation of ChREBP into the nucleus is enhanced upon 
dephosphorylation of Ser196. Dephosporylation of Thr666 enhances the binding activity of 
ChREBP to DNA (9). AMP-activated protein kinase (AMPK) phosphorylates ChREBP on 
Ser196 and protein kinase A (PKA) phosphorylates ChREBP on both Thr666 and Ser196 and 
can thus inhibit ChREBP-mediated gene transcription (10). Activity of AMPK is increased 
upon elevated energy-usage (e.g., exercise) (11). Remarkably, most genes regulated by 
SREBP-1c also are regulated by ChREBP (12), i.e., Fas, Acc and Acs. Expression of the gene 
encoding pyruvate kinase (PK) is regulated by ChREBP, but not by SREBP-1c (10). In 
contrast, expression of the gene encoding glucokinase (GK) is regulated by SREBP-1c, but 
not by ChREBP (13). 
LXR has been identified as an oxysterol-activated nuclear receptor (14-16) that, after 
ligand-binding, forms a heterodimer with the retinoid X receptor (RXR). The LXR/RXR 
heterodimer binds to a LXR response element (LXRE), resulting in adaptation of gene 
transcription (17). LXR controls expression of various genes involved in DNL, in part via 
stimulation of Srebp-1c transcription (5,18,19), but also by direct effects on transcription of 
Fas (20). In experiments with SREBP-1c -/- mice, it was shown that pharmacological LXR 
activation increased Acc expression independent of SREBP-1c (21). The promoter region of 
the ACC-gene lacks an LXRE, suggesting indirect, SREBP-1c-independent LXR-effects. 
Recently, it was shown that LXR also regulates mRNA levels of ChREBP (22). Moreover, it 
was speculated that ChREBP activity was mediated by LXR via effects on AMPK (22). 
121 Insulin sensitivity of hepatic glucose and lipid metabolism in animal models of hepatic steatosis 
 
S4048 is a pharmacological inhibitor of glucoss-6-phosphate (G6P) translocase (G6PT) and, 
when given to animals, provides a model of glycogen storage disease type I (GSDI). GSDI 
patients have a defect in the glucose-6-phosphatase (G6Pase) enzyme complex, consisting of 
G6PT and G6P hydrolase (G6PH). As a result of this defect, the patients do not only show 
increased hepatic glycogen levels, but also massively increased DNL (23). Treatment of rats 
with S4048 resulted in elevated hepatic G6P levels (24) and increased lipogenesis (25), 
resulting in hepatic steatosis. Because Xu5P is an intermediate in the pentose phosphate 
pathway that is markedly enhanced upon increasing G6P levels (26), the data gathered so far 
strongly suggest a role of ChREBP in the S4048-induced lipogenesis, but the exact roles of 
the other lipogenic transcription factors have remained unclear. In the present study, we 
therefore questioned which lipogenic transcription factor(s) is critically involved in S4048-
induced DNL and hepatic steatosis.  
 
 
Material and methods 
 
In vivo experiments 
Male C57BL/6J OlaHsd mice (Harlan, Horst, The Netherlands) and LXRα -/- mice and their 
wild-type littermates on a mixed C57BL/6J Sv129/OlaHsd background were housed in a 
light- and temperature controlled facility and were fed a commercially available lab chow 
(RMH-B, Hope Farms BV, Woerden, The Netherlands) and had free access to water. The 
mice received humane care and experimental procedures were in accordance with local 
guidelines for use of experimental animals. S4048 was infused to the mice via a permanent 
catheter in the right atrium of the heart (27) from which the entrance was attached to the skull. 
The mice were allowed a recovery period of at least five days after surgery. Mice were kept in 
metabolic cages during the experiment and the preliminary fasting period, allowing frequent 
collection small tail blood samples under conscious and unrestrained conditions (28). After 
nine hours of fasting, the mice were infused for six hours with S4048 (a generous gift of 
Aventis Pharma, Frankfurst, Germany) (5.5 mg S4048/ml PBS with 6% DMSO, 0.135 ml/h). 
Blood glucose levels were measured in a small tail blood sample that was taken every hour 
during the experiment. After the six hours of infusion, the mice were killed by cardiac 
puncture and the liver was immediately removed, weighed and freeze clamped. The liver was 
powdered and stored in separate portions until later analyses.  
 
Hepatic  analyses 
Hepatic concentrations of TG, free cholesterol and total cholesterol were measured using 
commercial kits (Roche Diagnostics, Mannheim, Germany, and Wako Chemicals, Neuss, 
Germany) after lipid extraction according to Bligh and Dyer (29). Phospholipid content of the 
liver was determined according to Böttcher et al. (30) after lipid extraction. Protein 
concentrations in livers were determined according to Lowry et al. (31) using bovine serum 
albumin (Pierce, Rockford, IL) as standard. Hepatic glycogen and G6P levels were 
determined as described by Bergmeyer (32). 
 
Pharmacological LXR activation 
Male C57BL/6J mice received 10 mg/kg of the LXR agonist T0901317 (kindly donated by 
Organon Laboratories, Oss, The Netherlands) or its solvent by gavage daily for 4 days. 
T0901317 was dissolved in DMSO and Chremophor (both Sigma, St. Louis, MO, USA) in 
5% mannitol/water, to a final concentration of 2.5 mg/ml. On the morning of the fifth day, the 
liver was quickly removed, weighed and frozen in separate portions for RNA isolation. 
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Table 7.1. Primers and probes used for realtime-PCR analysis. 
 
Gene    Sequences (5’ to 3’)  GenBank
TM accession no. 
β-Actin  Forward AGCCATGTACGTAGCCATCCA NM 007393  
  Reverse TCTCCGGAGTCCATCACAATG
  Probe TGTCCCTGTATGCCTCTGGTCGTACCAC
Pk  Forward CGTTTGTGCCACACAGATGCT NM 013631 
  Reverse CATTGGCCACATCGCTTGTCT
  Probe AGCATGATCACTAAGGCTCGACCAACTCGG
Acc1  Forward GCCATTGGTATTGGGGCTTAC NM 133360 
 Reverse  CCCGACCAAGGACTTTGTTG
  Probe CTCAACCTGGATGGTTCTTTGTCCCAGC
Acc2  Forward CATACACAGAGCTGGTGTTGGACT NM 133904 
 Reverse  CACCATGCCCACCTCGTTAC
  Probe CAGGAAGCCGGTTCATCTCCACCAG
Fas  Forward GGCATCATTGGGCACTCCTT NM 007988  
 Reverse  GCTGCAAGCACAGCCTCTCT
  Probe CCATCTGCATAGCCACAGGCAACCTC
G6pt  Forward GAGGCCTTGTAGGAAGCATTG NM 008063 
 Reverse  CCATCCCAGCCATCATGAGTA
  Probe CTCTGTATGGGAACCCTCGCCACG
G6ph  Forward CTGCAAGGGAGAACTCAGCAA NM 008061 
  Reverse GAGGACCAAGGAAGCCACAAT
  Probe TCGTTCCCATTCCGCTTCGCCT
Chrebp  Forward GATGGTGCGAACAGCTCTTCT NM 021455 
  Reverse GGCTGTGTCATGGTGAA
  Probe CCAGGCTCCTCCTCGGAGCCC
Srebp-1c  Forward GGAGCCATGGATTGCACATT AF286470   
 Reverse  CCTGTCTCACCCCCAGCATA
  Probe CAGCTCATCAACAACCAAGACAGTGACTTCC
Gk  Forward CCTGGGCTTCACCTTCTCCTT NM 010292 
  Reverse GAGGCCTTGAAGCCCTTGGT
  Probe CACGAAGACATAGACAAGGGCATCCTGCTC
 
 
 
RNA isolation and measurement of mRNA levels by Real Time-PCR (Taqman) 
mRNA expression levels in liver was measured by realtime-PCR as described before (6). PCR 
results were normalised to β-actin mRNA levels. The sequences of the primers and probes 
used are listed in table 7.1. 
 
Nuclear translocation of ChREBP 
Hepatic nuclear extracts of livers were made according to Itoh et al. (33). In short, powdered 
livers were homogenized with pre-chilled glass douncers in a cytosolic lysis buffer containing 
10 mM Hepes, pH 7.5; 1.5 mM MgCl2; 10 mM KCl; and protease inhibitors (Complete, 
Roche Diagnostics). The homogenate was centrifuged 5 min 5,000 rpm at 4ºC. The 
centrifugation procedure was repeated with the received supernatant. The supernatant thus 
received contained the cytosolic fraction. The pellet from the first centrifugation step was 
dissolved in a nuclear extract buffer containing 50 mM Tris HCl, pH 7.2; 140 mM NaCl; 2 
mM EDTA; 1% N-P450; and protease inhibitors (Complete, Roche Diagnostics), and 
incubated for 30 minutes on ice followed by centrifugation at 15,000 rpm at 4ºC for 5 min. 
The supernatant retrieved is the nuclear fraction. Protein content was determined using BCA-
kit (Pierce) and equal amounts of protein were used to determine ChREBP by Western 
blotting, using an antibody raised in rabbit (Novus Biologicals, Littleton, CO).  
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Hepatic insulin signaling experiment 
After 5:45 hours of S4048-infusion, two C57BL/6J mice in each group (vehicle and S4048) 
received an i.p. injection of 200 µl water containing 50 mU insulin (Actrapid, Novo Nordisk, 
Bagsvaerd, Denmark), 2.7 µg somatostatin (UCB, Breda, The Netherlands), 10% glucose and 
1% bovine serum albumine (Sigma-Aldrich, St. Louis, MO). Fifteen minutes after the 
injection, the mice were killed by cardiac puncture and the liver was immediately removed, 
weighed and freeze clamped until later analysis. 
Hepatic lysates were made in buffer (30 mM Tris.Cl pH 7.4; 2.5 mM EDTA pH 8.0; 
150 mM NaCl; 1.3 M glycerol; 0.5 mM Na3VO4; 5 mM NaF; 5 mM MgCl2; and protease 
inhibitors (Complete, Roche Diagnostics)) and cleared by centrifugation. Protein content was 
determined using BCA-kit (Pierce) and equal amounts of protein were used to determine 
PKB-Ser473 and αAMPK-Thr172 by Western blotting, using antibodies against protein 
kinase B-Ser473P (PKB-Ser473P) and αAMPK-Thr172P raised in rabbit (Cell signaling, 
Beverly, MA).  
 
Statistics 
All values represent mean ± standard deviation for the number of animals indicated. 
Statistical analysis was assessed by Mann-Whitney U test. Level of significance was set at 
p<0.05. Analyses were performed using SPSS for Windows software (SPSS, Chicago, IL, 
USA). 
 
 
Results 
 
ChREBP but not SREBP-1c is involved in S4048-induced DNL and hepatic steatosis 
Previous experiments from our laboratory (24,25) showed that pharmacological inhibition of 
G6PT with S4048 resulted in severe hepatic steatosis in rats. In the present study, conscious, 
unrestrained mice were infused during 6 hours with S4048. In S4048-treated C57BL/6J 
OlaHsd mice, blood glucose levels were significantly reduced within 1 hour (figure 7.1). At 
the end of the 6-hour infusion, blood glucose levels were 64% lower in the treated mice 
compared to untreated mice. In livers of S4048-treated mice, concentrations of glycogen, G6P 
and TGs were increased compared to control mice (table 7.2). Hepatic cholesterol and 
phospholipid levels were not affected.  
In the livers of S4048-treated mice, expression of genes encoding enzymes involved in 
DNL, i.e., Fas, Acc1 and Acc2, was markedly increased compared to control mice (figure 
7.2), suggesting that enhanced DNL contributes to S4048-induced hepatic steatosis in mice. 
Expression of the genes encoding the G6Pase enzyme complex, G6PT and G6PH, was also 
increased upon G6PT inhibition. Compared to control mice, hepatic mRNA levels of Chrebp 
and Pk in S4048-treated mice were increased by 90% and 400%, respectively. Taken together, 
this strongly suggests that S4048-induced hepatic steatosis is related to ChREBP-induced 
DNL, because Pk gene expression is regulated by ChREBP but not by SREBP-1c (10). 
Moreover, upon S4048-infusion, expression of Srebp-1c was not affected and mRNA level of 
its target gene Gk was even reduced by 70% (figure 7.2). This suggests that SREBP-1c is not 
involved in S4048-induced hepatic steatosis, because Gk expression is regulated by SREBP-
1c and not by ChREBP (13).  
To investigate whether ChREBP protein nuclear translocation was affected upon 
S4048-infusion, we determined the cytosolic and nuclear ChREBP protein levels by Western 
blotting. Figure 7.3 shows that most of the ChREBP protein is located in the cytosol and that 
G6PT inhibition, surprisingly, does not affect the subcellular translocation of ChREBP. 
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Table 7.2. Hepatic parameters of C57BL/6J OlaHsd mice treated with 30 mg·kg
-1·h
-1 glucose-6-phosphate 
translocator inhibitor S4048 or vehicle. 
 
  Vehicle S4048 
Liverweight (% of body weight)  5.2 ± 2.2  5.1 ± 0.5 
Proteins (mg/g liver)  194 ± 20  222 ± 33 
Triglycerides (nmol/mg liver)  25.7 ± 6.9  60.3 ± 22.6 * 
Free cholesterol (nmol/mg liver)  8.1 ± 1.5  8.2 ± 1.6 
Cholesterylester (nmol/mg liver)  1.9 ± 0.7  2.5 ± 1.7 
Phospholipids (nmol/mg liver)  37.7 ± 11.8  40.3 ± 5.8 
Liver glycogen (nmol/mg
 liver)  16.1 ± 3.4  254.8 ± 85.4 * 
Liver G6P (nmol/g
 liver)  21.4 ± 15.0  574.9 ± 133.7 * 
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Figure 7.1. Relative blood glucose levels in C57BL/6J OlaHsd mice during of 30 mg·kg
-1·h
-1 glucose-6-
phosphate translocase inhibitor S4048 or vehicle. Data are mean ± S.D.; n=7; *, p<0.05 S4048 vs. vehicle; #, 
P<0.05 vs. t=0. 
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Figure 7.2. Changes in hepatic gene expression patterns upon treatment with 30 mg·kg
-1·h
-1 glucose-6-phosphate 
translocase inhibitor S4048. Results were normalized to β-actin mRNA levels, data from untreated mice defined 
as ‘1’. Pk, pyruvate kinase; Acc, acetyl-CoA carboxylase; Fas, fatty acid synthase; G6pt, glucose-phosphate 
translocase; G6ph, glucose-6-phosphate hydrolase; Chrebp, carbohydrate responsive element binding protein; 
Srebp-1c, sterol-regulatory element-binding protein-1c; Gk, glucokinase. Data are mean ± S.D.; n=5; *, p<0.05. 
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Figure 7.3. ChREBP Western blots of cytosolic (C) and nuclear (N) liver extracts of mice treated with 30   
mg·kg
-1·h
-1  glucose-6-phosphate translocase inhibitor S4048 or vehicle. 
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Figure 7.4. Hepatic AMPK-phosphorylation and PKB-phosphorylation Western blots of mice treated with 30 
mg·kg
-1·h
-1 glucose-6-phosphate translocase inhibitor S4048 or vehicle, with or without injection of insulin. Each 
lane represents an individual mouse. 
 
 
Increased AMPK-phosphorylation upon S4048-treatment 
To test whether AMPK activity was changed and whether insulin could suppress this 
activation, as reported by Witters and Kemp (34), hepatic AMPK phosphorylation was 
determined by Western blotting in livers from control and S4048-treated mice with or without 
insulin injection (figure 7.4). Remarkably, in livers of mice not treated with insulin, the 
phosphorylation at Thr172 of the α-subunit of AMPK was clearly increased by S4048-
treatment mice. Phosphorylation subsequently decreased to the same extent in control and 
S4048-treated mice. Moreover, insulin-induced phosphorylation and activation of PKB, the 
main transducer of insulin-effects on lipid and glucose metabolism (35), was not affected in 
the S4048-induced fatty livers.  
 
Pharmacological LXR activation regulates expression of the ChREBP target gene Pk 
Treatment of C57BL/6J mice with the pharmacological LXR ligand T0901317 for 4 days 
resulted in increased hepatic mRNA levels of Pk (figure 7.5). Pharmacological LXR 
activation did not affect Chrebp mRNA levels. Taken together, these results show that LXR-
induced DNL might, in part, be mediated via ChREBP. 
 
S4048-induced de novo lipogenesis and hepatic steatosis is independent of LXRα 
To test whether S4048-induced hepatic steatosis is dependent on LXRα, the isoform most 
likely involved in regulation of lipogenic gene expression, LXRα -/- mice and their wild-type 
littermates were treated with S4048. Infusion of S4048 resulted in hypoglycemia in all mice 
with no differences between the knockouts and the wild-type littermates (figure 7.6). After 6 
hours of infusion, blood glucose levels were decreased by 45% and 43% in LXRα +/+ and 
LXRα -/- mice, respectively. Hepatic glycogen, G6P and TG levels increased upon S4048-
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infusion in both knockouts and wild-types (table 7.3), although hepatic TG levels upon 
S4048-treatment remained somewhat lower in the LXRα +/+ mice. The hepatic 
cholesterylester content was not affected by S4048 in the wild-types, but rose 3.4-fold in the 
LXRα -/- mice.  
To test whether LXRα deficiency affected S4048-induced transcription of lipogenic 
genes, we measured hepatic gene expression by realtime RT-PCR (figure 7.7). Expression of 
Pk, Acc1, Acc2 and Fas was induced by S4048 with no differences between LXRα -/- and  
LXRα +/+ mice. Thus, S4048-induced expression of lipogenic genes is independent of LXRα. 
In both type of mice, S4048-infusion induced transcription of G6pt, G6ph and Chrebp. Srebp-
1c mRNA levels were lower in LXRα -/- mice compared to the wild-types, and its expression 
decreased even more upon S4048-infusion. mRNA levels of Gk were not affected upon 
S4048-infusion in either type of mice. 
  Comparable with the C57BL/6J OlaHsdmice, translocation of ChREBP protein was 
not affected by S4048 (figure 7.8): there was also no difference between LXRα +/+ and  
LXRα -/- mice in this respect. 
 
0
0.5
1.0
1.5
2.0
2.5
Chrebp Pk
control
T0901317 *
0
0.5
1.0
1.5
2.0
2.5
Chrebp Pk
control
T0901317 *
 
Figure 7.5. Changes in hepatic gene expression patterns upon treatment with the synthetic liver X receptor ligand 
T0901317. Results normalized to β-actin mRNA levels, data from untreated mice defined as ‘1’. Pk, pyruvate 
kinase; Chrebp, carbohydrate responsive element binding protein. Data are mean ± S.D.; n=3; *, p<0.05. 
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Figure 7.6. Relative blood glucose levels in LXRα +/+ and LXRα -/-mice during infusion with 30 mg·kg
-1·h
-1 
glucose-6-phosphate translocase inhibitor S4048. Data are mean ± S.D.; n=6; *, p<0.05 vs. t=0 in LXRα +/+ 
mice; #, p<0.05 vs. t=0 in LXRα -/- mice. 
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Table 7.3. Hepatic parameters of LXRα +/+ and LXRα -/-mice treated with or without 30 mg·kg
-1·h
-1 glucose-6-
phosphate translocater inhibitor S4048. 
 
  LXRα +/+  LXRα -/- 
  control S4048 Control S4048 
Liverweight (% of body weight)  4.6 ± 0.4  4.6 ± 0.0  4.54 ± 0.2  4.3 ± 0.3 
Proteins (mg/g liver)  180 ± 14  264 ± 15 *  186 ± 20  257 ± 27 * 
Triglycerides (nmol/mg liver)  18.1 ± 11.0  38.1 ± 2.5 *  24.7 ± 5.6  71.2 ± 15.3 * 
Free cholesterol (nmol/mg liver)  7.4 ± 0.6  8.6 ± 1.4  7.2 ± 0.4  7.6 ± 0.3 
Cholesterylester (nmol/mg liver)  1.1 ± 0.1  1.9 ± 0.4  0.9 ± 0.4  3.1 ± 0.3 * 
Phospholipids (nmol/mg liver)  44.0 ± 3.7  45.2 ± 3.7  39.5 ± 3.5  45.1 ± 5.0 
Liver glycogen (nmol/mg
 liver)  78.8 ± 26.2  183.0 ± 6.1 *  101.6 ± 53.0  336.0 ± 40.1 * 
Liver G6P (nmol/g
 liver)  262.5 ± 66.0  998.8 ± 288.9 *  340.7 ± 136.8  624.5 ± 50.6 * 
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Figure 7.7. Changes in hepatic gene expression patterns in LXRα +/+ and LXRα -/- mice upon treatment with 30 
mg·kg
-1·h
-1 glucose-6-phosphate translocase inhibitor S4048. Results were normalized to β-actin mRNA levels, 
data from untreated mice defined as ‘1’. Pk, pyruvate kinase; Acc, acetyl-CoA carboxylase; Fas, fatty acid 
synthase;  G6pt, glucose-phopshate translocase; G6ph, glucose-6-phosphate hydrolase; Chrebp, carbohydrate 
responsive element binding protein; Srebp-1c, sterol-regulatory element-binding protein-1c; Gk, glucokinase. 
Data are mean ± S.D.; n=7 (control mice); n=3 (S4048-treated mice); *, p<0.05 S4048 vs. control; #, P<0.05 vs. 
control LXRα +/+ mice. 
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Figure 7.8. ChREBP Western blots of cytosolic (C) and nuclear (N) liver extracts of LXRα +/+ and LXRα -/- 
mice treated with or without 30 mg·kg
-1·h
-1 glucose-6-phosphate translocase inhibitor S4048.  
 
 
Discussion 
 
The regulation of hepatic lipid metabolism, and especially of DNL, is regulated by several 
transcription factors, including SREBP-1c, ChREBP and LXR. Numerous studies have 
addressed the roles of SREBP-1c and LXR in control of DNL and development of hepatic 
steatosis (2,36,37). Other studies have focussed on the interplay between these two factors 
(5,6,21). So far, few studies have addressed the role of ChREBP in control of DNL (9,12,13) 
and only very recently it was shown that LXR regulates ChREBP activation and transcription 
(22). The present study indicates that pharmacological inhibition of G6PT with S4048 in 
C57BL/6J OlaHsd mice, resulting in increased hepatic G6P and glycogen levels, induces 
DNL exclusively via ChREBP. Because Gk  expression was not increased upon S4048-
infusion, SREBP-1c is probably not involved in S4048-induced hepatic steatosis. Moreover, 
LXRα does also not play a role: S4048-treatment had comparable hepatic effects in LXRα +/+ 
and LXRα -/- mice. Surprisingly, nuclear ChREBP translocation was not increased upon 
S4048-infusion. This is probably due to changes in phosphorylation state upon S4048-
treatment. In livers of both control and S4048-treated mice, insulin decreased AMPK 
phosphorylation via its effects on PKB.  
In previous experiments in rats, blood glucose levels of S4048-treated animals were 
60% of that of control rats. (24). More drastic hypoglycemic effects were seen in the 
C57BL/6J mice (figure 7.1): 6 hours of S4048-infusion resulted in a 64% decrease of the 
blood glucose levels. The S4048-mediated increases of hepatic TG, G6P and glycogen 
concentrations were also more pronounced in C57BL/6J mice (table 7.2) than in rats (25). 
Compared to control rats, hepatic G6P, glycogen and TG levels increased 3-, 2.8-, and 4.6-
fold respectively  upon S4048-infusion in rats. In C57BL/6J mice, these increases were 27-, 
16-, and 2.4-fold, respectively. The differences between S4048-mediated effects in rats and 
C57BL/6J mice could be due to the increased metabolic flux in mice compared to rats. Our 
laboratory used stable isotopes from intermediates in hepatic glucose metabolism to study in 
vivo hepatic glucose fluxes. The flux through G6Pase was 39.9 ± 3.8 µmol·kg
-1·min
-1 in 
Wistar rats (24) whereas this was 228 ± 16 µmol·kg
-1·min
-1 in C57BL/6J mice (38). When the 
G6Pase flux is higher, inhibition of this flux will lead to more drastic effects, i.e., more 
strongly increased hepatic G6P and glycogen levels after 6 hours of S4048-infusion. In the 
LXRα +/+ and LXRα -/- mice on a mixed C57BL/6J Sv129/OlaHsd background, however, 
blood glucose levels decreased only by 44% after 6 hours of S4048-infusion (figure 7.6). The 
elevations of hepatic G6P, glycogen and TG were also less severe in these mice (table 7.3), 
indicating lower hepatic glucose flux rates. Indeed, previous studies showed that hepatic 
G6Pase flux in Sv129 mice was ~70% of that of C57BL/6J mice (39).  
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Because SREBP-1c and ChREBP control transcription of largely the same genes, it is hard to 
distinguish effects of both transcription factors on lipogenic gene expression in vivo. 
However,  Pk expression is regulated by ChREBP but not by SREBP-1c (10) and Gk 
expression is regulated by SREBP-1c but not by ChREBP (13). Focussing on changes in the 
expression of these two genes in C57BL/6J OlaHsd mice upon S4048 treatment (figure 7.2), it 
is evident that G6PT inhibition and hence increased G6P levels resulted in enhanced hepatic 
transcriptional activity of ChREBP but not of SREBP-1c. The fact that levels of the Xu5P 
precursor G6P were clearly increased upon S4048-infusion also indicates a role for ChREBP. 
Furthermore, the decreased Gk expression upon S4048 infusion could be the result of SREBP-
1c mediated effects of insulin (40): it was shown in rats that S4048-infusion resulted in 
significantly reduced plasma insulin levels (24). Of course, studies with SREBP-1c -/-, 
ChREBP -/- and/or SREBP-1c -/- ChREBP -/- double knockout mice should be performed to 
investigate the roles of ChREBP and SREBP-1c in S4048-induced de novo lipogenesis. Using 
the LXRα +/+ and LXRα -/- mice, it was already possible to exclude a role for LXRα in 
S4048-induced de novo lipogenesis. Effects of S4048 on hepatic gene expression and hepatic 
TG levels did not differ between LXRα +/+ and LXRα -/- mice (figure 7.7 and table 7.3).  
So far, the data suggested a role for ChREBP in S4048-induced DNL and we therefore 
measured ChREBP protein nuclear translocation in C57BL/6J OlaHsd mice as well as in 
LXRα +/+ and LXRα -/- mice. (figures 7.3 and 7.8). However, no effects of S4048 were seen 
in either of the three types of mice. Figures 3 and 8 show clearly that ChREBP is 
predominantly present in the cytosol, as was already shown by Dentin et al. (41). The fact that 
the amount of ChREBP within the nucleus was not changed does not necessarily mean less 
active ChREBP because it is the dephosphorylation of ChREBP at Thr666 within in the 
nucleus that enhances its binding to the DNA (10). The phosphorylation state of Ser196 
mediates its localization in the cytosol or nucleus (10). Until phospho-specific ChREBP 
antibodies are available, Western blotting techniques cannot be used to study the effects of 
S4048 on active ChREBP within the nucleus. In the future, studies with primary hepatocytes 
and stable cell-lines should be used to study the effects of S4048 on subcellular ChREBP 
protein localization and DNA-binding.  
In the present study, we could not confirm the suggested role of ChREBP in LXR-
induced hepatic DNL (22): pharmacological LXR activation nor LXRα deficiency affected 
hepatic Chrebp mRNA levels (figures 7.5 and 7.7). On the other hand, increased Chrebp 
mRNA levels upon S4048-infusion (figures 7.2 and 7.7) did not translate into increased 
ChREBP protein levels (figures 7.3 and 7.8). The effects of LXR activation on Pk mRNA 
levels (figure 7.5) are therefore presumably mediated by the ChREBP 
phosphorylation/dephosphorylation state. As mentioned, more advanced ChREBP antibodies 
and/or in vitro experiments should be used to study the effects of S4048 on ChREBP in more 
detail.  
Using Western blotting techniques, we noticed increased phosphorylation of the α-
subunit of AMPK upon S4048-treatment (figure 7.4), reflecting increased activity of this 
kinase. AMPK is known to regulate, at least, the phosphorylation of ChREBP on Thr666, thus 
reducing its binding to DNA (10). Activity of AMPK is enhanced upon increased AMP 
and/or decreased ATP levels, thus upon increased energy expenditure (11). In the present 
hepatic steatotic model, enhanced hepatic AMPK activity could be the result of the increased 
production of fatty acyl-CoA from fatty acids. This process, mediated by ACS, uses ATP and 
produces AMP (42). Expression of Acs is regulated by both SREBP-1c and ChREBP (7,12). 
Because insulin reduces AMPK-activity (34), we injected mice with insulin. In control and 
S4048-treated mice, insulin injection reduced AMPK phosphorylation. Moreover, the key-
regulator of insulin signaling, PKB, was also showed increased phosphorylation upon insulin 
injection, with no difference between S4048-treated and control mice.  
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PKA is known to phosphorylate ChREBP at both Thr666 and Ser196 (10), suggesting that 
subcellular ChREBP localisation is presumably regulated by PKA and not by AMPK. Like 
AMPK, PKA activity is also increased upon increasing energy usage. Thus, enhanced AMPK 
and/or PKA activity might provide a mechanism to shut off ChREBP-induced DNL.  
In conclusion, the present studies strongly suggest that ChREBP, but not SREBP-1c 
and LXRα, is involved in induction of DNL and development of hepatic steatosis upon 
pharmacological inhibition of G6PT. Hence, increased DNL in GSDI patients (23) might also 
be due to effects on ChREBP activity and/or transcription, suggesting that ChREBP might be 
an important target for future pharmacological interventions in these patients. 
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Abstract 
 
Diabetes mellitus type 2 is associated with hepatic fat accumulation (hepatic steatosis) and 
dyslipidemia, the latter a major risk factor for the development of diabetes-associated 
coronary heart disease. The components of diabetic dyslipidemia are elevated plasma 
triglyceride (TG) levels, low concentrations of high density lipoprotein (HDL) cholesterol and 
the presence of small, dense low density lipoprotein (LDL) particles. An increased production 
of large, TG-rich very low density lipoprotein (VLDL) particles is considered a major cause 
of all aspects of diabetic dyslipidemia. In this review, we will discuss the role of transcription 
factors that (indirectly) control the actions of insulin, glucose and lipids on hepatic fatty acid 
and TG metabolism and hence on VLDL production. Key “lipogenic” transcription factors 
that regulate expression of genes encoding enzymes and transporters involved in hepatic lipid 
and glucose metabolism are sterol-regulatory element-binding protein-1c (SREBP-1c), 
carbohydrate responsive element binding protein (ChREBP), and liver X receptor (LXR). 
However, only speculative data exist about their roles in controlling (insulin sensitivity of) 
VLDL secretion. Thus, only well-conducted in vivo studies, i.e. with knockout mice and 
pharmacological ligands, will give proper information about the role of lipogenic gene 
transcription in (insulin sensitivity of) VLDL production and hence diabetic dyslipidemia. 
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The metabolic syndrome, diabetes and dyslipidemia 
 
Related to the increased incidence of obesity in the Western world, the combination of 
metabolic abnormalities collectively referred to as the metabolic syndrome shows a rapidly 
increasing prevalence. Components of the metabolic syndrome are hyperglycemia, insulin 
resistance, central obesity, dyslipidemia, and hypertension. According to the various 
guidelines (WHO 1999, European Group for the Study of Insulin Resistance 1999, and the 
ATP-III 2001) a person that has at least three of these components has attracted the metabolic 
syndrome (1). The guidelines agree that insulin resistance and/or diabetes mellitus type 2 are 
core components of the metabolic syndrome. 
Diabetes mellitus type 2 is characterized by elevated blood glucose levels as a result of 
absent or decreased secretion of insulin by the pancreatic B-cells. In general, dysfunctional B-
cells are a consequence of decreased sensitivity of the body for insulin (insulin resistance), for 
which the pancreas firstly compensated for by enhancing its insulin production. Insulin 
stimulates uptake of glucose by the peripheral tissues, i.e., muscle and adipose tissue, and 
inhibits hepatic glucose production (HGP). Patients with diabetes mellitus type 1 have 
elevated blood glucose levels because their pancreas does not produce insulin. In these 
patients, administration of exogenous insulin can lower blood glucose levels to normal values. 
In diabetes mellitus type 2 patients, however, liver and peripheral tissues are insensitive to the 
actions of insulin and exogenous insulin will not have the desired metabolic effects. 
Diabetes mellitus type 2 is also associated with hepatic fat accumulation (hepatic 
steatosis) (2) and dyslipidemia, the latter a well-known risk factor for the development of 
cardiovascular disease (3). Studies have shown that patients with diabetes mellitus type 2 
have a markedly increased risk for heart attacks (4,5). The components of diabetic 
dyslipidemia are increased plasma triglyceride (TG) levels, low concentrations of high density 
lipoprotein (HDL) cholesterol and the presence of small, dense low density lipoprotein (LDL) 
particles. An increased production of large, TG-rich very low density lipoprotein (VLDL) 
particles is considered a major cause of all aspects of diabetic dyslipidemia (6). In general, it 
is thought that diabetic patients secrete more large VLDL particles (7) and that insulin is not 
able to suppress the production rate of the large VLDL particles.  
In this review, we will discuss the role of proteins that are able to regulate gene 
transcription (transcription factors) that can (indirectly) control the actions of insulin, glucose 
or lipids on fatty acid and TG metabolism and eventually VLDL production.  
 
 
Whole-body fatty acid and triglyceride homeostasis 
 
TG molecules are the most energy-dense molecules in mammalian physiology and consist of 
three fatty acids esterified to a glycerol backbone. Normally, a surplus of (dietary) energy is 
incorporated into TG and stored in adipose tissue. Upon fasting, the adipose TG store is used 
to deliver energy in the form of free fatty acids (FFA) to maintain whole-body energy 
balance. Transport of dietary and de novo synthesized lipids from the liver to the peripheral 
tissues (i.e., adipocytes), and from the adipocytes back to the liver is important in this balance. 
The liver plays a crucial role because it can synthesize, store, secrete and oxidize fatty acids.  
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Because TGs are very hydrophobic, they need to be transported in blood as lipoproteins, 
together with cholesterol, phospholipids and proteins. The core of a lipoprotein contains TG 
and esterified cholesterol whereas the surface consits of phospholipids and free cholesterol. 
Embedded in the lipoprotein surface are the so-called apolipoproteins, proteins are needed for 
stabilisation of the particle and solubility of the core lipids (8). Moreover, apolipoproteins act 
as ligands for receptors and are required for the actions of specific enzymes (8).  
 
 
Triglyceride-rich lipoproteins 
In the enterocytes, dietary TGs are incorporated into lipoproteins called chylomicrons. 
Apolipoprotein B (apoB) is the main protein of TG-containing lipoproteins (chylomicrons and 
VLDL). In the surface of chylomicrons, a truncated form of apoB is present, consisting of 
only 48% of the N-terminal part and is therefore called apoB48. Editing of the apoB100 
mRNA into apoB48 mRNA is regulated by the apoB editing complex-1 (apobec1) (9). In the 
circulation, the TG content of these particles is lipolysed primarily by lipoprotein lipase (LPL) 
secreted by muscle and adipose tissue. ApoC-III inhibits the actions of LPL while apoC-II 
enhances its lipolytic actions. The released fatty acids can be taken up and are reesterified into 
TGs (e.g., in adipocytes) or used as an energy source (e.g., in muscle). As a result of lipolysis, 
chylomicrons are depleted of TGs, become smaller and are referred to as chylomicron 
remnants. Both chylomicrons and chylomicron remnants are cleared by the liver upon binding 
to the LDL receptor, the LDL receptor related protein (LRP) or hepatic lipase (HL) (10).  
TG transport from the liver to peripheral tissues induces their incorporation into 
VLDL particles. VLDL-TGs are lipolyzed by LPL in a similar way as chylomicrons and the 
fatty acids are taken up by the peripheral tissues. Upon lipolysis, the TG content of the VLDL 
particle becomes depleted and, as a result, the particle size decreases and the relative 
cholesterol concentration increases. The cholesterol-dense VLDL remnant particles are called 
intermediate density lipoprotein (IDL) or LDL particles, depending on their size and density. 
With increasing VLDL particles size, the ratio of TG over phospholipid will also increase 
(11) and the resulting LDL particle will contain relatively more cholesterol: small, dense LDL 
particles. It is known that small, dense LDL particles are associated with increased 
cardiovascular risk (3,12). 
 
Reverse fatty acid flux 
β-oxidation of fatty acids is considered the primary source of the energy and reducing 
equivalents (ATP, NADH) needed for de novo synthesis of glucose (gluconeogenesis) during 
fasting. Moreover, ß-oxidation generates ketone bodies, an additional fuel source for the brain 
when glucose levels are low. In the ß-oxidation process, fatty acyl-CoA’s are broken down 
into shorter chains by a series of dehydrogenases. For this process, FFAs are released from 
the adipose stores after lipolysis of TG by triglyceride hydrolase (TGH) (also called adipose 
TG lipase (ATGL) (13)) and hormone sensitive lipase (HSL) (14) and carried by serum 
albumin to the liver. Insulin inhibits lipolysis in peripheral tissues. Thus, upon fasting, when 
insulin levels are low, the insulin-mediated inhibition of lipolysis is absent and FFAs are 
released into the circulation, taken up by the liver and partly used in the ß-oxidation process 
and partly reesterified to form TG. This latter process gives rise to the fasting induced hepatic 
steatosis (15). 
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Assembly of very low density lipoproteins 
 
Lipidation of apolipoprotein B 
Production of VLDL is considered a two-step process that takes place in two distinct parts of 
the liver cell (figure 8.1). Firstly, the apoB molecules become co-transcriptionally lipidated to 
form a small pre-VLDL particle in the rough endoplasmic reticulum (ER), a process catalyzed 
by the microsomal triglyceride transfer protein (MTTP) (16). When insufficient lipid is 
available, the apoB translocation is halted and the protein is degraded. The  pre-VLDL 
particle is transported in Sar1/COPII vesicles to the smooth ER where the second step will 
take place. It is known that the ADP ribosylation factor-1 (ARF1) can control the formation of 
VLDL. It is thought that, because ARF1 is part of the COPI secretory complex involved in 
transport from the ER to the Golgi apparatus, it is able to influence the sorting procedure of 
pre-VLDL from the rough to the smooth ER (17).  
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Figure 8.1. Schematic representation of VLDL assembly and secretion, located in the endoplasmic reticulum 
(left part of the figure) and its membrane. ARF1, ADP ribosylation factor-1; CACT, carnitine acylcarnitine 
translocase; CPT, carnitine palmitoyl transferase; DAG, diacylglycerol; DGAT2, diacylglycerol acyltransferase; 
FA, fatty acid; FFA, free fatty acid; MTTP, microsomal triglyceride transport protein; PL, phospholipid; PLD, 
phospholipase D; TG, triglyceride; TGH, triglyceride hydrolase. 
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Lipidation of pre-VLDL particles 
In the second step of VLDL assembly, the pre-VLDL particle is further lipidated and 
transported to the cellular membrane. This second step again involves the action of MTTP but 
also that of phospholipase D (PLD), the enzyme controlling conversion of 
phosphatidylcholine into phosphatidic acid, a TG precursor needed in VLDL assembly (18). 
Activation of PLD is regulated by ARF1 and recent data show that overexpression of ARF1 
not only  resulted in increased pre-VLDL translocation to the smooth ER, but, as a result, also 
in enhanced lipidation of pre-VLDL (17). 
 
Amount vs. size of VLDL particles 
The amount and size of VLDL particles depends on lipidation of apoB and pre-VLDL in the 
first and second step, respectively. Depending on the lipidation of the pre-VLDL particle, the 
liver can secrete VLDL particles that vary in size. The large VLDL particles (VLDL1) and the 
smaller VLDL2 particles are thought to be secreted via seperate pathways by the liver and to 
follow seperate routes within the VLDL-IDL-LDL pathway (reviewed by Taskinen (6)). In 
general, it is thought that diabetic patients secrete more VLDL1 particles (7). Major issues that 
need to be resolved are whether insulin regulates lipidation of pre-VLDL rather than the 
assembly of pre-VLDL. And if this is the case, how insulin regulates VLDL lipidation and 
hence secretion. We will first briefly review how insulin controls sorting of apoB towards 
lipidation or degradation.  
 
 
Direct effects of insulin on apoB degradation and VLDL assembly 
 
Effects of insulin on hepatic lipid metabolism are predominantly mediated via the 
phosphatidylinositol-3-kinase pathway 
Upon binding of insulin to the insulin receptor (a member of the tyrosine kinase receptor 
family), the receptor autophosphorylates and activates two distinct downstream signaling 
pathways: the phosphatidylinositol-3-kinase (PI3K) pathway and the MAP kinase/ERK 
kinase (MEK) pathway. The PI3K-pathway is mainly of relevance for the metabolic processes 
discussed in this review and will therefore be discussed.  
Upon autophosphorylation of the insulin receptor, a downstream insulin receptor 
substrate (IRS) will be phosphorylated. Phosphorylated IRS has an increased affinity for the 
p85 subunit of PI3K. Activated PI3K will start the production of the second messenger 
phosphatidylinositol 2,4,5-trisphosphate (PIP3) from the phospholipid PI4,5P2 (PIP2). This 
second messenger activates, amongst others, protein kinase B (PKB) via phosphorylation, the 
protein involved in regulation of many steps in insulin-mediated hepatic glucose and lipid 
metabolism. For instance, PKB phosphorylates and hence inhibits activity of glycogen 
synthase kinase-3β (GSK3β), an inhibitor of glycogen synthase (GS). Thus, via its actions on 
PKB and GSK3, insulin stimulates conversion of glucose into glycogen (19). Nowadays, the 
PKB-mediated phosphorylation of a member of the forkhead transcription factor family, 
FoxO1, is intensively studied (20,21). Phosphorylation of FoxO1 blocks induction of 
expression of various genes involved in gluconeogenesis. In peripheral tissues, PKB 
stimulates the translocation of vesicles containing the glucose transporter-4 (GLUT4) to the 
membrane (22,23). Via this route, insulin stimulates peripheral glucose uptake. 
 
Direct effects of insulin  
Insulin regulates VLDL assembly in various ways. ApoB protein secretion is largely 
dependent on its intracellular degradation (24): increased or decreased apoB mRNA levels do 
not translate into similar changes in apoB protein secretion. Elegant in vitro studies showed 
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that insulin is able to inhibit VLDL production via acceleration of the apoB degradation (25). 
This process mediated by PI3K (26) but probably independent of PKB (27). Via this route, 
insulin affects the number of VLDL particles secreted. On the other hand, insulin inhibits 
transcription of the gene encoding for MTTP (28,29), probably via activation of the 
transcription factor sterol regulator element binding protein-1c (SREBP-1c) (30). The role of 
SREBP-1c in insulin-mediated lipid metabolism will be discussed later in this review. 
Activation of PLD, important in the lipidation of VLDL, is prevented when PIP2 levels are 
low, thus under conditions of high insulin (26,31).  
Taken together, these data show that insulin impairs the production of large VLDL1 
particles via its effects on MTTP and PLD. Thus, the overall effect of insulin is the secretion 
of less and smaller VLDL particles. We recently confirmed this effect of insulin in vivo in 
mice in which we measured the VLDL-TG production rate under hyperinsulinemic, 
euglycemic conditions (32): VLDL-TG production rate decreased during hyperinsulinemia, 
partly due to the secretion of smaller particles. 
Because a VLDL particle contains a single apoB molecule, the amount of apoB 
secreted directly reflects the number of VLDL particles produced. As discussed, the amount 
of apoB secreted by the liver depends, in part, on its lipidation (33). Therefore, one can 
imagine that, when the amount of TG available for VLDL is increased to a larger extent than 
the amount of apoB, the size of VLDL particles will increase. Moreover, insulin regulates 
whole-body energy balance, including TG storage and fatty acid fluxes via its inhibitory 
effects on peripheral lipolysis. Thus, insulin might also affect VLDL secretion via its effects 
on hepatic lipid availability.  
 
 
VLDL production and hepatic lipid availability 
 
Sources of fatty acids 
TGs are needed for lipidation of both the apoB and the pre-VLDL particle (33). The fatty 
acids that constitute the hepatic TG pool originate from three sources: from (i) the diet, (ii) the 
peripheral (adipose) stores, and (iii) de novo lipogenesis. Fatty acids taken up by the 
hepatocyte are not directly used for VLDL production but first esterified and stored as a 
cytoplasmic lipid droplet (33,34). Utilization of TG from this pool for VLDL assembly 
requires hydrolysis followed by re-esterification.  
 
De novo lipogenesis 
During de novo lipogenesis, fatty acids are made out of acetyl-CoA moieties (figure 8.2). The 
source of acetyl-CoA may be the glycolytic breakdown of glucose via pyruvate, a process in 
which pyruvate kinase (PK) is thought to be a major regulator (35). When glucose is taken up 
in the hepatocyte by the glucose transporter 2 (GLUT2), it is rapidly phosphorylated into 
glucose-6-phosphate (G6P) by glucokinase (GK). Then, G6P can either be used for 
production of glycogen, a process mediated by GS, or G6P can enter the glycolytic pathway 
to yield pyruvate, as mentioned above. The reverse pathway, de novo synthesis of glucose, is 
called gluconeogenesis. Herein, one G6P  molecule is produced from two pyruvate molecules 
via intermediates such as oxaloacetate, phosphoenolpyruvate (PEP) and fructose 1,6-
bisphosphate (for an exhaustive review, see (36)). The conversion of oxaloacetate into PEP is 
controlled by PEP carboxykinase (PEPCK), an enzyme considered rate-controlling in 
gluconeogenesis. The last step in gluconeogenesis, dephosphorylation of G6P, is controlled 
by the glucose-6-phosphatase complex. 
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Figure 8.2. Schematic representation of the interplay between hepatic glucose and triglyceride metabolism. ACC, 
acetyl-CoA carboxylase; ACL, ATP citrate lyase; ACS, Acyl-CoA synthase; FAS, fatty acid synthase; G6P, 
glucose-6-phosphate; GLUT2, glucose transporter-2; GPAT, glycerol-phosphate acyltransferase; GS, glycogen 
synthase; PEP, phosphoenolpyruvate; PK, pyruvate kinase; TCA, tricarboxylic acid cycle. 
 
 
In the flux from glucose to TG, pyruvate enters the tricarboxylic acid (TCA) cycle and the 
citrate produced herein can be converted into acetyl-CoA by ATP citrate lyase. Two acetyl-
CoA’s are covalently linked to each other to form malonyl-CoA. This coupling of acetyl-
CoA’s is regulated by acetyl-CoA carboxylase (ACC). Two different forms of ACC have 
been identified: activity of ACC1 produces malonyl-CoA that is used in de novo lipogenesis 
whereas ACC2 generates malonyl-CoA that inhibits carnitine palmitoyl transferase-1 (CPT1) 
(37), an enzyme that has been shown to be rate-controlling for hepatic ß-oxidation (38). The 
two different functions of malonyl-CoA probably reflect the localization of ACC1 and ACC2 
in the cytosol and anchored in the mitochondrial outermembrane, respectively (37). Upon 
actions of fatty acid synthase (FAS), the malonyl-CoA subunits are covalently linked to form 
fatty acids. The fatty acyl-CoA needed for esterification of the fatty acid into TG is generated 
by the actions of acyl-CoA synthase (ACS), while the subsequent esterification into TG is 
controlled by glycerol-phosphate acyltransferase  (GPAT). More background about the role of 
various enzymes in TG synthesis can be found in the excellent review by Coleman et al. (39). 
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In healthy subjects fed a “normal” diet, de novo lipogenesis contributes only 6% to the TG 
found in both liver and VLDL (40). In patients with nonalcoholic fatty liver disease, however, 
the contribution of de novo lipogenesis to both TG pools was found to be increased to 26% 
(41). Yet, the major source of fatty acids found in hepatic and VLDL TGs originate from 
FFAs derived from peripheral tissues (40,41). 
 
Novel aspects concerning the relationship between hepatic TG content and VLDL-TG 
production rate 
Although it is commonly thought that the availability of TG at specific hepatocellular sites is 
a major determinant of number and size of the VLDL particle (33), a number of recent animal 
studies from our and other laboratories revealed that the hepatic TG content per se does not 
stimulate the VLDL-TG production rate. For instance, the commonly used leptin-deficient 
ob/ob mice have severe hepatic steatosis, high plasma FFA and increased hepatic de novo 
lipogenesis, but do not show an increased VLDL-TG production rate under basal conditions 
(42). Furthermore, hepatic steatosis associated with inhibition of glucose-6-phosphatase 
activity was also without effect on VLDL production (43). Acute hepatic steatosis upon 
inhibition of hepatic β-oxidation did not affect VLDL production nor impair hepatic insulin 
sensitivity (32). Various factors, apart from the accumulation of TG, might contribute to 
changes in VLDL production. TGs are not the sole components of VLDL: hepatic cholesterol 
and phospholipid availability or synthesis might also influence the secretion and assembly of 
VLDL. It has been suggested that de novo synthesis of cholesterol (44) and phospholipids 
(45), rather than their concentrations, are  determinants of VLDL production. Moreover, both 
cholesterol and phospholipids are also secreted into bile by the hepatocyte. So far, it is not 
known whether cholesterol and phospholipids have different preferences for entry into VLDL 
or bile secretory pathways, but that might, in part, depend on the location of both processes in 
the liver and the availability of the lipids at these locations.  
Studies show that in fasted conditions, the plasma FFA pool contributes the majority 
of  fatty acids secreted by the liver in VLDL (46). Recently, its was shown in humans that 
fatty acids from the FFA pool are predominantly used by the liver for VLDL-TG synthesis in 
both fed and fasted state (47). CD36 is the fatty acid transporter in peripheral tissues. 
Therefore, CD36 knockout mice have an increased FFA flux to the liver (48), a condition 
resulting in increased hepatic TG concentrations. However, this condition is not associated 
with increased VLDL-TG production rates (49), thus suggesting that increased plasma FFA 
levels and hepatic steatosis per se do not necessary lead to increased VLDL production. 
 
 
Lipogenic transcription factors 
 
Hepatic de novo lipogenesis is, to a large extent, regulated by lipogenic transcription factors. 
Work in various animal models suggest, but did not yet prove, an independent role for these 
factors in the regulation of VLDL production. Transcription and/or activation of these factors 
is regulated by insulin or metabolites of glucose, fatty acids and cholesterol. Very important 
lipogenic transcription factors that regulate expression of genes encoding for enzymes 
involved in hepatic lipid and glucose metabolism are SREBP-1c, carbohydrate responsive 
element binding protein (ChREBP), and liver X receptor (LXR).  
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Figure 8.3. Schematic representation of different ways in which the activity of transcription factors can be 
regulated: via ligand activation, via subcellular translocation, via the phosphorylation state, and via availability 
of the co-activator complex. 
 
 
Transcription factors 
Transcription of genes by the polymerase II complex results in production of RNA. 
Controlling transcription of a gene is the first step in controlling the production of a protein. 
The promotor regions of genes contain reponse-elements that can bind certain transcription 
factors depending on the sequences of the elements (Figure 3). Conformational changes of a 
transcription factor, i.e., upon binding of its ligand or upon its phosphorylation/ 
dephosphorylation, will change its affinity for co-activator and co-repressor complexes. These 
complexes consist of different proteins that can inhibit or induce activity of the polymerase-II 
complex and hence inhibit or induce gene transcription. 
Thus, whether a transcription factor regulates transcription of a gene depends on the 
presence of its endogenous ligands, its phosphorylation state, its localisation (cytosolic vs. 
nuclear), the presence of specific repsonse-elements in the promotor region and the 
availability of the corepressor or coactivator complexes (figure 8.3).  
 
SREBP-1c 
SREBP-1c is a member of the basic-helic-loop-helic-leucine zipper (bHLHLZ) transcription 
factor family that is synthesized as an inactive precursor protein embedded in the ER 
membrane. Upon decreasing cellular cholesterol contents, the SREBP-1c precursor protein is 
translocated to the Golgi membrane, escorted by the SREBP cleavage activation protein 
(SCAP) (50,51). In the Golgi, the SREBP-1c isoform is cleaved to form ‘mature’ SREBP-1c, 
a process mediated by the membrane-bound serine protease site 1 protease (S1P) (52,53) and 
the membrane-bound zinc-metallo-protease site 2 protease (S2P) (54,55) (figure 8.4). The 
mature SREBP-1c translocates to the nucleus where it binds to direct repeat sterol regulatory 
elements (SREs; consensus sequence: 5’-TCACnCCAC-3’) located in the promotor regions 
of several genes.  
SREBP-1c induces transcription of almost all genes encoding for enzymes involved in 
both de novo fatty acid synthesis and esterification of fatty acids into TG (56). SREBP-1c 
knockout mice show markedly decreased mRNA levels of all of these genes (56,57). Upon 
fasting, when insulin levels are low, the expression of lipogenic genes is decreased. Hepatic 
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overexpression of SREBP-1c in mice prevented this fasting-induced effect on gene expression 
(58), suggesting that SREBP-1c is a key regulator of the early response of the liver to insulin. 
A recent study indeed confirmed that both transcription and activation of SREBP-1c is 
regulated by insulin (59), via a PI3K-dependent mechanism (60). The effect of insulin on 
nuclear translocation is, at least in part, due to the effect of reduced levels of the SCAP 
inhibitory protein Insig-2 (61). Additionally, insulin reduces the turnover rate of nuclear 
SREBP-1c (62).  
The ob/ob mouse shows elevated liver TGs and increased blood glucose and insulin 
levels (63) but also increased nuclear SREBP-1c protein levels, despite severe hepatic insulin 
resistance (64). This suggests that SREBP-1c is very sensitive for the actions of insulin, even 
under conditions of reduced whole-body insulin sensitivity. This is, in part, explained by the 
fact that the insulin effects on glucose production are mediated via IRS1, which is 
downregulated in insulin-resistant animals whereas the effects of insulin on lipid metabolism 
are largely regulated via IRS2 (65). However, Shimomura et al. (66) showed that, despite 
IRS2-deficiency due to chronic hyperinsulinemia in ob/ob mice, insulin still stimulated 
transcription of SREBP-1c.  
N
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Figure 8.4. Schematic representation of SREBP-1c maturation and cleavage regulated by insulin. ER, 
endoplasmic reticulum; S1P, site 1 protease; S2P, site 2 protease; SCAP, SREBP cleavage activation protein; 
SREBP-1c, sterol-regulatory element-binding protein-1c. 
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In conclusion, insulin increases the nuclear activity of SREBP-1c in at least three manners: (i) 
via upregulation of SREBP-1c gene transcription, (ii) by stimulating production of the mature 
SREBP-1c form, and (iii) by decreasing the turnover rate of mature SREBP-1c. Of interest is 
the fact that the effects of insulin on SREBP-1c transcription and translocation are opposed by 
glucagon via increased intracellular cAMP levels which probably affect SREBP-1c activity 
via inhibition of the insulin-inhibited nuclear SREBP-1c turnover (62). 
Although plasma TG levels are ~60% lower in SREBP-1c knockout mice (57), only 
speculative data exist about the role of SREBP-1c in the hepatic VLDL-TG production rate in 
basal and hyperinsulinemic states. Therefore, the precise role of SREBP-1c in the regulation 
of VLDL production and hence in development of diabetic dyslipidemia remains speculative. 
Moreover, the role of (insulin-mediated) SREBP-1c activity in the control of hepatic glucose 
metabolism is largely unknown, but is probably minor because lipid and glucose metabolism 
are controlled by insulin via distinct routes, i.e., IRS2 and IRS1, respectively (65).  
 
ChREBP 
When glucose is taken up by the liver and subsequently converted to G6P by GK, G6P is 
mainly directed into the glycogen pool or broken down in the glycolytic pathway, as 
mentioned before. However, when the flux through G6P is increasing, an ‘escape’ route 
called the pentose phosphate pathway becomes active (Figure 5). In this pathway, ribulose-5-
phosphate is generated from G6P or from its glycolytic product fructose-6-phosphate via 
oxidative or non-oxidative routes, respectively (67). Via an epimerase, ribulose-5-phosphate 
is converted into xylulose-5-phosphate, an activator of protein phosphatase 2 A (PP2A). A 
few years ago, it was shown that the increased activity of PP2A upon increasing xylulose-5-P 
levels were associated with induced transcription of PK (68). Recently, the members of 
Uyeda’s laboratory clearly showed that a novel transcription factor, ChREBP, is responsible 
for this effect (69,70). 
ChREBP is a member of the bHLHLZ transcription factor family and binds to the 
carbohydrate reponse element (ChoRE) present in promoters of several genes, that is 
composed of two E-box (5’-CACGTG-3’) or E-box-like sequences. The ChREBP protein 
probably binds as a heterodimer with Mlx (71) to its response elements. Upon increasing 
xylulose-5-phosphate levels, PP2A dephosphorylates ChREBP. ChREBP can be transported 
into the nucleus after dephosphorylation of Ser196 and dephosporylation of a second amino 
acid (Thr666) enhances the binding activity of ChREBP to DNA (72). ChREBP 
phosphorylation is regulated by AMP-activated protein kinase (AMPK) and protein kinase A 
(PKA) (73). The activity of AMPK becomes induced upon increasing usage of energy, e.g., 
exercise. AMPK is considered to play a pivotal role in the control of lipid metabolism. For 
instance, AMPK phosphorylates and inhibits ACC1 and ACC2 (74) as well as SREBP-1c 
(75).  
ChREBP induces transcription of various genes encoding enzymes involved in de 
novo lipogenesis (76). Remarkably, most lipogenic genes regulated by SREBP-1c are also 
regulated by ChREBP, i.e., ACC, FAS, ACS and GPAT. Thus, glucose not only regulates 
lipogenic gene expression via its effects on pancreatic insulin secretion and hence insulin-
mediated SREBP-1c transcription and activation, but also via ChREBP.  
Treatment of rats with the pharmacological glucose-6-phosphatase inhibitor S4048 
resulted in elevated hepatic G6P levels (77) and increased lipogenesis (43), a process 
presumably mediated via ChREBP. Upon S4048 treatment, the VLDL-TG production rate 
was not affected (43), but hepatic glucose production was severely decreased (77). Because 
the data strongly suggest a role of ChREBP in the S4048-induced lipogenesis, more 
experiments are needed to elucidate the role of ChREBP on the VLDL production and particle 
size.  
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Figure 8.5. Schematic representation of hepatic ChREBP activation induced via dephosphorylation enhanced by 
xylulose-5-phosphate. 6PG, 6-phosphogluconate; AMPK, AMP-activated protein kinase; ChREBP, carbohydrate 
responsive element binding protein; F1,6P2, fructose-1,6-bisphosphate; F6P, fructose-6-phosphate; G6P, 
glucose-6-phosphate; G6PDH, glucose-6-phosphate dehydrogenase; GAP, glyceraldehyde-3-phosphate; GK, 
glucokinase; GLUT2, glucose transporter-2; PGDH, 6-phosphogluconate dehydrogenase; PP2A, protein 
phosphatase 2A; R5P, ribulose-5-phosphate; Xu5P, xylulose-5-phosphate. 
 
 
 
LXR 
LXR is a member of the family of nuclear hormone receptors that needs to bind a ligand to 
become active and to induce or inhibit transcription of target genes. Other members of this 
family are the peroxisome proliferator-activated receptors (PPARs), the glucocorticoid 
receptor (GR) and many others (table 8.1). Two subtypes of LXR are known: LXRα is 
expressed mainly in the liver while LXRβ is ubiquitously expressed (78,79). Activated LXRs 
heterodimerize with the retinoid X receptor (RXR) and bind to the LXR response element 
(LXRE), consisting of two hexameric nucleotide direct repeats separated by four nucleotides 
(DR4; consensus sequence: 5’AGGTCAnnnnCGGTCA-3’) (78,79). Oxysterols are 
oxygenated metabolites of cholesterol and they constitute the physiological ligands for LXR. 
The most potent LXR-activating oxysterols are 22(R)-hydroxycholesterol, 24(S)-
hydroxycholesterol and 24(S),25-epoxycholesterol (80). The first effects of activated LXRs 
were seen on genes encoding proteins invloved in (reverse) cholesterol metabolism, but 
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pharmacological LXR activation studies showed that LXR also induces transcription of 
SREBP-1c (81-84), but not its translocation (59). Apart from indirect actions through SREBP-
1c, LXR also directly influences transcription of Fas (85) and of genes encoding LPL (86) 
and stearoyl-CoA desaturase-1 (SCD1) (57). The latter protein is involved in the production 
of monounsaturated fatty acids, i.e., conversion of palmitic acid (C16:0) and stearic acid 
(C18:0)  into palmitoleic acid (C16:1) and oleic acid (C18:1), respectively (87).  
We previously showed that pharmacological LXR activation resulted in severe fatty 
liver and with 2-fold induced VLDL-triglyceride production rate in mice (84). This increased 
production was completely the result of the secretion of large, TG-rich particles, a condition 
similar to that of diabetic dyslipidemic patients. However, studies suggested anti-diabetic 
effects of LXR activation (88,89), presumably via the effects of LXR on the transcription of 
the gluconeogenic gene Pepck. In contrast, in vivo studies on insulin sensitivity showed no 
differences between LXR agonist treated and untreated lean and ob/ob mice (90). So far, no 
direct data exist on the direct role of LXR on the insulin sensitivity of VLDL production. 
 
Table 8.1. The nuclear receptor superfamily 
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Androstane receptor (AR) 
Glucocorticoid receptor (GR) 
Mineralocorticoid receptor (MR) 
Retinoid acid receptor (RAR) α, β, γ 
Thyroid receptor (TR) α, β 
Vitamin D receptor (VDR)  
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Retinoid X recptor (RXR) α, β, γ 
Peroxisome proliferator-activated receptor (PPAR) α, β/δ, γ 
Liver X receptor (LXR) α, β 
Farnesoid X receptor (FXR) α, β 
Pregnane X receptor (PXR)
2
Constitutive androstane receptor (CAR) 
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Steroidogenic factor 1 (SF-1) 
Liver related hormone-1 (LRH-1) 
DAX-1
3 
Short heterodimer partner (SHP) 
TLX
4 
Photoreceptor cell-specific nuclear receptor (PNR) 
NGFI-B α, β, γ
4 
Retinoid related orphan receptor (ROR) α, β, γ 
Estrogen-related receptor (ERR) α, β, γ 
RevErb α, β, γ
4 
Germ cell nuclear factor (GCNF) 
TR 2,4
4 
Hepatocyte nuclear factor-4 (HNF-4) 
COUP-TF α, β, γ
5
 
1, the EcR is found in insects and is the only nonvertebrate nuclear receptor with a known ligand; 
2, in humans, 
the rodent PXR is called steroid X receptor (SXR); 
3, abbreviation of: dosage-sensitive sex reversal-adrenal 
hypoplasia congenita critical region on the X chromosome, gene 1; 
4, no full name; 
5, abbreviation of: chicken 
ovalbumin upstream promoter-transcription factor. 
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Concluding remarks 
 
Because the lipogenic transcription factors mentioned (SREBP-1c, ChREBP, and LXR) 
tightly control de novo lipogenesis and their activation and/or expression is controlled by 
insulin, carbohydrates and lipids (factors whose plasma levels are increased in type 2 diabetic 
subjects), one might expect that these factors play a role in the (insulin sensitivity of) VLDL 
production. However, proper studies relating these transcription factors with the insulin 
sensitivity of VLDL production have not been reported. Of course, one can question whether 
these factors play a huge role herein, because fatty acids produced in the de novo lipogenic 
pathway do not contribute that much to the VLDL-TG content (40,91). Only well-conduted in 
vivo studies, i.e. with knockout mice and pharmacological ligands, will give proper 
information about the role of lipogenic transcription in (insulin sensitivity of) VLDL 
production and hence diabetic dyslipidemia. 
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Chapter 9Insulin sensitivity of hepatic glucose and lipid metabolism in animal models of hepatic steatosis 
World-wide prevalences of nonalcoholic fatty liver diseases, such as nonalcoholic 
steatohepatitis (NASH), and diabetes mellitus type 2 have and will increase markedly during 
the coming years (1-4). The hallmark of the fatty liver is an excessive accumulation of 
triglycerides (TGs) and various human studies showed that tis fat accumulation is associated 
with insulin resistance and diabetes mellitus type 2 (5-10). The increasing prevalence of these 
conditions are a result of the prevailing sedentary life-style, characterized by high food 
consumption and low physical activity (11). The metabolic syndrome, often referred to as a 
readout of the sedentary life-style in Western societies, comprises a cluster of metabolic 
abnormalities, among which obesity and insulin resistance are key features (5,12,13).  
Although the condense summary of human data suggest a strong association between 
increased hepatic TG concentrations and insulin resistance, only a few basal studies on 
metabolic and cellular processes involved have been published. The primary research 
question addressed in this thesis was therefore whether increased hepatic TG concentrations 
induced by any cause, by definition, lead to (hepatic) insulin resistance. 
Metabolism of the energy-bearing molecules glucose, fatty acids and TGs is closely 
linked in the liver and insulin plays a pivotal role in this interaction. In the liver, glucose is 
stored as glycogen, but this organ is also capable to produce glucose. Energy needed for de 
novo glucose production (gluconeogenesis) can be generated by hepatic oxidation of fatty 
acids (β-oxidation). On the other hand, the liver can convert glucose into fatty acids and TGs 
(de novo lipogenesis) and subsequently secrete TGs in very low density lipoprotein (VLDL) 
particles. In fed conditions, when blood glucose levels rise, the blood glucose lowering 
hormone insulin is secreted by the pancreas. Insulin inhibits hepatic glucose production 
(HGP), enhances conversion of glucose into glycogen, stimulates de novo lipogenesis, and 
inhibits gluconeogenesis and VLDL secretion.  
Defects in the actions of insulin on lipid and glucose metabolism are thought to result 
in various hallmarks of insulin resistance, the metabolic syndrome and diabetes mellitus type 
2. The work described in this thesis addresses the (patho)physiological effects of hepatic 
steatosis on these metabolic pathways in several animal models. The models used were the 
leptin-deficient  ob/ob mouse, pharmacological activation of the liver X receptor, 
pharmacological inhibition of β-oxidation, and pharmacological inhibition of glucose-6-
phosphatase. 
 
 
The ob/ob mouse 
 
Leptin-deficient  ob/ob mice are obese, hyperinsulinemic, hyperglycemic, have hepatic 
steatosis, and are a commonly employed animal model of diabetes mellitus type 2. In the 
studies described in chapter 2, we used novel stable isotope techniques to quantify the hepatic 
glucose fluxes and metabolic clearance rate (MCR) of glucose in ob/ob mice compared to 
wild-type, lean littermates. These studies showed that HGP did not differ between ob/ob and 
lean mice, despite higher plasma insulin levels in the ob/ob mice. Because the elevated 
plasma insulin levels did not suppress HGP, the hepatic steatosis of ob/ob mice is by 
definition associated with decreased insulin sensitivity of hepatic glucose metabolism. 
Previous experiments of our laboratory showed that hyperinsulinemia did not suppress the 
VLDL production rate in ob/ob mice (14). Thus, the ob/ob mouse is an useful animal model 
of hepatic steatosis associated with insulin resistance of both hepatic glucose and lipid 
metabolism. In the studies described in chapter 4, insulin sensitivity of glucose metabolism 
was studied in more detail in ob/ob mice. For this, we used the ‘golden standard’ to determine 
insulin sensitivity: the hyperinsulinemic euglycemic clamp. In this technique, mice receive an 
infusion with insulin to achieve a stable, relatively high plasma concentration of the hormone. 
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Upon the hyperinsulinemia thus created, blood glucose will start to decrease. To maintain 
euglycemia, a glucose solution is also infused. The infusion rate of the latter solution can be 
adjusted so that euglycemic conditions are met. The glucose infusion rate is a measure of the 
insulin sensitivity of, in this case, the mouse. Addition of [U-
13C]-glucose to the solutions 
allowed us to calculate HGP and MCR. Hyperinsulinemia suppressed HGP by 94% in lean 
mice but by only 48% in ob/ob mice. This underscores insulin resistance of hepatic glucose 
metabolism in ob/ob mice. Moreover, hyperinsulinemia increased MCR 5.5-fold in lean mice, 
whereas no increase was seen in ob/ob mice, indicating insulin resistance of peripheral 
glucose metabolism.  
In conclusion, hepatic steatosis in ob/ob mice is associated with decreased insulin 
sensitivity of hepatic glucose and lipid metabolism. Concerning glucose metabolism, ob/ob 
mice are also insulin resistant in the periphery. Because plasma FFA levels are elevated in 
ob/ob mice, peripheral lipid metabolism (e.g., insulin-mediated suppression of lipolysis) is 
probably also affected. Although ob/ob mice are commonly used in diabetic and obesity 
research, one should carefully interpret results gathered with these animals because leptin 
deficiency is not a normal cause of obesity, hepatic steatosis and insulin resistancein humans. 
Only few families are known that are homozygous for a mutation in the leptin gene (15,16). 
In general, monogenetic obesity in humans is scarce (17). A monogenic animal model of 
obesity and/or hepatic steatosis is therefore probably not the best model to study hepatic 
steatosis. On the other hand, because ob/ob mice are commonly used, detailed and 
physiologically-relevant information about this model is available.  
For the latter reason, we used ob/ob mice in the studies described in chapter 5 to assess 
the metabolic consequences of the iminosugar derivative N-(5’-adamantane-1’-yl-methoxy)-
pentyl-1-deoxynojirimycin (AMP-DNM), a novel inhibitor of glucosylceramide transferase. 
When administered to ob/ob mice, AMP-DNM normalised elevated tissue glucosylceramide 
levels and improved insulin sensitivity of both peripheral tissues and the liver. Because 
ceramide levels were not affected, these data strongly suggest that ceramide metabolites may 
be involve din the link between increased fatty acids and insulin resistance. 
 
 
Pharmacological activation of the liver X receptor 
 
The liver X receptor (LXR) is a member of the 48-member superfamily of nuclear receptors 
that can activate or inhibit transcription of genes upon their activation by, in most cases, a 
small-molecular ligand. Oxysterols are oxygenated metabolites of cholesterol and are 
considered the endogenous ligands of LXR. The synthetic LXR ligands T0901317 and 
GW3965 are useful tools in LXR-related research. Upon activation, LXR stimulates 
transcription of various genes, i.e., those encoding enzymes involved in the transport of 
cholesterol from the peripheral tissues to the liver and in secretion of cholesterol into bile and 
subsequently the feces (18). Clinical application of synthetic LXR ligands is hampered by the 
fact that LXR also stimulates transcription of genes encoding enzymes involved in de novo 
lipogenesis. Administration of synthetic LXR ligands to rodents results in severe hepatic 
steatosis (19). In the studies described in chapter 3, T0901317-induced hepatic steatosis was 
accompanied by a more than 2-fold induction of VLDL production. The secretion of large, 
TG-rich VLDL particles completely accounted for this increase. It is known that large VLDL 
particles will finally be converted in the very atherosclerotic small, dense low density 
lipoprotein (LDL) particles. In the studies described in chapter 4, hyperinsulinemic 
euglycemic clamp techniques and stable isotopes were used to study the effects of LXR 
activation on glucose metabolism and insulin sensitivity. GW3965-induced hepatic steatosis 
was not associated with reduced insulin sensitivity of hepatic glucose metabolism: in LXR- 
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ligand treated mice, HGP was suppressed by 86% and hepatic glucose fluxes were not 
affected. In ob/ob mice, in contrast, LXR activation resulted in slightly improved insulin 
sensitivity of peripheral glucose metabolism. This improvement was mainly due to effects of 
the LXR ligand on adipose tissue. 
In conclusion, LXR-induced hepatic steatosis is not associated with decreased insulin 
sensitivity of hepatic glucose metabolism. So far, no studies have been performed to 
investigate the effects of LXR activation on insulin sensitivity of lipid metabolism, e.g., 
peripheral lipolysis and hepatic VLDL production. The studies described in chapter 4 were 
among the first to show that hepatic steatosis per se does not lead to (hepatic) insulin 
sensitivity. Moreover, the studies from chapters 3 and 4 and those of others (19) were among 
the first to show that clinical use of pharmacological broad-acting LXR ligands as anti-
atherosclerotic or anti-diabetic drugs, is hampered by their undesirable side effects. Potential 
application of LXR modulators in diabetes treatment will require the development of gene- 
and/or organ-specific compounds. 
 
 
Pharmacological inhibition of β-oxidation 
 
In fasted conditions, dietary glucose supply is absent. In this condition, the body largely 
depends on the liver for maintaining euglycemia because only the liver (and the kidney to a 
small extent) is capable to produce glucose. For this, glycogen is broken down into glucose, 
but gluconeogenesis is also facilitated. Fatty acid β-oxidation, acoording the textbook 
biochemistry, yields the energy needed for gluconeogenesis. With low insulin levels, lipolysis 
of peripheral (adipose) TGs is enhanced and the free fatty acids (FFAs) thus generated are 
transported to the liver. Fatty acids are broken down in the β-oxidation process localised to 
hepatic mitochondria. Transport of fatty acids over the mitochondrial membranes, controlled 
by carnitine palmitoyl transferase (CPT) -1 and –2, is considered rate-limiting in the β-
oxidation processes. In the studies described in chapter 6 we showed that pharmacological 
CPT1 inhibition with tetradecylglycidic acid (TDGA) resulted in severe microvesicular 
hepatic steatosis and hypoglycemia upon fasting. VLDL production rates did not differ 
between the TDGA-treated and control mice and hyperinsulinemic euglycemic clamps 
equally suppressed VLDL production in control and treated mice. Moreover, hepatic 
intracellular insulin signaling was not affected upon TDGA treatment. In conclusion, hepatic 
steatosis due to pharmacological inhibition of β-oxidation is not associated with reduced 
insulin sensitivity of hepatic lipid metabolism. 
In humans, most fatty livers show large lipid droplets, referred to as macrovesicular 
steatosis. Only few clinical fatty liver diseases are microvesicular, i.e., fatty livers due to 
disturbances in β-oxidation. For instance, medium chain acyl-CoA dehydrogenase (MCAD) 
deficiency, assumed to be the most common inherited disorder of fatty acid metabolism (20) 
is associated with microvesicular fat accumulation. Upon fasting, MCAD deficient patients 
develop lethargy which may proceed into coma or sudden death (20). It is not known whether 
this syndrome is associated with insulin resistance.  
  
 
Pharmacological inhibition of glucose-6-phosphatase 
 
In the past, our laboratory has performed detailed studies with S4048, a pharmacological 
inhibitor of glucose-6-phosphate translocase (G6PT). G6PT is an enzyme of the glucose-6-
phosphatase (G6Pase) complex and its inhibition leads to a condition similar to glycogen 
storage disease type I (GSDI). In rats, inhibition of G6Pase resulted in increased de novo 
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lipogenesis and hepatic steatosis (21,22). Remarkably, the VLDL production rate was not 
affected in S4048-treated animals (22). The studies described in chapter 7 showed that S4048 
treatment also resulted in hepatic steatosis in mice. This condition was not associated with 
decreased intracellular hepatic insulin signaling, i.e., phosphorylation of protein kinase B 
(PKB) upon insulin injection. Although it was expected that the transcription factor 
carbohydrate responsive element binding protein (ChREBP) was involved in the development 
of hepatic steatosis, the translocation of this transcription factor to the nucleus was not 
enhanced. The increased phosphorylation and activity of AMP-activated protein kinase 
(AMPK) upon S4048 treatment might, in part, be responsible for this phenomenon. However, 
expression of genes encoding proteins involved in de novo lipogenesis was clearly increased 
upon S4048-treatment, in a LXR-independent fashion.  
  It is known that liver enlargement in GSDI patients is not solely the result of glycogen 
accumulation, but also of increased TG levels due to enhanced de novo lipogenesis (23). To 
study the role of ChREBP in S4048-induced hepatic steatosis and its role in the livers of 
GSDI patients, more experiments should be performed, especially with ChREBP knockout 
mice (24).  
 
 
Overall conclusion 
 
From the studies described in this thesis, it is clear that hepatic TG accumulation per se does 
not necessarily negatively interfere with insulin sensitivity of hepatic glucose and lipid 
metabolism. However, one should be aware that all studies described, except those with the 
ob/ob mice, were conducted in mice with “short-term” hepatic steatosis. Moreover, all fatty 
livers were the result of manipulation of de novo lipogenesis and/or β-oxidation. Various 
research groups have performed studies with other mouse models of hepatic. For instance, 
hepatic steatosis in CD36 knockout mice is due to increased FFA flux to the liver and 
associated with decreased insulin sensitivity (25,26). In addition, decreased hepatic TG levels 
in hormone sensitive lipase (HSL) knockout mice resulted in improved insulin sensitivity 
(27). Comparison of these latter studies with the ones described in this thesis strengthens the 
overall conclusion that hepatic steatosis in mice is not always associated with insulin 
resistance. Upon prolonged fasting, for instance during the night, humans also develop 
hepatic steatosis as a result of increased FFA flux from peripheral tissue to the liver. So far, it 
has not been reported that this “daily fatty liver” is associated with insulin resistance. Also in 
mice, 16-h fasting did not show an effect on insulin sensitivity of HGP, despite increased 
hepatic TG levels (28). 
 
Properties of the fat droplets 
In the future, more studies should be done to precisely determine the effects lipid droplet-
associated factors. First, the size of the fat droplets within the cells, i.e., the metabolic 
differences between macro- and microvesicular hepatic steatosis, might play a role. At first 
sight, one could argue that because larger fat droplets use more cytosolic space, they can harm 
more of the intracytosolic processes, for instance insulin signaling. Smaller droplets, as seen 
in livers of patients with β-oxidation disorders, use less cytosolic space and leave the 
intracellular organelles more intact. However, microvesicular hepatic steatosis implies a more 
severe disease than macrovesicular steatosis (reviewed by Fromenty and Pessayre (29)). The 
reason for this is probably the fact that the main cause of microvesicular hepatic steatosis, 
impairment of mitochondrial β-oxidation, is a severe condition itself, with clinical features 
such as hypoglycemia, hyperammonemia, brain disorders and eventually death.  
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Secondly, different sources of fatty acids within the droplets might have different effects. As 
described above, there are differences in (hepatic) insulin sensitivity in animals with hepatic 
steatosis due to high fat diets and hepatic steatosis due to enhanced de novo lipogenesis and/or 
reduced β-oxidation. The localisation of the lipids within the liver might play a role herein. In 
the periportal zone dietary fatty acid accumulation co-localises with processes involved in 
gluconeogenesis and β-oxidation. Glycolysis and lipogenesis are presumably located 
predominantly in the perivenous zone (30). It is of importance to notice that diabetes-
associated steatosis is predominantly present in the perivenous zones of the liver. 
Thirdly, as already discussed, the duration of the hepatic steatosis and duration of 
adverse effects might be related. Ob/ob mice, for instance, have a life-long hepatic steatosis 
and also suffer from the adverse effects of this condition. Considering this, the effects of 
hepatic TG concentrations seen in the CD36 and HSL knockout mice (25-27) might also be 
the result of life-long fat accumulation. As mentioned in the introduction of this thesis, 
inflammation is the major factor in the transition of simple hepatic TG accumulation towards 
fibrosis and cirrhosis (31). Adipose tissue and tissues with excessive TG concentrations are 
intrinsically inflammatory active, and thus longer existing hepatic steatosis might, via 
inflammatory molecules, disturb intra- and extrahepatic insulin sensitivity.  
The structure of the fatty acids (saturated, monounsaturated, and polyunsaturated) 
could differentially affect hepatic metabolism and insulin sensitivity, This is, of course, 
closely related to the source of the fatty acids. Various studies have shown that 
polyunsaturated fatty acids (PUFAs) are healthier: they suppress activity of the major 
lipogenesis regulatory factor sterol-regulatory element-binding protein-1c (SREBP-1c), 
antagonize LXR and improve plasma TG profiles (32). Moreover, PUFAs reduce de novo 
lipogenesis via inhibition  translocation and activation of ChREBP (33). Studies with 
monounsaturated fatty acids also showed less negative effects compared to saturated fatty 
acids (34). 
 
Extrahepatic regulation 
Next to the intrahepatic aspects mentioned, other organs might also play roles in the (lack of) 
association between hepatic steatosis and insulin resistance, for instance, via the adipocyte-
derived hormones leptin and adiponectin. Deficiency of leptin is associated with both obesity 
and insulin resistance (14-16;35). Low plasma adiponectin levels are associated with the 
development of insulin resistance (36). Administration of adiponectin to mice resulted in 
decreased liver TG concentrations and increased insulin sensitivity (37). Next to these 
hormones, the brain can also influence hepatic insulin-mediated effects (38-40). In 
conclusion, complex interactions between endocrine, metabolic, and transcriptional pathways 
are involved in TG-induced hepatic insulin resistance, as recently discussed by Den Boer et 
al. (41). 
 
What does lead to what? 
The question that remains unsolved is whether hepatic steatosis is caused by insulin 
resistance, or that hepatic steatosis predisposes for insulin resistance. The majority of studies 
described in this thesis started with the assumption that insulin resistance is a result of hepatic 
steatosis, or, in other words, that fatty acids, TGs and/or their metabolites and derivatives 
interfere with insulin signaling. However, this seemed be true in ob/ob mice only. In other 
studies, in which endogenous fatty acid fluxes were manipulated, hepatic TG concentration 
showed a negative correlation with the insulin sensitivity (25-27,42). More studies focussing 
on the role of fatty acid derivatives ceramide and glycosphingolipid will be necessary to gain 
insight about their role in mediating peripheral and hepatic insulin signaling and insulin 
sensitivity.  
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The two “hits” hypothesis (43) suggests that hepatic steatosis is due to reduced (peripheral) 
insulin sensitivity. Upon decreased insulin sensitivity, insulin-mediated suppression of 
lipolysis is hampered and, as a result, more fatty acids are directed to the liver. As a result, 
these fatty acids are stored upon esterification as TGs but will also enhance β-oxidation via 
activation of peroxisome proliferator activated receptor α (PPARα). Finally, this will result in 
enhanced gluconeogenesis and HGP. In the future, experiments need to be performed with 
rodents upon a high fat diet to study the time-course of development of insulin resistant. 
Everybody agrees that obesity and hepatic steatosis upon enhanced caloric intake and reduced 
physical activity is truly associated with insulin resistance and type 2 diabetes mellitus in 
humans (2-4,11,44,45). In the experiments with mice upon a high fat diet, the questions that 
need answers are (i) whether different diets, i.e., different fatty acid compositions, cause more 
or less insulin resistant, and (ii) whether hepatic steatosis firstly affects peripheral or hepatic 
insulin sensitivity resistance In studies with non-diabetic patients with NAFLD, it became 
clear that NAFLD is associated with reduced insulin sensitivity of the periphery, not of the 
liver. For instance, hyperinsulinemia suppressed HGP in both NAFLD and control subjects, 
but insulin-enhanced glucose disposal was severely in the NAFLD subjects compared to 
controls (46) Using the hyperinsulinemic clamp technique, Marchesini et al. (9) also 
demonstrated a reduction of insulin-mediated glucose disposal in NAFLD.  
In conclusion, fatty liver per se is not associated with reduced insulin sensitivity of 
hepatic glucose and lipid metabolism. Factors related with duration, inflammatory grade, fatty 
acid composition, and size of the fat droplets might influence severity of the fatty liver and its 
association with other clinical symptoms, for instance insulin resistance and diabetes mellitus 
type 2. 
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Het toenemend vóórkomen van overgewicht gaat hand in hand met een toename in het 
vóórkomen van diabetes mellitus type 2 op steeds jongere leeftijd. Patiënten met diabetes 
mellitus type 2 hebben een verhoogd bloedglucose als gevolg van het feit dat de alvleesklier 
geen of onvoldoende insuline produceert. Deze situatie wordt voorafgegaan door een 
afgenomen insulinegevoeligheid van het lichaam, een conditie die insulineresistentie wordt 
genoemd. Insulineresistentie is onderdeel van het ‘metabool syndroom’, een verzameling van 
factoren die ieder op zich een verhoogde kans geven op het krijgen van hart- en vaatziekten. 
Componenten van het metabool syndroom, naast insulineresistentie, zijn onder andere 
overgewicht, een verhoogde bloeddruk en een verstoord plasma lipid profiel (teveel ‘slecht’ 
LDL-cholesterol en te weinig ‘goed’ HDL-cholesterol). 
De lever is belangrijk in de regulering van het metabolisme van zowel koolhydraten 
(bijvoorbeeld glucose) als lipiden (bijvoorbeeld vetzuren). De lever kan glucose opslaan als 
glycogeen maar tevens glucose produceren en uitscheiden in de circulatie. Daarnaast is de 
lever in staat glucose om te zetten in triglycerides, energierijke moleculen die bestaan uit drie 
vetzuren gekoppeld aan glycerol. De lever kan vetzuren ook verbranden, hetgeen energie 
oplevert voor de gluconeogenese (de productie van glucose uit verschillende andere stoffen, 
zoals melkzuur en aminozuren). Tenslotte scheidt de lever triglycerides (en cholesterol) uit in 
de circulatie in zogenaamde ‘very low density lipoprotein’ (VLDL) deeltjes.  
Insuline is het bloedglucose-verlagende hormoon dat door de alvleesklier wordt 
uitgescheiden als reactie op toegenomen bloedglucose concentraties na een maaltijd. Insuline 
remt de glucoseproductie door de lever en stimuleert de opname van glucose door met name 
spieren en vetweefsel. In de lever stimuleert insuline de omzetting van glucose in glycogeen, 
vetzuren en triglycerides. Daarnaast onderdrukt insuline de uitscheiding van triglyceride-rijke 
VLDL-deeltjes. In het vetweefsel remt insuline de omzetting van de triglycerides in vetzuren 
en zorgt daarmee voor een daling van de hoeveelheid vrije vetzuren in het bloed. In gevaste 
toestand, wanneer de insulineconcentratie laag is, is de remming van de triglyceride-afbraak 
afgenomen waardoor meer vrije vetzuren de lever bereiken. Deze vetzuren worden, zoals al 
vermeld, deels verbrand om aan de energiebehoefte van het lichaam te voldoen en deels in de 
lever opgeslagen in de vorm van triglycerides.  
Het continue transport van vetzuren en triglycerides dat (mede) wordt gereguleerd 
door insuline is van groot belang voor de energiehuishouding van het lichaam. Veranderingen 
in dit transport gaan gepaard met veranderingen in de triglyceride concentratie van de lever. 
Verhoogde hepatische triglyceride concentraties (vette lever of hepatische steatose) zijn 
geassocieerd met diverse klinische aandoeningen en kunnen een voorloper zijn van ernstige 
aantastingen van de lever, zoals cirrose. Uit klinische studies is naar voren gekomen dat 
hepatische steatose is geassocieerd met insulineresistentie en diabetes mellitus type 2.  
In de studies beschreven in dit proefschrift werd met behulp van diermodellen het 
effect van hepatische steatose op (insulinegevoeligheid van) het glucose- en vetmetabolisme 
in de lever onderzocht. Op deze manier is getracht de onderliggende moleculaire processen 
die ten grondslag liggen aan de verminderde insulinegevoeligheid bij hepatische steatose op te 
helderen. 
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Ob/ob muizen 
 
Leptine is een hormoon dat door het vetweefsel wordt geproduceerd en onder andere het 
verzadigingsgevoel reguleert. Ob/ob muizen zijn leptine-deficiënt en eten derhalve meer dan 
gewone muizen. Ob/ob muizen zijn in vergelijking met gewone muizen zwaarder en hebben 
een  hoger bloedglucose en meer triglycerides in hun bloed. Daarnaast hebben ob/ob muizen 
een hepatische steatose en zijn ze in ernstige mate insulineresistent. Onduidelijk was of de 
verhoogde bloedglucoses een gevolg zijn van een verhoogde hepatische glucoseproductie 
en/of een afgenomen glucose opname. In hoofdstuk 2 is gebruik gemaakt van stabiele 
isotopen om de glucose fluxen in de lever en de glucoseklaring te vergelijken tussen ob/ob en 
normale, slanke muizen. De netto hepatische glucoseproductie in ob/ob muizen verschilde 
niet met die van de controle muizen: de verhoogde glucosespiegels bleken primair het gevolg 
van een afgenomen glucoseklaring. Het feit dat de hepatische glucoseproductie, ondanks 
verhoogde insulinespiegels, niet verschilde tussen ob/ob muizen en slanke muizen duidt 
echter wel op hepatische insulineresistentie van de ob/ob muizen. 
Het glucosemetabolisme en de insulinegevoeligheid in ob/ob muizen is in hoofdstuk 4 
in meer detail onderzocht. De ‘gouden standaard’ voor het vaststellen van 
insulinegevoeligheid is de hyperinsulinemische euglycemische clamp. Hierbij krijgen 
wakkere, vrij bewegende muizen een intraveneuze infusie met insuline. Als gevolg hiervan 
stijgen de insulineconcentraties en door deze ‘hyperinsulinemie’ zal de bloedglucose 
concentratie dalen. Om een normale bloedglucose te handhaven (euglycemie) wordt een 
tweede oplossing met glucose geïnfundeerd. De hoeveelheid glucose die geïnfundeerd moet 
worden om euglycemie te handhaven is een maat voor de insulinegevoeligheid van de muis. 
Wordt aan de hyperinsulinemische euglycemische clamp een kleine hoeveelheid [U-
13C]-
glucose toegevoegd, dan is het mogelijk om de hepatische en perifere insulinegevoeligheid te 
meten. De hepatische gevoeligheid is de mate van onderdrukking van de glucoseproductie 
onder invloed van hyperinsulinemie, de perifere gevoeligheid de toename van de 
glucoseklaring. 
In  ob/ob muizen leidde hyperinsulinemie tot een 48% onderdrukking van 
glucoseproductie door de lever, terwijl dit percentage in de normale muizen 94% was. Dit 
onderstreept de insulineresistentie van het hepatische glucosemetabolisme in ob/ob muizen. 
Daarnaast bleek dat hyperinsulinemie leidde tot een vijfvoudige toename van de 
glucoseklaring in de slanke muizen terwijl er geen effect viel waar te nemen in de ob/ob 
muizen.  
De ob/ob muizen zijn dus een goed model voor insulineresistentie van het hepatische 
glucosemetabolisme in associatie met een hepatische steatose. Eerdere experimenten in het 
laboratorium Kindergeneeskunde hebben daarnaast insulineresistentie van het hepatische lipid 
metabolisme in ob/ob muizen aangetoond. 
Ceramide en glycosphingolipiden hebben, net als triglycerides, vetzuren als 
bouwstenen. Er is gesuggereerd dat ceramide en/of glycosphingolipiden ook betrokken zijn 
bij de insulineresistentie geassocieerd aan de hepatische steatose in ob/ob muizen. De 
aandacht gaat daarbij vooral uit naar de glycosphingolipiden omdat zij samen met de 
insulinereceptor in grote concentraties aanwezig zijn in het celmembraan in zogenaamde 
‘rafts’. In de studies beschreven in hoofdstuk 5 is onderzocht of behandeling van ob/ob 
muizen met AMP-DNM, een nieuwe farmacologische remmer van de omzetting van ceramide 
in glycosphingolipiden, effect had op de insulinegevoeligheid. Het bleek dat zowel de perifere 
als de hepatische insulinegevoeligheid verbeterde na AMP-DNM behandeling. Omdat de 
ceramide concentraties van de weefsels niet veranderden na behandeling terwijl de 
glycosphingolipid concentraties daalden, kan geconcludeerd worden dat niet ceramide maar 
glycosphingolipiden betrokken zijn bij insulineresistentie.  
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Farmacologische activering van de liver X receptor 
 
De liver X receptor (LXR) is een transcriptiefactor: een eiwit dat de transcriptie van genen 
reguleert. Oxysterolen zijn metabolieten van cholesterol en zij kunnen door middel van 
binding aan LXR de activiteit van LXR stimuleren en daarmee dus ook de transcriptie van 
diverse genen beïnvloeden. Cholesterol reguleert via deze oxysterolen zijn eigen stofwisseling 
want LXR stimuleert de transcriptie van genen betrokken bij het ‘reverse cholesterol 
transport’: transport van cholesterol van plaatsen waar het kwalijke gevolgen kan hebben 
(zoals atherosclerotische plaques in bloedvaten) via de lever naar de darm en de feces. Uit 
experimenten met synthetische LXR liganden blijkt dat LXR tevens de transcriptie stimuleert 
van genen betrokken in de productie van vetzuren en triglycerides, zowel direct als indirect. 
De indirecte stimulering verloopt via ‘sterol-regulatory element-binding protein-1c’ (SREBP-
1c), een belangrijke regulator van de vetzuur en triglyceride synthese in de lever. 
Farmacologische LXR activering heeft dus niet alleen positieve effecten (toename van het 
‘reverse cholesterol transport’), maar als bijwerking leververvetting. In de studies beschreven 
in hoofdstuk 3 is onderzocht of LXR-geïnduceerde hepatische steatose leidt tot veranderingen 
in de VLDL-productie. Het geven van de synthetische LXR ligand T0901317 gedurende vijf 
dagen aan muizen resulteerde in een meer dan tweevoudige toename van de VLDL-
triglyceride productie. De uitscheiding van grote, triglyceride-rijke VLDL deeltjes kon deze 
toename volledig verklaren. Uit de literatuur is bekend dat grote VLDL deeltjes meer 
atherosclerotische eigenschappen hebben dan kleine VLDL deeltjes. 
Ondanks het feit dat hepatische steatose en de uitscheiding van grote VLDL deeltjes, 
samen met insulineresistentie, karakteristiek zijn voor het metabool syndroom, zijn onlangs 
enkele studies gepubliceerd waarin synthetische LXR-liganden anti-diabetische 
eigenschappen worden toegedicht. We onderzochten de effecten van farmacologische LXR 
activering op glucose metabolisme en insulinegevoeligheid in meer detail en hiertoe werden 
normale, slanke muizen en ob/ob muizen gedurende 10 dagen behandeld met de synthetische 
LXR ligand GW3965. Hoofdstuk 4 beschrijft de experimenten met de hyperinsulinemische 
euglycemische clamp in combinatie met stabiele isotopen. In normale muizen veranderde de 
insulinegevoeligheid en het hepatische glucosemetabolisme niet na farmacologische LXR 
activering. In behandelde ob/ob muizen werd wel een lichte verbetering van de 
insulinegevoeligheid waargenomen, maar dit bleef nog ver achter bij de insulinegevoeligheid 
in normale muizen. LXR activering bleek weinig tot geen effect te hebben op de glucose 
fluxen in de levers van ob/ob muizen, maar de glucoseklaring onder hyperinsulinemische 
condities was wel verbeterd in deze muizen. Uit metingen van de genexpressie bleek dit effect 
vooral gelokaliseerd te zijn in het vetweefsel.  
Concluderend kan gesteld worden dat de marginale anti-diabetische effecten van 
synthetische LXR liganden in ob/ob muizen het gevolg zijn van een lichte toename in de 
glucose opname door het vetweefsel. Opvallend is dat LXR activering leidt tot hepatische 
steatose die niet gepaard gaat met een afgenomen insulinegevoeligheid. 
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Farmacologische remming van de β-oxidatie 
 
Om onder niet-gevoede omstandigheden aan de energiebehoefte te voldoen is het lichaam 
afhankelijk van vetzuurverbranding door de lever, een proces dat β-oxidatie wordt genoemd 
en plaats vindt in de mitochondria. Verbranding van vetzuren levert de energie die nodig is 
voor de synthese van glucose uit diverse substraten zoals lactaat (gluconeogenese). Carnitine 
palmitoyl transferase-1 (CPT1) transporteert vetzuren over de mitochondriale membranen en 
is derhalve cruciaal in de eerste stappen van de β-oxidatie. Farmacologische remming van 
CPT1 met behulp van tetradecylglycidic acid (TDGA) heeft tot gevolg dat vetzuren in de 
lever minder snel verbrand worden en in sterkere mate opgeslagen worden als triglyceride. 
Behandeling van muizen met TDGA tijdens vasten resulteert dan ook in microvesiculaire 
hepatische steatose, zoals vermeld in hoofdstuk 6. In muizen met een TDGA-geïnduceerde 
hepatische steatose werd de insulinegevoeligheid van de VLDL-productie onderzocht, 
wederom met behulp van de hyperinsulinemische euglycemische clamp. Tevens werd de 
intracellulaire insuline signaleringscascade onderzocht. De hepatische steatose had geen 
invloed op de insulinegevoeligheid: insuline onderdrukte nog steeds de VLDL-productie en 
stimuleerde de intracellulaire signaleringscascade.  
Kortom, de acute TDGA-geïnduceerde hepatische steatose is niet geassocieerd met 
een afgenomen insulinegevoeligheid van het vetmetabolisme in de lever. Daarnaast bewijst 
deze studie dat de hoeveelheid lever triglyceride niet per se de VLDL-productie hoeft te 
beïnvloeden. In andere studies in ons laboratorium, onder andere met ob/ob muizen, is dit 
eveneens aangetoond. 
 
 
Farmacologische remming van glucose-6-fosfaat translocase 
 
Naast SREBP-1c en LXRα is de ‘carbohydrate responsive element binding protein’ 
(ChREBP) een derde factor die transcriptie stimuleert van genen betrokken bij de synthese 
van vetzuren en triglycerides. Opvallend is dat de activiteiten van ChREBP en SREBP-1c 
elkaar grotendeels overlappen en dat LXRα naar alle waarschijnlijkheid zowel de transcriptie 
van SREBP-1c als de activiteit van ChREBP positief beïnvloedt. In de lever wordt de 
activiteit van ChREBP gestimuleerd door xylulose-5-fosfaat, een metaboliet van glucose. 
Eerdere experimenten van ons laboratorium toonden aan dat ratten die waren behandeld met 
S4048, een remmer van het enzym glucose-6-fosfaat translocase, een hepatische steatose 
ontwikkelden in combinatie met toegenomen glucose-6-fosfaat concentraties in de lever. In de 
studies beschreven in hoofdstuk 7 is in muizen onderzocht welke transcriptie factor (SREBP-
1c, LXRα of ChREBP) betrokken is bij de S4048-geinduceerde transcriptie van ‘lipogene’ 
genen. Analyse van de genexpressies na S4048-infusie toonde aan dat niet SREBP-1c, maar 
ChREBP hiervoor verantwoordelijk was. De sterk toegenomen glucose-6-fosfaat 
concentraties in de lever wezen hier eveneens op. Infusie van S4048 bij LXRα-knockout 
muizen resulteerde eveneens in een sterke toename van de expressie van de lipogene genen.  
Geconcludeerd kan worden dat remming van glucose-6-fosfatase resulteerde in een 
toename van glucose-6-fosfaat en dat dit de activiteit van ChREBP beïnvloedde. ChREBP, en 
niet SREBP-1c of LXRα, was vervolgens betrokken in de daarop volgende inductie van de 
expressie van lipogene genen. Patiënten met glycogeen stapelings ziekte type I (GSDI) 
hebben een defect in het glucose-6-fosfatase eiwit en tevens een verhoogde hepatische 
lipogenese. Een verhoogde ChREBP activiteit is naar alle waarschijnlijkheid in GSDI-
patiënten de oorzaak van de hepatische steatose. 
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De rol van transcriptiefactoren in diabetische dyslipidemie 
 
In dit proefschrift is een aantal factoren naar voren gekomen dat van invloed is op de 
expressie van genen betrokken bij het vetzuur en triglyceride metabolisme: LXR, SREBP-1c 
en ChREBP. Omdat deze factoren een grote rol spelen in het hepatische vetmetabolisme en 
hun activiteit en/of transcriptie wordt geactiveerd door vetten, glucose en insuline (factoren 
die in hoge concentraties voorkomen in diabetische patiënten), lijkt het niet meer dan logisch 
om te onderzoeken wat hun rol is in diabetes en daaraan gerelateerde verstoringen in het 
vetmetabolisme. Hoofdstuk 8 geeft een overzicht van wat bekend is over de rol van de drie 
factoren in de aan diabetes gerelateerde verstoring in plasma lipiden profielen (diabetische 
dyslipidemie). Opvallend is dat zeer weinig bekend is over het relatieve belang van LXR, 
SREBP-1c en ChREBP in het bepalen van de insulinegevoeligheid van het glucose- en 
vetmetabolisme in de lever. Over de effecten van de transcriptiefactoren op de 
(insulinegevoeligheid van de) VLDL-productie is derhalve ook weinig bekend. Onderzoek 
met farmacologische activatoren, manipulaties met voedingsmiddelen en het gebruik van 
muizen die deficient zijn voor één of meer van de genoemde transcriptiefactoren zijn dan ook 
zeer gewenst om meer hierover te weten te komen.  
 
 
Algemene conclusie 
 
Aan de hand van de studies in dit proefschrift kan geconcludeerd worden dat de hoeveelheid 
triglycerides in de lever op zich weinig zegt over de mate van hepatische 
insulinegevoeligheid: zowel de LXR- als de TDGA-geïnduceerde hepatische steatose zijn niet 
geassocieerd met een afname van de hepatische insulinegevoeligheid. Andere factoren zijn 
naar alle waarschijnlijk belangrijke determinanten voor het wel of niet optreden van 
insulineresistentie. Te denken valt bijvoorbeeld aan de oorsprong van de triglycerides, de duur 
van de hepatische steatose, de locatie van de triglycerides in de lever en de grootte van de 
vetdruppels in de cellen. Hoofdstuk 5 laat daarnaast zien dat ook andere vetzuur-bevattende 
lipiden, zoals de glycosphingolipiden, insulineresistentie kunnen induceren.  
Uit klinische studies is gebleken dat obesitas, hepatische steatose, insulineresistentie 
en diabetes mellitus type 2 zeer nadrukkelijk met elkaar geassocieerd zijn. Daarom is verder 
fysiologisch onderzoek naar onderliggende moleculaire processen aan te raden. Te denken 
valt bijvoorbeeld aan onderzoek naar de rol van de genoemde transcriptiefactoren, de effecten 
van een dieet met veel vetten (oorzaak nummer één van diverse metabole problemen in de 
Westerse samenleving) en de effecten van duur en ‘type’ van de hepatische steatose. 
Technieken die hierbij een rol kunnen spelen zijn de al genoemde hyperinsulinemische 
euglycemische clamp en het gebruik van stabiele isotopen om de hepatische glucose, vetzuur 
en triglyceride fluxen te meten. Qua analytische bepalingen valt in dit kader te denken aan het 
meten van de veranderingen in genexpressie met behulp van RT-PCR en micro-arrays, maar 
omdat het belangrijk is om verder te kijken dan de genen, is het ook aan te raden veel 
aandacht te besteden aan het kwantificeren van de fosforylerings status van (signaal-
transductie-) eiwitten, het meten van de daadwerkelijke enzym activiteiten en de concentraties 
van metabolieten en eindproducten in het hepatische vet- en glucosemetabolisme. Kortom, 
een volledige integratie van het toepassen van hightech in vivo technieken naast het meten van 
verschillende specifieke parameters zal in de (nabije) toekomst meer informatie over de 
daadwerkelijke rol van hepatische vetstapeling in de insulinegevoeligheid opleveren. Tevens 
zal meer informatie over de rol van (hepatische) lipiden in de modulering van 
insulinegevoeligheid bijdragen aan de ontwikkeling van dieetgerelateerde en farmacologische 
strategieën voor de behandeling en/of preventie van insulineresistentie. 
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De afgelopen vier jaar (en een beetje) heb ik met heel veel plezier gewerkt aan de studies die 
beschreven staan in dit proefschrift. Mijn plezier in het werk kwam niet alleen door het 
boeiende onderwerp, maar vooral ook door de goede sfeer op het laboratorium 
kindergeneeskunde. Mocht ik de afgelopen jaren wat hebben geleerd, dan is het wel dat werk 
in het algemeen en wetenschap in het bijzonder gebaat is bij een goede, prettige en 
motiverende samenwerking tussen collega’s.  
De grote initiator voor, tijdens en zelfs na mijn promotieonderzoek is niet geheel 
toevallig tevens de man die grotendeels verantwoordelijk is voor het creëren van die prettige 
sfeer op het laboratorium kindergeneeskunde: Folkert Kuipers. Zonder zijn rustige maar 
honderd procent gedreven inzet voor alles wat met wetenschapsbeoefening te maken heeft 
was dit proefschrift nooit geworden wat het nu is. Aan de ene kant wees hij mij op nieuwe 
studies, of schoof mij deze in de schoenen, en aan de andere kant wist hij in no-time altijd net 
die mooie zin te vinden waar ik niet op kon komen. Folkert, bedankt voor al je vertrouwen. 
Wie weet ga ik de met sigarenlucht doordrenkte correcties nog missen in de VS.  
Aansluitend moet ik bij deze (nogmaals) mijn excuses maken bij Louis Havekes en 
Hans Romijn voor het feit dat ik toch de voorkeur gaf aan Groningen. Louis en Hans, ik ben 
blij dat jullie als mede-promotores willen optreden, wat gezien jullie wezenlijke bijdragen aan 
meerdere hoofdstukken van dit proefschrift niet meer dan vanzelfsprekend is!  
Volgens mij is Theo van Dijk dé man van het in vivo glucose metabolisme in 
Nederland! Helaas moet hij dat zelf nog even meer doorhebben. Ik heb het geluk gehad veel 
met hem samen te mogen werken. Als men ons tegen kwam op ADL08 met de muisjes 
gezellig op tafel, soepje erbij, kopje koffie en de Sudoku’s, zullen niet velen hebben gedacht 
dat er baanbrekende in vivo technieken werden ontwikkeld of uitentreuren toegepast. Theo, 
laat ik eens eerlijk zijn: zonder jou geen ‘clamp’ of ‘MIDA’ en dus ook een veel dunner 
proefschrift. Eén woord is dus op zijn plaats: bedankt! 
Bij in vivo experimenten kun je in ons laboratorium niet om Rick Havinga heen, maar 
dat blijkt helemaal niet erg te zijn. Rick, zonder jouw operatieskills, het gevraagd en 
ongevraagd meedenken bij experimenten was dit boekje een droom gebleven danwel een 
nachtmerrie geworden. PS. De Havinga-Kuipers roddeluurtjes zal ik nog gaan missen in 
Dallas!  
Onderzoek doe je niet alleen maar als team. Ik vond het erg prettig (en zeer productief) 
om als kersverse AIO door mede-AIO’s op gang te worden geholpen. Baukje, ik had me geen 
betere start van mijn wetenschappelijke carrière kunnen bedenken dan onze gezamenlijke 
LXR experimenten. Bedankt voor die fantastische vliegende start. Robert, ook jouw hulp bij 
experimenten en het theoretisch en praktisch meedenken had ik, achteraf gezien, niet kunnen 
missen. Daarnaast ben de overige mede-energie AIO’s veel dank verschuldigd voor de 
prettige samenwerking op diverse fronten. Terry, Maaike en Marijke, bedankt voor de uren 
gezelschap op ADL08, de hulp bij de experimenten en analyses en jullie motiverende 
aanwezigheid. Dat wordt een aantal mooie proefschriften!  
Ik heb het geluk gehad te mogen werken met zowel één van de beste geneeskunde als 
wel Life Science studenten. Jildou en Annelies, ik heb stiekem veel van jullie geleerd. Succes 
met jullie verdere carrières. Vergeet de wetenschap niet, want mensen zoals jullie zijn er 
volgens mij voor geknipt.  
Ik ben blij om nog steeds (in de wandelgangen) te vernemen dat Y2.117 AIO-kamer 
nummer 1 is en blijft! Coen, Janine, Thierry, Antonella, Anja, Alberto en Laura: bedankt!, 
merci!, grazie!, ¡gracias! voor de fantastische sfeer, het beantwoorden van telefoontjes, de 
goede gesprekken en het meedenken in al die jaren! En natuurlijk, ook de ‘andere’ AIO’s, 
postdocs en stafleden van zowel Kindergeneeskunde als MDL maakten de afgelopen tot wat 
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ze waren: meer dan geslaagd! Bedankt (in volstrekt willekeurige volgorde) Leonie, Jelske, 
Tineke, Jaap, Torsten, Christian, Frans, Esther, Hester, Niels, Jan Peter, Anniek (2x), Yan, 
Renate, Jenny, Titia, Martijn, Axel, Jannes, Krzysztof, Hans, Marieke, Jacqueline, Rebekka, 
Sandra, Ekkehard, Anna, Ewa, Gloria, Han (2x), Klaas-Nico, Thomas, Uwe, Frans, Henkjan, 
Edmond, Karin, Dirk-Jan (zou ik nog zonder hem naar een congres durven?), Feike, Klary, 
Marion en Roel. 
Analisten zijn de kurk waarop een goed laboratorium drijft. Zonder mijn met een 
gouden strotje gezegende ‘overbuurman’ Renze, de PCR-o-fiel Fjodor, Anke, Vincent, Henk, 
Nicolette, Janny, Juul, Frank, Albert, Mariska, Janette, Fiona, Lisette, Kyrjon, Manon, Hermi, 
Pim (2x), Klaas, Theo ↑, Trijnie, Fettie, Jenny, Janneke (2x), Marius, Marianne, Karloes en 
Desiree zou het een ontzettende puinhoop worden in de laboratoria van Kindergeneeskunde, 
MDL, metabole ziekten en proteomics. 
We hebben nog meer vrienden in Leiden. Bedankt Margriet en Peter voor jullie 
ondersteuning in de afgelopen jaren. Tot slot een staande ovatie voor de verzorgers van de 
hoofdpersonen in dit proefschrift: de dierverzorgers van ADL08. Harm, Ralph, Diana en 
Natasha, bedankt voor jullie goede zorgen! 
Tot zover het werk… Laten we niet vergeten dat dingen buiten het werk vaak veel 
belangrijker zijn. Al sinds het begin van mijn Groningse loopbaan mag ik me gelukkig prijzen 
met een fantastische groep vrienden. Van de ene kant uit de groep ex-Dizkartianen verenigd 
in Nevadí (die naam zien we ook niet vaak meer, hè). Zonder hen was Groningen nooit zo 
leuk geweest dat ik er nog wel wat jaartjes tegenaan wilde gooien. Bedankt! Arnout, ik ben 
blij je als vriend (uit deze groep) mijn paranimf wilt zijn. Laten we maar eens een lange 
woensdagavond proosten dat de vriendschap nog lang mag blijven duren en dat de afstand 
Heiligerlee en Dallas geen belemmering zal zijn. 
Daarnaast de zeven medefarmaceuten! Ik vind het telkens weer fantastisch om te zien 
dat elke ‘farmaboy’ op geheel eigen wijze met farmacie bezig is. Mannen, ik prijs me 
gelukkig met zo’n groep waarin ik niet alleen mijn eigen wetenschappelijk gezwets kwijt kan, 
maar ook nog eens verneem hoe het er aan toe gaat in apotheek, ziekenhuis en industrie.  
Ronald, broertje, ik vind het fantastisch dat je mijn paranimf wilt zijn! Op de ons eigen 
nuchtere manier laten we toch regelmatig aan elkaar blijken hoe gesteld we op elkaar zijn. Dat 
ik dat nu nog eens extra kan bestendigen tijdens mijn promotie maakt het alleen maar beter 
op! 
Mijn ouders hebben me altijd zo opgevoed dat ik gedurende het bewandelen van mijn 
eigen weg toch het beste uit mezelf kan halen. Vaders, moeder, met jullie nuchtere maar 
natuurlijke manier van opvoeden hebben jullie zeer nadrukkelijk aan de wieg gestaan van dit 
proefschrift. Bedankt in het vertrouwen, de kansen en de vrijheid!  
Er is iemand in mijn leven die me meer lief is dan wie of wat dan ook. Maaike, ik ben 
blij dat je onvoorwaardelijk in mij blijft geloven en zelfs zo gek bent om je studie minimaal 
een jaar in de ijskast te leggen om met mij mee te gaan naar het grote onbekende Amerika. 
Waaraan zou ik al dit geluk te danken hebben? Trouwens, had ik je vandaag al gezegd… 
En dan is het nu tijd voor een drankje… Mocht ik iemand vergeten zijn, dan drinkt die 
er maar één extra op mijn kosten. 
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On page 54: 
Figure 3.1. Uniform Oil-Red-O (ORO) staining for neutral fat in livers of T0901317-treated mice. No staining 
was observed in liver sections from male C57BL/6J mice receiving the solvent (A). Massive staining was found 
in liver sections from mice treated four days with 10 mg/kg of the LXR agonist T0901317 (B). V, central vein; 
P, portal vein. Original magnification 50x.  
 
On page 110: 
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Figure 6.2. Oil-Red-O staining for neutral lipids in livers of mice treated with or without CPT1-inhibitor TDGA. 
V, central vein; P, portal vein.  
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